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Abstract
Despite years of research, numerous aspects of gene regulatory mechanisms and their contri-
butions to shaping phenotypic characteristics remain elusive. In this thesis, I gain insights
into mechanisms of transcriptional regulation, focusing particularly on the binding activity of
transcription factors (TFs). In the comprised projects and analyses, I use models of closely
related mouse species, as in vivo systems that leverage a pool of molecular variation, in order
to study the activity and roles of TF binding within wider functional contexts. The molecular
variation is manifested as variation in the sequence context and/or in the binding activity
of the TFs, and it may be naturally fixed by evolution among the different species, and/or
induced variation among different conditions, for example as a result to carcinogen exposures.
The reflection of the underlying molecular variation in the functional roles of TF binding is
also tied to some extent to functional outputs and is examined as part of general functional
contexts, such as higher-order genome organisation or the neoplastic transformation of a
tumour cell in cancer development.
In the first part of the thesis, I explore the evolutionary dynamics of the CTCF (CCCTC-
binding factor) binding among mouse species and its interplay with the establishment and
maintenance of topologically associating domains (TADs). TADs make up a level of the
3D genome organisation that dictates formation of regulatory landscapes. Although it is
known that CTCF plays an important role in TAD formation, evidence of TAD boundaries
being robust to CTCF depletion interferences has confounded the understanding of its exact
role. My study reveals the occurrence of dynamically evolving clusters of neighbouring
CTCF sites at the boundaries of TADs, which contribute to the resilience and flexibility of
the TAD structures. My findings also highlight the necessity of examining the binding of
CTCF not only as individual binding sites, but also as an ensemble of potentially functional
sites that can exert their actions synergistically, additively or interchangeably, and contribute
to fostering phenotypic features.
In the second part of the thesis, I present a project I worked on as a member of a collaborative
effort of the Liver Cancer Evolution (LCE) consortium. The project makes use of a model of
x
chemically induced liver carcinogenesis in different mouse species, which offer a controlled
biological system with natural genomic and epigenomic variation. Here, I characterise the ex-
pression profile of the cell-of-origin, the hepatocyte, of chemically induced liver tumours and
the shift of its cell-type specific phenotype along neoplastic transformation, which is under-
lined by gene dysregulation. In addition, I further explore associations of gene dysregulation
in the cell-of-origin with mutagenesis (induced genetic variation as a result of carcinogen
exposure) in liver TF binding sites that potentially underlie the onset of hepatocyte dediffer-
entiation in tumour development. My results disentangle patterns of mutation accumulation
among distinct categories of TF binding sites based on their functional characteristics, such
as combinatorial binding or association with with cis-regulatory elements. Also, they reveal
sets of hyper-mutated TF binding sites in liver tumours, which are functionally enriched for
liver-specific biological processes, cellular stress response and abnormal liver phenotype,
and they are associated with dysregulated genes with hepatocyte-specific functions. Finally,
these findings also highlight the necessity of studying the activity of TFs bound both in a
singleton manner and in concert and within their broader functional context.
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Contemplating the tremendous range of phenotypes occurring in the living world can be
astounding if we consider that a) morphologically dissimilar organisms from different taxa
share a substantial part of their gene repertoire, and b) highly variable cells of a single
organism have the same genome. Yet similar gene repertoires, or even the same genetic
code can give rise to greatly diverse phenotypes among distinct species, but also among
functionally specialised tissues of a single organism. It is now known that a major factor
underlying diversification of phenotypes are the molecular mechanisms that regulate gene
expression. Therefore, unravelling the molecular basis of phenotypic diversity requires a
profound understanding of the gene regulatory mechanisms; their components, their func-
tions, and the way they differentiate, among lineages, or among tissues and cells, and even in
genetic diseases and cancer.
1.1 "DNA makes RNA" - but how is this regulated?
The genes speak:
“Functional units of DNA, we are;
Ultimate for all cellular activities;
Tailored to express as per tissue demands;
Mystery of our molecular actions await unfolding” [1]
1.1.1 Central Dogma of Molecular Biology
“DNA makes RNA, and RNA makes protein” has probably been the shortest circulated
synopsis of the Central Dogma of Molecular Biology. Describing the flow of information
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from genes to proteins, the Central Dogma was accurately summarised for the first time
by Francis Crick in 1957 and published later in 1970 [2–4]. According to that, the DNA
sequences of genes are transcribed into RNA molecules, which in turn provide the information
for the synthesis of proteins through the process of translation. The genetic information can
be passed on from nucleic acid to nucleic acid 1 and from nucleic acid to protein. As stated
by Crick, “The central dogma of molecular biology deals with the detailed residue-by-residue
transfer of sequential information. It states that such information cannot be transferred back
from protein to either protein or nucleic acid” [3].
1.1.2 Gene expression in brief
The conversion of the genetic information into proteins, or in a broader context the process
through which the genotype gives rise to the phenotype, is what we call gene expression. It is,
in fact, a multi-step process that includes a series of complex, yet well-tuned mechanisms. It
all starts with the transcription, the process through which a DNA strand is used as a template
by RNA polymerase to generate a messenger RNA (mRNA) strand (described in further
detail in 1.2). The generated mRNA molecule can go through further post-transcriptional
processing steps, such as mRNA splicing, where introns are spliced out and the remaining
exons are linked together into a mature mRNA molecule. The resulting mature mRNA is then
transferred from the nucleus of the cell to the cytoplasm and directed to the ribosome to be
translated, that is to instruct the polymerisation of amino acids into polypeptide chains with
the help of the tRNAs. Synthesized peptides can subsequently fold into secondary structures
and then, frequently combined with other peptides, make up proteins, which can often un-
dergo post-translational modifications. The resulting functional proteins are then transported
to specific places of the cell or to the extracellular matrix to perform various cellular functions.
1.1.3 Gene expression regulation
Eukaryotic cells do not express all of their genes continuously. In fact, different subsets of
genes display distinct expression patterns, depending on their functional role in the cell, as
well as the intra- and extra- cellular conditions at any given time point. For example, only a
subset of genes that are involved in fundamental cellular functions, typically referred to as
housekeeping genes, are expressed relatively constantly and in all cell types of an organism.
On the contrary, genes that code for proteins involved in tissue-specific functions—the so-
1from DNA to RNA with transcription, from DNA to DNA with DNA replication, or from RNA to DNA
with reverse transcription
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called tissue-specific genes—are expressed only in certain cell types, while inducible genes
are expressed as a response to environmental stimuli, or at certain phases of the cell cycle.
Overall, spatial and temporal differences in gene expression underlie the high level of cell
specialisation in multicellular eukaryotic organisms. These complex -yet precise- expression
programs, being established during embryonic development, give rise to morphologically and
functionally distinct cell types, while they also maintain cell type specificity in adult organs.
The establishment and maintenance of these spatial and temporal gene expression patterns is
governed by specialised programmes of gene regulation. Disruption of these tight regulatory
programmes can lead to genetic diseases and cancer. It is therefore clear that unravelling the
details of gene expression regulation is of utmost importance in understanding development,
regeneration, aging, as well as disease onset.
In addition to phenotypic diversity within a single organism, variation in gene expression
patterns as a function of distinct gene regulatory programmes also underlies -to a great extent-
phenotypic diversity between different individuals, as well as species and lineages. A fair
amount of evidence suggests that evolution of organismal complexity has been importantly
facilitated by the progressive evolution of highly complex and precise gene regulatory mech-
anisms [5–7]. The extensive expansion of transcription factor families and the regulation
of genes by combinatorial transcription factor binding (reviewed in section 1.2.2), the com-
binatorial use of cis-regulatory elements (reviewed in section 1.2.1) and the deployment
of complex elaborate gene regulatory networks are only some of the manifestations of this
progressive regulatory complexity [5, 8].
Gene regulation encompasses a range of mechanisms that can act at different levels of gene
expression, including the initiation and rate of gene transcription, post-transcriptional process-
ing and stability control of the RNA molecules, translation, post-translational modifications
and stability of a synthesized protein [9].
Transcriptional regulation, in particular, is considered to be the most fundamental and fre-
quent level in regulating gene expression [10, 9]. It is orchestrated by chromatin features,
transcription factors, and other proteins working in concert to finely tune the amount of
RNA being produced through a variety of mechanisms. Besides the various transcriptional
regulatory proteins, additional factors, such as the organisation of DNA into chromatin, its
modifications and structures, represent further levels of complexity to the transcriptional
control [11].
4 Chapter 1
This thesis focuses on the study of mechanisms of transcriptional regulation.
1.2 Transcriptional regulation
In eukaryotes, transcription mainly takes place in the nucleus of the cells, where DNA is -at
a first level- packaged into chromatin shaping core structural units called nucleosomes, and
further organised into higher level chromatin structures. The process of transcription includes
three main phases: transcription initiation, elongation of RNA and termination. The newly
synthesized RNA molecule can undergo further processing until it is used as a template
for protein synthesis or to serve some other cellular function. Different types of RNA can
be generated, including messenger RNA (mRNA), which is then used for the assembly of
peptide sequences for proteins, transfer RNA (tRNA) and ribosomal RNA (rRNA), which
are involved in the translation process, long non-coding RNA (lncRNA) molecules, as well
as several classes of small non-coding RNA molecules that play various roles in modulating
gene expression.
Transcription is regulated by a variety of mechanisms. These mechanisms involve a number
of proteins that interact with specific regulatory DNA sequences and additional co-factor
proteins, but they are also a function of the elaborate structure and packaging of DNA in the
nucleus. Therefore, regulation of transcription involves information that is stored in the DNA
sequence itself, specifically in cis-regulatory elements and in genes that encode trans factors,
but also on top of the DNA sequence as epigenomic information. Epigenomic features are
fostered through various mechanisms, such as DNA methylation, post-translational histone
modifications, nucleosome positioning, and higher-order chromatin structures, small RNA-
mediated regulation, and RNA editing [12].
Below I am presenting basic transcriptional procedures, as well as features of the genome
and epigenome that constitute important checkpoints of transcriptional control. I start with
transcription initiation, RNA Pol II and regulatory elements (section 1.2.1), transcription
factors and their regulatory functions (section 1.2.2), as well as the genome organisation into
chromatin (section 1.2.3) and into higher-order structures (1.2.4), which also have a powerful
interplay with transcriptional regulation.
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1.2.1 Transcription initiation and cis-regulatory elements
Transcription initiation, RNA Pol II and promoters
Transcription is performed by polymerase, an enzyme that uses as a template the sequence
of DNA nucleotides to add one-by-one the complementary RNA nucleotides to a growing
RNA strand. In eukaryotes, there are three types of RNA polymerases in the nucleus, each of
which specialises in transcription resulting in different types of RNA. RNA polymerase I
(RNAPI, or RNA Pol I) catalyses the transcription of ribosomal RNA (rRNA) genes, while
RNA polymerase II (RNAPII, or RNA Pol II) transcribes all protein coding genes and some
non-coding RNAs (e.g. snRNAs, siRNAs, miRNAs or lnc RNAs), and RNA polymerase III
(RNAPIII) is responsible for the transcription of transfer RNAs (tRNAs) genes and small
non-coding RNAs, such as 5S rRNA, U6 snRNA, SRP RNA [9]. Each polymerase needs
a specified DNA sequence, called promoter and a particular set of proteins to initiate gene
transcription.
Initiation of transcription is considered a crucial step in transcriptional regulation. It starts
with the recruitment of RNA Pol II at the gene promoter region, which together with other
proteins, the general transcription factors (GTFs; TFIIA, TFIIB, TFIID, TFIIE, TFIIF and
TFIIH), form the pre-initiation complex (PIC) [13, 14]. Specifically, first TFIID binds to the
promoter and it then mediates recruitment of RNA Pol II, which is followed by PIC assembly.
This is facilitated by a carboxyl terminal domain (CTD) in one of the RNA Pol II subunits
that is rich in serine residues. When these residues are phosphorylated, the CTD can bind to
and bring together different proteins that will assemble the PIC. Subsequent modifications
of the CTD peptides throughout the transcription cycle will modulate the activity of RNA
Pol II and its binding to other factors, as required, to facilitate elongation and termination of
transcription, as well as provide the link to post-transcriptional processing [15]. Transcription
ends when the RNA Polymerase encounters a sequence called terminator.
The promoter is the region upstream of the gene that harbours regulatory sequences, which
can modulate gene transcription. A prerequisite for transcription initiation is for RNA Pol
II to specifically bind to the core promoter (Fig. 1.1), which includes the transcription start
site (TSS) at the 5’ end of the gene, and a ~100 base pair window around it. Core promoters
can also include short sequence motifs, such as the TATA box or the Initiator (Inr), that
are recognised and bound by the GTFs, which subsequently recruit RNA Pol II [14]. The
formation of the pre-initiation complex promotes the separation of the two strands in the
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Fig. 1.1 Transcription initiation at core promoters. Transcription initiates at core promot-
ers upon recruitment of RNA polymerase II (RNA Pol II) and general transcription factors
(GTFs) that assemble the pre-initiation complex (PIC). Transcription can be activated by
enhancers, typically distal regulatory elements, with the mediation of transcription factors
(TF), and cofactors (COF). (Figure adapted from Haberle and Stark [16])
helical DNA, facilitating RNA pol to start the synthesis of a new RNA chain [17].
Enhancers
The positioning of RNA Pol II at the TSS, although necessary, is usually not sufficient to
generate more than just low basal transcriptional activity [14]. Transcription can be enhanced
or repressed by distal, cis-acting regulatory elements, the enhancers (Fig. 1.1).
Enhancers are usually up to several hundreds of base pairs long and contain short sequence
motifs, called transcription factor binding sites, that are recognised and bound by transcrip-
tion factor (TF) proteins. A combination of TFs can bind at the enhancer regions, and in turn,
they can recruit additional cofactors, protein factors that might not be capable of binding to
DNA themselves but serve enzymatic functions important in transcriptional regulation, such
as post-translational modifications of histones (reviewed in 1.2.3) [18]. Transcriptional cofac-
tors are not required for basal transcription; they can be either activators or repressors, which
can respectively increase or decrease the transcription from the core promoters. Co-activators
can increase the transcriptional activity by enhancing the interaction of RNA Pol II with
the DNA or appropriately regulating the structure of the double-stranded DNA [19, 20], as
opposed to repressors, which prevent the binding of RNA Pol II to the promoter. Enhancers
can act on their target core promoters, usually irrespectively of their distance and orientation
[21, 22]. A number of studies provide evidence that sequence variation in enhancer regions
and their TF binding sites is associated with diseases [23].
Tissue-specific expression patterns are largely attributed to the function of enhancers, as most
enhancers have been shown to promote tissue-specific gene transcription. An example is
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lymphoid cell-specific gene expression, where the synthesis of immunoglobulins is enabled
via the association of an enhancer with Ig genes between J and C regions [9].
Other long-range regulatory elements are the insulators and silencers. These are also bound
by TFs and have repressive effects on gene transcription [24, 25].
1.2.2 Transcription Factors
Transcription factors are proteins that recognise and bind specific short DNA sequences, and
regulate transcription [26, 27]. TFs contain: a) a DNA-binding domain (DBD) that interacts
with specific DNA sequences [28, 29], and b) an activation domain (AD), which bears sites
where transcriptional coregulator proteins can bind [30]. It is possible for these two domains
to reside on different subunits of the transcription factor complex. Sometimes TFs may
also contain a signal-sensing domain (SSD) that can receive external signals, such as ligand
binding, and transmit them to the rest of the protein complex generating a cascade for up-
or down-regulation of genes. Overall, the ultimate function of TFs is to identify regulatory
signals in the DNA sequence and transmit them into the process of gene expression control,
as part of cellular functions and response to cellular environments.
DNA binding specificity as a function of DBDs, TF binding motifs, and combinatorial
binding
Interaction of TFs with their target sequences largely depends on the structural features of
their DNA-binding domains (DBDs). These features include conformations shaped by alpha
helices, beta sheets, or disordered regions [31]. Based on their DBDs, TFs are classified
into distinct groups and further into families [32, 27]. The largest fraction of the human and
mouse TF repertoires is composed of three TF families: C2H2 zinc-finger TFs, including the
CCCTC-binding factor (CTCF), homeodomain TFs and helix-loop-helix TFs [27, 33]. The
differences in the structural characteristics of DNA binding domains (DBD) between distinct
TF families are reflected to some extent in differentiation of their DNA binding specificities
and, sometimes, also in their functional specificities. For example, many TFs that contain
homeodomains are associated with developmental processes [32, 27]. On another note, the
use of more than one DBD can increase the TF’s recognition specificity. This can happen via
repetition of tandem DBDs in a single TF or dimerisation of TF proteins.
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Through its DNA binding domain (DBD) a TF can interact with specific DNA sequences
(sometimes referred to as response elements), which can occurr in cis-regulatory elements
and are associated with specific genes. The interaction of TFs with the nucleotide sequences
is the result of electrostatic and Van der Waals forces. Nevertheless, not all nucleotides in the
sequences are in direct interaction with the TF. As a result, the binding sites of TFs do not
include a specific unique sequence but rather a set of varying, yet closely related sequences,
with a varying binding affinity for the TF. These sets of short, specific DNA sequences where
TFs preferentially bind, namely TF binding motifs, are usually represented as position weight
matrices (PWMs). Generated from the alignment of the multiple motif sequences that bind a
TF, a PWM illustrates the probability of each of the four DNA nucleotides being present in
each position of the multiple sequence alignment [34].
Since the sequences that are bound by TFs can be variable to some extent, and given their
short length, TF binding sites can sometimes occur by chance in the genome. Nevertheless,
this does not mean that they will all bind TFs, at least not in a stable or functionally relevant
manner. Furthermore, the numerous TF binding sites existing in a genome are not all occu-
pied continuously by TFs. Other components, such as chromatin accessibility or cofactor
binding, can affect TF binding at those sites.
Another factor that affects DNA binding specificity is the synergistic activity of distinct TFs
through their combinatorial binding, either directly or indirectly, on certain genomic loci [35].
Combinatorial TF binding is also considered to contribute to the specificity and flexibility
required for orchestrating transcriptional regulation programmes in different tissues [5]. A
possible distinction in a TF’s functional role has been suggested based on whether it binds
alone or in a combinatorial manner with other TFs. A potential scenario proposes that
binding of a single TF might control more fundamental cellular transcription, as opposed to
its combinatorial binding with other TFs that might help establish or maintain tissue-specific
regulatory programs. Another hypothesis is that the more ubiquitous binding of a single TF
can set up a general regulatory pattern for certain genes, while its more specific combinatorial
binding can facilitate further fine-tuning of the expression patterns [27]. Several aspects of
the combinatorial TF binding phenomenon, though, still require a better understanding [35].
Transcriptional regulation through transcription factors (TFs) and TF regulation
In addition to direct recruitment of RNA Pol II at core promoters, the other main mechanism
through which mammalian TFs regulate transcription is the recruitment of cofactors, i.e.
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coactivators or corepressors [36]. Cofactors in turn contribute to transcriptional regulation
through different mechanisms. A commonly used mechanism for activating transcription
of various genes is the recruitment of the Mediator complex, a coactivator that mediates
interaction between the TFs and RNA Pol II [37, 38]. Other cofactors include domains
that catalyse modifications of RNA Pol II or modification of other TFs. Moreover, some
cofactors are involved in remodelling nucleosomes and catalysing histone modifications
[39], therefore having an impact on increasing or decreasing chromatin accessibility to the
transcriptional machinery (nucleosome structures and histone modifications are reviewed
in section 1.2.3). Finally, another way TFs can interfere with gene transcription is simply
by occupying genomic sites, thus excluding RNA Pol II or other proteins from the region
[40]. Importantly, many TFs bind cooperatively to specific sites in individual enhancers and
mediate their physical interaction with distal promoters, which can also accommodate TF
binding sites. Such TF-mediated promoter-enhancer interactions are facilitated through the
formation of DNA loops and can regulate transcription of proximal or distant genes.
However, how are TF coding genes themselves regulated? One way of regulating TF gene
expression is via negative feedback looping, where the TF protein -upon reaching a certain
concentration threshold in the cell- can bind to its own gene body and prevent further tran-
scription [41]. Alternatively, the function of TFs synthesized via translation in the cytoplasm
can depend on binding a ligand that will help them translocate to the nucleus where they can
exert their gene regulatory activity. This ligand binding step, or the lack thereof, can act as
a regulatory point of their activity [42]. Another regulation mechanism is TF activation or
deactivation through phosphorylation of the TF or activation through ligand binding to the
signal-sensing domain of the TF. Furthermore, an important factor that can affect TF activity
is also chromatin accessibility, which facilitates binding of TFs to their target sites and is
controlled by nucleosome positioning and histone modifications, or methylation of CpG sites
(reviewed in section 1.2.3). Finally, the function of a TF often depends on the availability
of cofactors or other TFs with which the given TF can co-bind or interact to regulate the
transcription of target genes in a synergistic manner.
Biological roles of TFs
Functionally, transcription factors can be divided into those involved in basal transcription
and those responsible for differential enhancement or repression of transcription to establish
or maintain certain temporal and spatial expression programmes in different cells. The
former include the GTFs, while the latter involve numerous TFs that serve a variety of
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biological roles. One of these roles is regulation of the cell cycle [43] via control of cell
growth and apoptosis by tumour suppressor or proto-oncogene TFs [43, 44], such as the Myc
oncogene. Other TFs have important roles in cell differentiation and organ morphogenesis
during development, through response to cellular stimuli; a well known example is the Hox
TF family with roles in body pattern formation at embryonic stages [45]. Importantly, TFs
also have important roles in cellular responses to endogenous stimuli, for instance hormone
release, and environmental stimuli, such as oxygen concentration, as downstream effectors of
signalling cascades. A particularly important functional role of TFs in downstream signalling
cascades is in immune response [46]. Finally, it has been shown that TFs are also capable of
inducing de-differentiation or transdifferentiation, i.e. reprogramming of a differentiated cell
into a pluripotent cell or another cell type [47].
TFs in establishment of cell type-specific regulation programmes
The ensemble of TFs that are active in any given cell type regulates transcriptional activation
or repression of specific gene sets, defining the cell type-specific expression repertoire. It
is generally suggested that the set of TFs involved in setting up and maintaining distinct
cellular expression programmes include quite a limited number of TFs. These TFs are
often referred to as master transcriptional regulators and in some cases, when they are
ectopically expressed in other cell types, they are capable of reprogramming cell identity
[48–59], (reviewed in Lee and Young [60]). Examples of known master regulators that dictate
cell fate determination during development and maintenance of tissue-specific expression
programmes in adult vertebrate organs are: the hepatocyte nuclear factor 4a (HNF4A) in
liver, the myoblast determination protein 1 (MYOD1) in muscle, as well as the homeobox
protein NKX2-5 in heart. A number of studies have suggested that the contribution of master
TFs to regulating cell expression programmes is often through transcription elongation of
cell type-specific genes (examples are provided by Bai et al., Park et al., Oven et al. [61–63]).
An alternative view of expression differences between cells underlines the role of gene
regulatory networks (GRNs) in establishing and maintaining cell type-specific expression,
considering the concept of “master” regulators as oversimplified – but not mutually exclusive.
According to this view, and in contrast to the master regulators scenario, the concept of
GRNs takes into consideration the synergy and cooperativity of TFs and context-dependent
activity in transcriptional control, pointing out that no single TF can regulate transcription
of its target genes alone [46]. As an example in support of this viewpoint, the myogenic
transcriptional regulator (MyoD), known to be capable of regulating transdifferentiation
of multiple mammalian cell types into muscle cells when expressed ectopically [64], was
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shown to in fact be part of a GRN that includes a number of TFs with potential in inducing
transdifferentiation [46].
Tissue-specific gene expression patterns are largely conserved among mammalian species
[65, 66], which implies that tissue-specific regulatory networks must also be under high evo-
lutionary constraints, probably as a means to safeguard the functional specialisation of organs.
Evolution of TFs, TF binding sites, and regulatory networks
Increase of organismal complexity is, to a large extent, associated with the evolution of
highly complex gene regulatory networks, including increased complexity of TF repertoires
and their employment in gene regulatory mechanisms.
It has been suggested that evolution of the eukaryotic lineage has been underlined by bursts
of acquisition and expansion of TF families [5, 67]. There are a few TF classes, for example
those involved in the basal transcription machinery such as the TATA box-binding protein
(TBP or TFIIB), that originated in pre-eukaryotic taxa [68, 69]. However, most TFs in eu-
karyotes have originated in the lineage of the last eukaryotic common ancestor (LECA). This
burst likely coincided with structural innovation in the eukaryotic nucleus and organisation of
the genome in the form of chromatin [67]. More TF classes emerged after the LECA within
different eukaryotic lineages, especially in plant and animal lineages, boosting the potential
of cells for developing complex regulatory networks [67]. The major mechanisms mediating
expansion of TF classes are gene duplications that resulted in large TF gene families, often
with new domains [70, 71], and exaptation of transposable elements (TEs), such as in the
case of the MUSTANG and FAR/FHY TF families in plants [72–75]. Finally, emergence
of new TF classes via de novo gene birth might be another possible, although much less
widespread mechanism [67].
Despite these innovations in TF expansion throughout the evolution of eukaryotes, TFs gen-
erally evolve much slower than their regulatory sites [35]. Many TFs are largely conserved
from Drosophila to human, even displaying highly similar sequence specificities as well
as highly conserved physiological roles. One such example is the HOX family of TFs that
contribute to body pattern formation during development [45, 35].
However, notwithstanding their functional constrains, the binding sites of the TFs are usually
not as conserved, especially within the mammalian lineage. For example, OCT4 and NANOG
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TFs display remarkable functional conservation between human and mouse, which, however,
is not analogous with the conservation of their binding sites. It has been particularly shown
that even though binding of OCT4 and NANOG is enriched around OCT4 target genes
(genes downregulated upon OCT4 depletion) in both human and mouse, the exact location
of their binding sites is largely nonconserved (reviewed in Villar et al. [76]). Similarly,
CEBPA binding has also been shown to be highly variable among vertebrate species [77].
However, in this and other cases, it has been demonstrated that there is an extensive trend of
turnover events, i.e. losses of TF binding sites and emergence of compensatory events nearby,
especially among different mammalian species. Even over short evolutionary distances,
binding of TFs exhibits large extent of variation among mammalian species. For example, a
study on the binding of three liver-specific TFs (CEBPA, HNF3A that is encoded by Foxa1,
and HNF4A) in closely related mouse species has shown substantial diversification of the
binding events in orthologous regions among the mouse species [78]. The prevalence of
such compensatory events suggests their role in maintaining expression outputs throughout
evolution, while their evolution might be in line with the evolution of combinatorial binding
of different TFs (reviewed in Villar et al. 2014 [76]). Combinatorial binding of TFs must
be evolving in clusters of binding sites in the same vicinity that is co-bound by different
TFs. Also, there is a correlation between binding strength and cross-species conservation. It
is noted that in other taxa, such as in insects as seen by studies in Drosophila spp., the TF
binding profiles are more conserved across species, compared to mammals.
An emerging question is whether variation in TF binding events across species is reflected
in variation of the underlying binding sequences. Villar et al. provide a review of relevant
studies, and summarise that there is no clear association between TF binding alterations and
sequence divergence among species [76]. This means that although a relatively restricted
amount of TF binding changes is underlined by differences in the respective bound sequences,
most TF binding differences are not associated with any change in the proximal genetic
sequences. Nevertheless, they point out that the combination of the whole sum of regulatory
sequences that exert their function in concert can be driving TF binding divergence. In
some cases, a change of TF binding in absence of nucleotide substitutions in its binding
motif sequence can be associated with sequence changes in other proximal TF binding motifs.
In any case, nucleotide substitutions in sequences that bind TFs can lead to degeneration
of binding and loss of binding sites, but it is not likely for single substitutions to generate
de novo binding sites. A widespread mechanism for acquisition of new binding sites, espe-
cially in mammalian lineages, is via expansion of different classes of transposable elements
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Fig. 1.2 Evolutionary mechanisms of TF binding divergence. Birth of a TF binding event
driven by: a) changes in the underlying sequence (efficient mostly in cases of birth of short
binding motifs), b) expansion of transposable elements that deposit motif sequences at
genomic sites, c) employment of ancient repetitive sequences, following sequence changes
that increase binding affinity for the TF. Figure adapted from Villar et al. [76]
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(TEs). Repeat elements might deposit short sequences with TF binding potential upon their
insertion in mammalian genomes (Fig. 1.2). Alternatively, existing degenerate sequences in
ancient repeats can at some point be repurposed by the genome and employed as a regulatory
sequence in different regulatory networks (Fig. 1.2).
Overall, changes in TF binding, either as a result of sequence alteration or not, can be driven
either by purifying and positive selection, but also be the effect of neutral evolution, mediated
by genetic drift. Importantly, evolution of TFs is associated with evolution of gene regulatory
networks (GRNs), which in turn can be the driving forces of phenotypic diversity.
Implications of TFs in mutagenesis and disease
Disruption of the regulatory function of TFs has been linked to many disease phenotypes,
including developmental disorders and cancer. Boyadjiev and Jabs reported in 2000 [79]
that one third of developmental disorders in humans are associated with mutations in genes
that encode TFs. Moreover, a large subset of tumour suppressors and oncogenes are TFs,
whose dysregulated expression can have major implications in various cancer types [44, 80].
These misregulations are attributed to mutations within or near TF genes. However, more
recent studies are also revealing a role for mutagenic processes in the binding sites of TFs in
inducing development of tumours and other disorders (for examples see Zhou et al., Mazrooei
et al. [81, 82]). It is, therefore, not surprising that TFs are of clinical significance, as they
make up existing or potential drug targets in cancer therapies.
TF binding effect on mutational landscape
Elevated mutation rates in TF binding sites is a common phenomenon in various cancer types
[83–88]). This increase of mutation rates is attributed to reduced accessibility of the DNA
repair machinery to the underlying TF bound sequences.
How do these mutations occur? It is known that, as all genomes are exposed to environmen-
tal or endogenous agents, DNA can get damaged. DNA damage is manifested as lesions,
i.e. chemical alterations primarily at the nitrogenous bases, or alternatively at the sugar-
phosphodiester backbone of DNA nucleotides [89]. The occurrence of unrepaired lesions
can interfere with the process of DNA replication, which can result in the fixation of genomic
mutations during synthesis of a new DNA strand. Unrepaired lesions can also be encountered
by the transcription machinery and thus hinder the transcription process/transcriptional elon-
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gation. Luckily, the cell is equipped with repair mechanisms that can deal with and resolve
lesions. Mammals, in particular, recruit the nucleotide excision repair mechanism (NER).
NER is a pathway that includes two sub-pathways, the global genome NER (GG-NER, or
GGR) that deals with lesions throughout the whole genome and the transcription coupled
NER (TC-NER, or TCR), or transcription coupled repair (TCR), that resolves lesions in
actively transcribed genomic regions [90].
Sabarinathan et al. [84] have shown that both GGR and TCR enzymes have impaired access
and activity at sequences that are occupied by bound TFs. Potential unresolved lesions in
these sequences are therefore fixed into permanent mutations. As a consequence of the
inefficient local DNA repair, TF bound sites exhibit a peak in their mutation load compared
to the surrounding sequences. Similar to the bound TFs, the mutation rate in the flanking
sequences also shows some periodicity, which is attributed to the nucleosomal structures
hindering the access and action of repair enzymes to some extent (Fig. 1.3) [84].
Fig. 1.3 Mutation rate distribution is affected by TF binding and nucleosome posi-
tioning that impede access of the nucleotide excision repair (NER) machinery at the
underlying nucleotide sequence. Figure adapted from Sabarinathan et al. [84]
Global genome repair and transcription coupled repair mechanisms
The main difference between the two sub-pathways is the initiating step of lesion recogni-
tion and employment of the repair machinery. In eukaryotes, the initiating step of lesion
recognition in GG-NER requires the coordinated employment of XPC and UV-DDB proteins
[91–93]. In contrast, employment of TC-NER does not involve XPC and UV-DDB but seems
to initiate with the stalling of the transcribing RNA Pol II when it encounters a lesion in the
template DNA strand. Transcription elongation is hindered as RNA Pol II gets physically
blocked from further translocation along the template strand, and it recruits the repair ma-
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chinery [94]. However, if the lesion resides on the non-template strand, it will typically be
recognised and repaired by the GG-NER mechanism. This is measurable as a difference in
the speed of lesion repairs between template and non-template strands, making the repair on
the template strand appear faster [95].
After the lesion recognition step, the two different sub-pathways converge to using the same
mechanism. In brief, this includes recruitment of TFIIH and the XPA protein that will
stabilise TFIIH at the genomic site, and leads to the verification of the damaged strand.
TFIIH can then further “open” the damaged DNA strand [96] to facilitate the repair ma-
chinery’s access to the region. The endonucleases excision repair cross complementing-1
(XPF-ERCC1) and XPG incise the damaged strand segment at its 5’ and 3’ ends, causing
the excision of a ~25-30 nucleotide long segment. The DNA replication machinery is then
recruited, and its DNA polymerase components catalyse the synthesis of a short strand that
will be incorporated in the DNA molecule by DNA ligases to replace the excised segment
[97–100].
1.2.3 Chromatin architecture: small-scale organisation of the genome
and epigenome
At its most basic level the first-order structure of DNA, i.e. its nucleotide sequence, encodes
information for residue-by residue synthesis of proteins. At a further level though, the local
nucleotide composition of DNA sequences is a substrate for certain structural properties of
the DNA molecule, which can affect important molecular functions, such as the accessibility
of DNA to transcription factors and RNA Polymerase.
For example, poly-A strands of DNA have been shown to be more rigid [101], while AT-rich
DNA sequences are known to provide a higher local flexibility to genomic segments. These
structural properties can affect nucleosome positioning and the accessibility of chromatin to
transcriptional proteins [102], which in turn affect the rate of transcription. In addition, the
nucleotide cytosine can be converted to 5-methylcytosine (5mC), or 5-hydroxymethylcytosine
(5hmC) via methylation or hydroxymethylation, respectively, a property that makes up an
important epigenetic level of information that largely affects transcriptional control.
Beyond the nucleotide composition of the DNA sequence itself, described above, the pack-
aging of the eukaryotic genome in the form of chromatin is itself an important level of
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transcriptional control. Chromatin consists of DNA, proteins and RNA. Generally, transcrip-
tion of genes is facilitated/higher at regions where chromatin is less condensed, thus more
accessible to certain protein factors. The level of chromatin compaction is associated to
covalent modifications of histone tails and DNA.
DNA methylation
Cytosine methylation is catalysed by the enzyme family of DNA methyltransferases (DN-
MTs) which covalently add a methyl group to the fifth carbon of cytosine. In mammalian
genomes CpGs are relatively sparse and a large fraction of them, ~70-80%, are methylated
[103]. Cytosine is typically methylated in the context of CG dinucleotides (CpG), which
occur with a high frequency in short DNA sequences, namely CpG islands (CGI) [104].
However, despite its pervasiveness, mammalian CpG methylation is considered to have
different functional impacts on different genomic regions.
Typically, open chromatin regions are accessible to transcription factor binding, are more tran-
scriptionally active and display low levels of DNA methylation [105]. In contrast, high levels
of CpG methylation -which also have a reported role in heterochromatin formation [106]-
are associated with decrease or loss of transcriptional activity, due to the local occupancy
of methylated DNA by methylcytosine binding proteins. As a consequence transcription
factors, such as the CCCTC-binding factor (CTCF), and other proteins do not have access
in the methylated regions and are prevented from interacting with their specialised binding
sites [107, 108]. So, there have been reports of decreased binding of particular TFs to
their corresponding binding sites on the genome when they are highly methylated [109].
Impediment of TF binding and subsequent transcription activation by DNA methylation
is a regulatory mechanism in the promoters of genes, which often occur in CGI regions.
Nevertheless, CGI promoter methylation is not common, and promoter inactivation is usually
mediated through a histone modification, H3K27me3 (explained in the following section),
which is a more easily reversible form of transcription repression than CpG methylation [110].
It is important to note that, despite the generalised statement that TFs are excluded from
CpG methylated sites, emerging evidence suggests that there are cases of TFs, especially in
development, that do bind to methylated sequences [109, 111].
Seemingly contrary to the silencing role of DNA methylation in promoters, gene bodies are
often enriched in DNA methylation but positively correlated with transcriptional activity,
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especially nucleosome associated genic segments that are exon-rich, [112–114]. Proposed
explanations of this phenomenon are that DNA methylation within the gene bodies might
play a role in transcription elongation and mRNA splicing, or that it is involved in repression
of alternative cryptic promoters that may lie within the gene [115].
DNA methylation has been shown to play essential roles in transcriptional repression of
transposable elements, the monoallelic expression patterns of specific-parent-origin imprinted
genes, and the inactivation of the X chromosome [116].
Nucleosome positioning and histone modifications
Besides DNA methylation, chromatin accessibility is also modulated by nucleosome posi-
tioning and post translational modifications of the nucleosome histones. These are both key
components of chromatin architecture, which not only pack the ~2m long DNA in the cell
nucleus, is a primary component of its functional organisation with implications in regulating
selective access to its regulatory regions by regulatory factors of transcription [117, 118].
Chromatin organisation changes dynamically during the cell cycle phases, super-coiling the
DNA into coerced chromosomes during mitosis to facilitate the division of the chromosome
copies into the daughter cells, while getting a loose but complex distribution during the
interphase to allow for the regulated transcription of genes, as well as DNA recognition and
repair.
The nucleosome is the structural unit of chromatin organisation. The double-helical DNA
wraps around octamers of histone proteins to form nucleosomes. A nucleosome typically
includes ~147bp of DNA sequence, with up to ~90bp long linker DNA segments bridging
the nucleosomes, and the histone octamers include a dimer of each of the histone proteins
H2A, H2B, H3, and H4 [119, 120]. Each histone has an amino-terminal end, overhanging
from the nucleosome, that can undergo various post-transcriptional modifications (PTMs),
the most important and well-studied of which are methylation, acetylation, phosphorylation
and ubiquitylation [121]. The different types of histone modifications affect the way histones
interact with the nucleosome DNA and can be either positively or negatively correlated
with transcriptional activation, although transcriptional regulation is usually not exclusively
dependent upon a single histone PTM type. Acetylation on the lysine residues (K) of the
amino-terminal histone tails reduces the positive charges of the tails and decreases their bind-
ing affinity to DNA, which is negatively charged, resulting in looseness of the nucleosome
1.2 Transcriptional regulation 19
structure and local increase of chromatin accessibility [9]. Methylation of lysines in histone
tails can either increase or decrease the affinity between histones and DNA depending on
the lysine residue that is subject to the modification and the number of methyl groups added
to it. For example, core promoters of transcriptionally active genes are typically enriched
for H3K4me3 and H3K27ac, while active enhancers are associated with H3K4me1 and
H3K27ac. Within gene bodies, active transcription is associated with H3K36me3, while
transcriptional repression is paired with H3K9me3 or H3K27me3 [122]. H3K9me3 is also
involved in repair of double-strand breaks of DNA during homologous recombination, by
increasing local accessibility to repair enzymes [123].
The positioning of nucleosomes also has implications in transcription regulation. Specifi-
cally, accessibility of genomic regions to specific proteins can be modulated by nucleosome
remodelling or repositioning. This is performed by chromatin remodelling complexes that
can rotate the double helix of DNA around the nucleosomes to unwind TF binding sites, as
well as displace or slide nucleosomes along the chromatin structure to allow the interaction
of TFs with regulatory sequences around gene TSSs [124–126].
1.2.4 Higher-order chromatin structure
Eukaryotic genomes are organised in a refined three-dimensional conformation comprising
distinct structural layers, which associate with important regulatory functions, and range
across various scales [127–130]). These include chromatin loops, topologically associating
domains (TADs), compartmental domains and chromosome territories [131–135]. These
structural formations organise the regulatory information in distinct regulatory landscapes,
which promote specific interactions of regulatory elements and disable others [136–138].
Querying the characteristics of this structure has become easier and more accurate with
the advent of 3C-based (Chromosome-Conformation-Capture) techniques, especially with
Hi-C [131, 139]. Although the 3D genome structure has been thought of as a determinant of
genomic interactions, and by extension of transcriptional regulation, newer research shows it
can also be the result of functional components of chromatin and transcription [140].
Below, I will describe the traditional hierarchical layers of 3D genome structure (Fig. 1.4)
from lower to higher scales. In addition, I will provide further details for some of their
important architectural proteins components, such as CTCF and cohesin. Finally, I will
refer to open questions about the mechanisms of 3D genome structure formation, as well
as to a recent proposal for a revision of the hierarchical model towards the adoption of a
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non-hierarchical model.
Fig. 1.4 Three dimensional genome organisation presented as a hierarchical model. The
panel shows a cartoon version of a Hi-C contact map of relatively low resolution. a) At the
multi-megabase scale the geenome is organised into A and B compartments (respectively red
and blue). b) At the sub-megabase scale the genome is organised in topologically associating
domains (TADs), which further contain smaller sub-TADs and frequently coincide with
loops between interacting CTCF sites with convergent orientation; CTCF loops are identified
as strong punctate signals. c) A TAD that coincides with a CTCF loop and contains two
sub-TADs (Figure adapted from Rowley and Corces [140])
Chromatin loops
As explained in the previous sections, enhancers are essential players in transcriptional
control, as they bind TFs and interact with promoters to regulate the expression of specific
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genes. In a similar way, insulators can also act on gene promoters to block an enhancer’s
activity [21, 141, 142]. However, it is known that interacting cis-regulatory elements can
be located thousands of bases apart on the linear genome. Their interaction, which has an
effect on the transcriptional output, is enabled through the formation of chromatin loops
that bring these distal regulatory elements in close proximity in the 3D space of the nucleus
[143–145, 134], and the mediation of the transcription factors that are bound to them (Fig.
1.5). As an extension to an individual loop, more complex chromatin loop structures can be
formed when multiple genomic contacts occur simultaneously. Such structures/conformations
have been referred to as active chromatin hubs (ACH) (reviewed by Pombo and Dillon [146]).
Fig. 1.5 TF-bound enhancer promoting transcription initiation at a core promoter via
the formation of a chromatin loop. Left: Assembly of pre-initiation complex (PIC) and
recruitment of RNA Pol II at a core promoter. Right: Enhancer promoting PIC assembly
and RNA Pol II placement at a core promoter via recruiting transcription factors (TFs) and
cofactors (COFs) and upon chromatin looping. Figure adapted from Haberle and Stark [16]
In the human genome almost 10,000 loops have been identified, with many of them sharing
the same boundaries, or so-called loop anchors. The majority of loop anchor loci, i.e. the
distant genomic loci that interact, are less than 2Mb apart [134]. Moreover, a number of
loops are also shared between cell types, while others are cell type-specific. Genes whose
promoters are anchored by a loop display generally higher expression levels than genes not
associated with loops. By extension, cell type-specific loops were suggested to be associated
with expression differences between cell types [134]. Generally, chromatin loops are dynamic
and can differ among the cells of a population.
Rao et al. [134] also reported that 86% loops in the human genome are anchored by the
CCCTC-binding factor (CTCF) and/or cohesin. Indeed, CTCF together with cohesin have
been identified as essential factors in promoting interactions between distal genomic loci
[147–149]. The majority of CTCF-anchored loops -92% based on a Hi-C experiment and
65% based on ChIA-PET data- have been reportedly shaped by pairs of CTCF binding motifs
with convergent orientations, i.e. pointing to each other [134, 150] (see more details on
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CTCF motifs in the following section). Indeed, CRISPR -mediated inversion of a CTCF
binding motif was shown to cause ectopic loop formation and introduction of new interactions
between regulatory elements [151].
CTCF and cohesin
Cohesin
Cohesin is a protein complex with a ring-like structure and is made up of the subunits, SMC1,
SMC3, SCC3 and RAD21/SCC1 [152–154]. It is known to be involved in sister chromatid
cohesion for chromosome segregation, homologous recombination and DNA damage repair
action. As a function of its shape, cohesin can entrap two chromatin segments in cis resulting
in the formation of a chromatin loop. It has been shown to establish or maintain chromatin
loops between cis-regulatory elements and facilitate the binding of TFs at enhancer regions
[37, 155]. Cohesin-occupied sites on the genome largely colocalise with CTCF binding sites
[156], reflecting also their joined contribution to establishing three-dimensional genome
structures.
CTCF
CTCF is an 11 zinc-finger transcription factor that contains a deeply conserved DNA-binding
domain (DBD), from Drosophila to human [157–159] (Fig. 1.6a). In mammals, this DBD is
flanked by two loosely structured tails: an amino- and a carboxyl- terminal end [160, 161].
CTCF is ubiquitously expressed in all cell types. Initially, it was identified as a repressor of
the C-MYC oncogene [162, 159]. It was long considered just as an insulator protein, bind-
ing to insulators between pairs of enhancers and genes and thus blocking gene expression
[163]. However, numerous studies over the last decades have shown that it is an unusual
transcription factor with multiple biological roles, including promoting interactions between
regulatory elements, activating or suppressing genes, importantly contributing to gene im-
printing during development and X chromosome inactivation. One of its most important
properties is facilitating chromatin loop formation together with cohesin, explaining its
common characterisation as an architectural protein. As described above this property of
CTCF is essential in establishing and maintaining higher order genome structures, such as
TADs and compartments.
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CTCF preferentially binds to a 19 bp long primary motif (Fig. 1.6b), or sometimes to an
extended 40bp-long sequence, including its primary motif and shorter secondary ones [164].
Upon binding, it can bend the double helix of DNA in different ways [165]. It has been
demonstrated that only four out of the eleven Zn-fingers of its DNA binding domain are
essential for CTCF binding to the core 12 nucleotides of its primary motif [158]. Its ability
to bind chromatin is greatly affected by local CpG methylation, as CTCF preferentially binds
to hypomethylated regions [166].
Fig. 1.6 Structure of CTCF domains and CTCF binding motif. a)N-terminus domain,
DNA binding domain with eleven zinc fingers, and C-terminal domain. Figure adapted
from Arzate-Mejia et al. [167]. b) Position weight matrix (PWM) of CTCF binding motif
(MA0139.1), derived from JASPAR database [168]
High throughput interrogation of mammalian genomes via chromatin immunoprecipitation
has revealed the approximately 40,000–90,000 sites that bind CTCF, with the exact number
depending on antibody specificity and the computational parameters used in binding site
identification. About 30-60% of these sites are cell-type specific with around half of them
being in intergenic regions and half in promoter elements [169, 156, 170–173]. It has been
reported that during transcription, RNA Pol II can dislocate CTCF molecules from their
binding sites [174].
Cross-species comparisons of vertebrate CTCF binding profiles have shown that CTCF
binding sites are conserved to a greater extent among mammalian species, compared to
other, tissue-specific TFs [77, 175, 164, 76]. Different lines of evidence, especially but not
limited to studies in rodent species, support that a major evolutionary mechanism of CTCF
binding site expansion has been through insertion waves of transposable element families
that carried and deposited potential CTCF-binding sequences, which were then exapted by
the mammalian genomes [176, 175, 164, 177]. The relatively high species-conservation level
of CTCF binding profiles likely reflects the multitude of CTCF biological functions, which
might also be conserved to some extent, as well as its importance in organizing regulatory
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landscapes on chromatin.
CTCF can form homodimers or heterodimers, by physically interacting with other CTCF
molecules [148, 147, 178], cohesin or other proteins, respectively. A recent study has shown
that CTCF also contains an internal RNA binding region (“RBRi”), which can often be
utilised for RNA-mediated interaction between separate CTCF molecules that can come
together and form small CTCF hubs, i.e. CTCF protein clusters [179]. Among CTCF
anchored loops, some are RBRi-dependent, i.e. disappear upon RBRi-deletion from the
CTCF molecules [179], and some are RBRi-independent. Dysregulation of CTCF or its
binding is also known to be implicated in the emergence of diseases, such as developmental
and neurological disorders, immune disorders, and cancer. Interestingly, CTCF, as well as
cohesin subunits genes display some of the highest mutation rates in various cancer types
[180, 181].
Topologically associating domains
A number of studies have reported partitioning of the eukaryotic genome at a sub-megabase
scale into topologically associating domains (TADs) [133, 135, 182], referred to also as
topological domains [133], physical domains [182] or contact domains [134]. These regions,
ranging from tens to hundreds of kilobases in length, are characterised by high frequency
of self-interactions, while little or no interaction is observed between neighbouring regions.
This means that a genomic locus within a TAD is more likely to interact with another genomic
locus of the same TAD, rather than loci outside of this domain. The fact that these contact
frequency patterns are not continuous, but rather appear as distinct genomic blocks, indicates
that TADs have certain boundaries and are insulated from neighbouring TADs [183] (Fig.
1.7). The fact that TADs have been identified in taxa as diverse as humans, mice and flies,
demonstrates that chromatin organisation in such structures is an evolutionarily conserved
genomic feature [183]. It has also been suggested that TADs are highly conserved across
species and cell-types [133, 184].
As a consequence of their structure, TADs modulate interactions between regulatory elements
and, thus, play a prominent role in transcriptional control (Fig. 1.8) [135, 186, 187, 146].
Studies have revealed cases where disruption of the boundaries of TADs can lead to ectopic
cis-regulatory contacts that cause diseases [188–190]. Altogether, these findings underline
the importance of establishment and maintenance of these chromatin structures.
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Fig. 1.7 Organisation of the genome into topologically associating domains (TADs).
Cartoon illustration of a)chromatin conformation in TAD organisation, in the cell nucleus,
and b) Hi-C heatmap of TADs that contain intra-TAD genomic contacts. Figure adapted from
van Steensel and Furlong [185].
Fig. 1.8 Regulatory landscapes as a function of TAD formation. Enhancers can, typically,
interact with gene promoters lying within the same TAD, and not in different TADs. Figure
adapted from Zabidi and Stark [191]
A question that has emerged with the first reports of genome organisation into TADs was
how these domain structures are formed, or more specifically, how their boundaries are
defined. Evidence from these first studies on TADs had already shown that their boundaries
are enriched for CTCF sites [133, 135], indicating an important role of this architectural
protein in TAD formation. The proposed mechanism of TAD formation is via loop extrusion:
the cohesin protein complex acts in cis on chromatin and slides on it forming a growing
loop, until it meets two bound CTCF motifs that have convergent orientations and prevent
cohesin from further sliding (Fig. 1.9) [192–195]. The apparent requirement of CTCF
sites to be convergently oriented is often referred to as the convergent rule. The combined
action of CTCF and cohesin maintain the TAD as a chromatin loop structure until these two
architectural proteins dissociate from DNA. This indicates the dynamic nature of both the
loop establishment via the extrusion mechanism and loop maintenance [193, 173, 128].
Role of cohesin and CTCF in TAD formation
The importance of CTCF and cohesin in forming and maintaining TADs is supported by
reports of major disruption of TAD organisation of the genome upon acute depletion of these
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Fig. 1.9 Overview of loop extrusion model. a-b)Structure of mammalian cohesin (a) and
CTCF (b). c) Illustration of loop extrusion mediated by cohesin and convergently oriented
CTCF sites. (d) Parameters that can constrain loop extrusion models in mouse embryonic
stem cells and human HeLa cells. Figure adapted from Hansen [179].
two proteins [196–200]. Specifically, Schwarzer and colleagues (2017) deleted the Nipbl
cohesin loading factor to achieve four-fold to six-fold decrease of the total amount of cellular
cohesin that is loaded on chromatin, and they reported clear disappearance of TAD structures
[198] even though the CTCF site occupancy was not affected. In consistency with these
findings, Rao and colleagues (2017) also observed disappearance of TAD loop structures
upon cohesin loss and re-formation of TADs after cohesin recovery [197]. Furthermore,
Gassler and colleagues (2017) reported substantial or entire loss of TADs and loops upon
genetic knockout of the SCC3 protein (which forms cohesin’s ring structure that extrudes
chromatin) in zygotes, while the cohesin unloading factor WAPL affected the length of
the loops [200]. In another study, Wutz and colleagues (2017) once more underlined the
necessity of cohesin for TAD and loop formation, based on effects observed upon auxin-
induced proteolysis of the cohesin subunit SCC1 [199]. In addition, they also degraded
CTCF using auxin and observed some effect on the TAD and loop structures, although
clearly weaker compared to the effect of cohesin depletion. In a separate study, Nora and
colleagues (2017) reported a rather strong effect of acute auxin-driven CTCF depletion
on TAD structures; they observed loss of contact insulation between TADs, although some
TAD boundaries remained visible on the contact maps even after the depletion of CTCF [196].
The vast majority (i.e. more than 90%) of identified cohesin-occupied genomic sites in
mammalian genomes have been found to co-localise with CTCF binding sites [156, 173, 201–
203](reviewed by Hansen [171]). Insight from other studies shows that CTCF is essential for
localising and stabilising cohesin at specific genomic sites for loop formation, but not for
loading cohesin onto chromatin [196, 201, 201, 204] (reviewed by Hansen [171]).
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Despite the firm indications of the important role of CTCF binding in TAD formation, several
details about its functional implication remain unresolved and obscure its exact role. As
described above, the acute depletion of CTCF does affect TAD boundary determination but
to variable degrees. It is also known that CTCF binding is so abundant in the genome that
only a small fraction (15%) of CTCF binding sites coincide with TAD boundaries, meaning
that CTCF binding alone is not enough to demarcate the boundaries of these self-associating
regions [133]. With respect to the so-called convergent rule, not all CTCF sites oriented in a
convergent manner demarcate TADs, and, vice versa, not all TAD boundaries are marked
by convergent CTCF sites [134, 205, 151, 150]. In fact, although most TADs apparently
are defined by CTCF loops, as shown by a number of studies that measured the degree
of interaction bias upstream or downstream of a genomic region [133] to computationally
predict TADs [206, 133, 135, 182, 207], a small number of them are not flanked by CTCF
binding sites [140]. Such non CTCF-dependent TADs have also been called ordinary do-
mains, suggested to be “passively” formed as a consequence of the formation of adjacent
CTCF-flanked TADs or transitions between active and inactive chromatin states [134]. Nev-
ertheless, the appearance of ordinary domains might be a result of the dynamic nature of
TADs in a population of relatively heterogeneous cells, rather than being a simple passively
appearing phenomenon [128].
Compartments
Chromatin is also organised into two compartments, A and B, defined as sets of chromoso-
mal regions with distinct biochemical features, which display long-range interactions with
regions from the same set more frequently than expected by the “random polymer confor-
mation of a chromosome” [131, 132, 183]. Compartments were defined for the first time as
multi-megabase-scale structures, based on Hi-C contact maps that revealed a plaid pattern of
long-range chromosomal interactions (Fig. 1.10) [131]. Importantly, compartments A and B
have been found to associate with distinct biochemical features of chromatin. Compartment
A regions are enriched in active histone marks, such as H3K36me3, are more gene rich and
associated with increased transcriptional activity, while they also contain some genes that
are silenced, and are more accessible to DNase I. They generally overlap the so-called open
chromatin regions, as opposed to regions in compartment B, which are less rich in genes,
associate with inactive chromatin marks and low transcription rates [131]. The genome
organisation into A and B compartments also reflects the segregation of chromosomes re-
spectively into euchromatin and heterochromatin [183].
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Fig. 1.10 Organisation of the genome into compartments. Cartoon illustration of a)
compartment organisation in the cell nucleus as a result of aggregation of regions with
similar biochemical and functional features. The main compartments are heterochromatin
and euchromatin, and b) Hi-C heatmap that shows self-association of euchromatin and
heterochromatin domains over long genomic distances. Figure adapted from van Steensel
and Furlong [185].
Revision of the “hierarchical” model of 3D genome organisation
As outlined above, the different structural layers of spatial chromatin organisation -mainly
TADs and compartments- have been identified as structures at different size scales. Due to
this difference in relative sizes, TADs and compartments have been “traditionally” viewed
as components of a nested hierarchical model of genome structure [208, 209]. This view
was based on the first reports identifying and characterising TADs [133] and compartments
[131] based on Hi-C data that generated contact maps of megabase resolution. Later stud-
ies that improved the sample sizes, sequencing depth and algorithms for computational
identification of these features, reported Hi-C-based contact maps of higher resolutions, for
example binning the human genome up to 1kb [134]. That resulted in the identification of
self-associating contact domains -i.e. TADs of smaller size than previously thought, just
a few kilobases long on average. Some studies also reported sub-divisions of TADs into
smaller sub-TADs [210, 134]. Similarly, combined PCA and Hi-C data-based contact maps
of resolution as high as 10kb have identified compartments of smaller size than initially
reported [211, 212]. Specifically, in Drosophila melanogaster A compartmental domains (i.e.
A compartment regions of small size, as a result of high resolution) were identified with a
median size of 15kb, which also corresponded to transcriptionally active chromatin domains
[211]. Furthermore, high-resolution Hi-C contact maps allowed the identification of more
sets of chromosomal regions based on their epigenome marks and their interaction patterns
with each other, leading to the characterisation of six sub-compartments, rather than just
two major compartments: subcompartments A1 and A2 with mostly active histone marks,
and subcompartments B1, B2, B3 and B4 with features matching those of heterochromatin
[134]. These findings imply an apparent increase of the number and decrease of the size
of identified TADs, as well as of compartment types and regions, as the resolution of the
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contact maps increases [134, 213, 214, 183]. This shows that the characterisation of distinct
structural components based on their appearance on contact maps can be fluid and dependent
on the experimental and technical parameters, such as the sample size, the sequencing depth,
the experimental methods and algorithms used to identify and report them.
Another important aspect to account for is that the state of CTCF binding, cohesin sta-
bilisation on chromatin and the three-dimensional genomic structures are not static, but
rather dynamic features of the genome. They all re-model during the cell cycle, interplaying
with other dynamic molecular processes, such as chromatin accessibility and transcriptional
regulation [215, 216, 128, 217]. In addition, both the ChIP-seq profiles and the Hi-C maps
we obtain using the respective experimental methods represent only snapshots of the genome
state in the nuclei of populations of variable cells at a given time point.
Reviewing these aspects of chromatin organisation, Rowley and Corces propose the consider-
ation of the 3D genome more as a dynamic balance between compartmental domains and
CTCF loops and their functions, rather than a hierarchical structure model [140]. In another
review with respect specifically to TADs, Elzo de Wit suggests that “a more constructive path
will be to explain TADs in the light of the mechanisms that form them, rather than describing
TADs as we see them” [218], which can also more broadly be applied to compartments and
their interplay with TADs.
Chromosome territories
At the largest scale, interphase chromosomes occupy distinct spatial territories in the nucleus
in a preferential manner [219]. This preferential chromosome localisation can vary among
cell types [220], but has been shown to be conserved among higher primate species [221]. In
general, chromosomes are spatially organised in the nucleus such that gene-rich chromosomal
regions tend to be located in the inner part of the nucleus, while regions that are relatively
poorer in genes tend to locate in the nuclear periphery. For example, the lamina associated
domains (LADs) of chromatin are characterised by a relatively low gene density as well as
decrease transcriptional activity (reviewed in [146]. However, it has been demonstrated that
there is some extent of intermingling between chromosome territories, which is associated
with repositioning of genes outside of their territories and transcriptional activation [222].
As in the previous layers of three-dimensional chromatin organisation, chromosome territo-
ries also indicate that the 3D structure of the genome is closely associated with its function
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in gene expression regulation.
1.3 Sequencing technologies and functional genomics as-
says
Over the last few decades, technological advancements in molecular biology research have
generated great potential in performing large scale studies on the genome and its functions.
Specifically, the advent of numerous high throughput technologies has improved the ac-
curacy and enabled the automation of experimental procedures, allowing an unimaginable
extent of experiment reproducibility, generation of biological data and high powered analyses.
An outstanding milestone in the establishment of advanced molecular technologies has been
the development of the Sanger sequencing method in the late 70’s, by Frederic Sanger and his
colleagues [223, 224]. This method was the prevalent sequencing technology for more than
two decades. Implemented by the so-called “first generation” DNA sequencing machines, it
enabled the sequencing of the first whole genomes, including the human genome within the
massive collaborative effort of the Human Genome Project. This motivated the development
of more advanced, high-throughput Next Generation Sequencing (NGS) platforms that are
highly scalable and operate with higher accuracy and at a lower cost; these include Roche
454, SOLiD, Illumina (former Solexa), Ion Torrent. In recent years, a new generation of
high-throughput technologies that perform long-read sequencing has been developed and is
being used in “third generation” sequencing platforms. These include the SMRT and Oxford
Nanopore sequencing technologies.
HTS technologies have facilitated not just sequencing of whole genomes, but also their
functional characterisation, as they have provided the basis for the development of further
technologies and applications, including whole exome sequencing, transcriptome sequenc-
ing, genome and genome-protein interactions identification (ChIP-seq, ChIA-PET, Hi-C),
supporting also epigenome profiling (ChIP-seq, ATAC-seq, bisulfite sequencing). These
technological advancements have also spurred the development of new computational tools
and approaches for the analyses of the emerging large-scale data.
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1.3.1 NGS technologies
In the last decade NGS sequencing methods have introduced massive parallel sequencing
of vast amounts of short reads (i.e. sequence fragments) revolutionising genome analysis.
The underlying principle is a series of repeated cycles of DNA molecule synthesis, where
fluorescently labeled nucleotides (dNTPs) get incorporated into a DNA template strand. As
the dNTPs are being incorporated, they are identified by fluorophore excitation.
The vast majority of available sequencing data worldwide have been generated using the
Illumina sequencing platforms.
Illumina Sequencing
Illumina sequencing is performed in three main steps. These are: library preparation, cluster
generation and sequencing by synthesis. During the library preparation, the DNA is purified
and randomly sheared into short fragments. The resulting DNA fragments are ligated with
adapters at their 5’ and 3’ ends. The adapter ligated sequence fragments are then amplified
with polymerase chain reaction (PCR). Next, the prepared library is passed on the cluster
amplification step by getting loaded onto a chip with thousands of unlabeled short synthetic
DNA oligonucleotides. The DNA fragments hybridise with the oligos that are complementary
to their ligated adapters. Subsequently, each cluster is amplified into distinct clonal clusters,
meaning that a high number of copies of each read is generated. The reads are then separated
into single strands and are ready to be sequenced. Sequencing by synthesis is performed by
adding fluorescently labeled reversible terminators, primers and DNA polymerase and then
detecting the emitted fluorescence after laser excitation.
The generated Illumina sequencing data can then be analyzed and used in multiple ap-
proaches. The first step of the analysis is usually the alignment onto the reference genome of
the organism they originate from. Depending on the type of the study, they can be used for
various purposes.
NGS data processing
Quality control and filtering
NGS technologies generate high throughput sequencing reads with a high accuracy. How-
ever, sequence artefacts such as base calling errors, mainly at the 3’ends of reads and at a
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rate 0.5-2%, as well as adapter contamination can be common. Evaluation of the extent
of such errors, and thus the quality of reads can be done via performing quality controls
of the read dataset. Poor quality per base, low sequence content diversity, high duplica-
tion levels, and specific sequence overrepresentation are usually associated with high base
calling error rates, PCR over-amplification, or adapter contamination. A very commonly
used software package for quality control of high-throughput sequencing data is FastQC
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). FastQC calculates various qual-
ity metrics for the sequenced reads, including per-base quality scores, sequence content,
levels of read duplication which can be a result of PCR over-amplification, or sequence
over-representation which can be a result of adapter contamination. Based on the evaluation
of these metrics, read quality can be improved by using specialised software packages to
eliminate sequences with poorer quality. A versatile software toolkit is the fastx-toolikt,
which, among other, includes fastx-trimmer that can be used for trimming low quality called
bases at the 3’ end of the reads, and fastx-clipper that can be used to trim off adapter se-
quences form the reads. PCR and optical read duplicates can be identified or removed using
the MarkDuplicates tool from the picard tool suite [225].
Read mapping
Once it is ensured that the sequenced reads are of good quality, they can be mapped against
the reference genome of the corresponding organism. There are a number of available algo-
rithms for read alignment on genome assemblies, which can differ in their indexing strategies,
memory efficiency, mapping sensitivity and speed. Due to their computational efficiency,
BWA [226] and Bowtie2 [227], which are based on the Burrows-Wheeler transform (BWT
[228]) and the Feraggina Manzini index (FM index [229]), are some of the most commonly
used read mapping algorithms.
1.3.2 Protein-DNA interaction assays
ChIP-seq: experimental protocol and data analysis
Chromatin immunoprecipitation followed by sequencing (ChIP-seq) is a useful method for
profiling epigenomic features across a genome, as it enables identification and analysis of
protein-DNA interactions. It can be used for genome wide mapping of the binding sites
of a transcription factor, or more generally the genomic loci occupied by proteins, such as
polymerases or histones with specific modifications.
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The first step of the experimental method includes the use of formaldehyde for tissue fixation
and cross-linking of the protein-chromatin interactions, followed by homogenisation of the
fixed tissue and cell lysis. In this way, the chromatin is obtained and then fragmented into
small segments, usually 300-500bp long. The next step is chromatin immunoprecipitation
(ChIP) (Fig. 1.11). This includes the use of an antibody during incubation and centrifugation.
It is important that the antibody is specific for the protein of interest, so that the DNA
fragments that are bound by the target protein can be isolated. These immunoprecipitated
DNA fragments are then purified by reversing the cross-link between DNA and proteins
using heating. They are also size-selected and then used to prepare the sequencing library.
Specifically, oligonucleotide adaptors are added to the ends of the ChIP-ed DNA fragments,
which allows their massive parallel sequencing, commonly by Illumina Sequencing (Fig.
1.11).
Fig. 1.11 ChIP-seq experiment and data analysis. Step1: Chromatin is immunoprecipi-
tated using an antibody specific for the TF or the modified histone, followed by isolation of
DNA fragments that were bound by the protein. Step 2: High throughput sequencing of the
DNA fragments. Step 3: Raw sequencing data is obtained from the sequencer. Step 4: Reads
are aligned against the reference genome assembly. Step 5: Peaks of enriched read mapping
are identified with using a peak calling algorithm. Figure adapted from Mimura et al. [230]
The sequenced DNA fragments correspond to all the genomic locations the protein of interest
was bound to. However, ChIP-seq output is affected by sequence content, chromatin state
and DNA sonication bias, as GC-rich regions and open chromatin regions typically yield
higher read coverage in sequencing, while heterochromatic regions, which are more resistant
to shearing, can be under-represented in the sequencing output. To account for the effect
34 Chapter 1
of these factors in a ChIP-seq experiment, it is important to use a control, also known as
the input, sample. The same experimental protocol used for the ChIP-ed samples is applied
to the input, except for the step of immunoprecipitation. The resulting dataset is used as a
reference against which the ChIP-enriched regions are compared in the downstream analysis
to control for the relevant biases. Additional factors that might affect the efficiency of the
experiment are: the antibody specificity and the sequencing depth. For identifying genomic
interactions with proteins that occupy more or longer, on average, genomic intervals, a higher
sequencing depth is required.
The sequenced fragments from the ChIP-seq experiment correspond to genomic loci that
interact with the protein of interest. The first step in the processing of these sequenced
reads is to perform read quality controls and filtering, as described in section 1.3.1, and read
mapping using one of the available alignment algorithms, as described in section 1.3.1. Then,
the read alignment output can be passed on to a peak calling algorithm, so as to identify peaks
of ChIP-seq read enrichment, which represent genomic sites where the protein of interest
localises. A very popular peak caller is MACS2, which uses a window-based approach to
determine significantly enriched regions and randomly shuffles ChIP-ed and Input reads
to calculate an empirical false discovery rate (FDR). The identified peak regions with read
enrichment can be visualised on genome browsers, such as Ensembl and IGV. Moreover,
following the identification of ChIP-seq peaks, the underlying genomic intervals can then
be scanned to identify short sequence motifs that bind TFs. MEME suite is a commonly
used software that includes a range of tools for motif identification, for instance MEME
for de novo motif discovery, or FIMO for identification of specified motif matches in the
scanned sequences. A number of databases with identified sequence motifs can also be used
to complement motif search and analysis; one of them is JASPAR [168]. Finally, further
functional analyses of the identified ChIP-seq peaks can be performed to identify associations
of the ChIP-marked (regulatory) regions with genes and gene ontology terms.
Other assays for protein-DNA interactions
An alternative method, widely used before the establishment of the ChIP-seq protocol, is the
ChIP-on-ChIP. That includes the ChIP wet lab protocol just as in ChIP-seq, but is followed by
hybridisation of the purified DNA fragments with probe oligos on a DNA microarray, instead
of high throughput sequencing. Two more recently developed methods are the “cleavage
under targets and release using nuclease” followed by sequencing (CUT&RUN-sequencing
[231]) and "cleavage under target and tagmentation" followed by sequencing (CUT&Tag-
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sequencing [232]). These are based on cleavage of the antibody-targeted genomic sites by
using micrococcal nucleases or a nuclease-transposase fusion, respectively, and they both
require less material and offer a higher signal-to-noise ratio with shallower sequencing.
1.3.3 Chromatin conformation assays
Querying of the three dimensional genome structure has been enabled through the develop-
ment of technologies based on Chromosome-Conformation-Capture (3C) [233, 234]. The
main underlying principle of these techniques is the use of proximity ligation to identify
physical interactions between genomic regions. Some of the 3C-based protocols, specifically
chromatin interaction analysis with paired-end tag sequencing (ChIA-PET) and ChIP-loop
(also referred to as 6C) include an immunoprecipitation step to detect genomic interactions
that are mediated by specific proteins (reviewed in [139]). In contrast, the 3C, 4C, 5C and
Hi-C protocols determine chromatin interactions in a protein independent manner (reviewed
in [127]). Following the 3C-based technologies, genome architecture mapping (GAM) has
also been developed as a novel method to identify genome wide contacts based on cryosec-
tioning and DNA sequencing from thin nuclear sections, rather than using ligation [235].
The Hi-C protocol is very commonly used and allows for identification of chromatin interac-
tions across the whole genome, thus supporting the construction of genome-wide contact
frequency maps. In brief, Hi-C includes crossliniking of cells to form covalent links between
interacting genome fragments, DNA digestion by a restriction enzyme, ligation of the in-
teracting genomic fragments with biotin, DNA shearing and quantification of the ligated
products via high-throughput sequencing and subsequent data analyses. These analyses
estimate the frequency of genomic contacts [131]. Hi-C maps have revealed the organisation
of the genome into compratments A and B [131, 132], as well as in TADs [133, 135, 182].
Besides characterisation of global chromatin conformation features, Hi-C can be used for
identifying specific looping interactions that may also take place between genomic sequences
and that may have regulatory interactions. Popular software packages are HiCUP [236]
for pre-processing and HOMER [237] for quality control and analysis of Hi-C data. Hi-C
data analysis aims to quantify contact frequency maps between interacting genomic regions.
These can be visualised as two dimensional matrices where the row and column indices
represent genomic bins and the values in the matrix cells indicate the frequency of contacts
between the corresponding genomic bins. Therefore, the size of the genomic bins and the
sequencing depth are factors that affect the resolution of Hi-C contact maps.
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1.3.4 Gene expression assays
RNA sequencing (RNA-seq)
RNA sequencing has been established as a de facto approach for studying whole transcrip-
tomes and quantifying gene expression. The majority of RNA-seq data over the last decade
were generated with Illumina short-read sequencing platforms. The typical RNA-seq protocol
includes extraction of RNA, RNA fragmentation, reverse transcription to cDNA, adaptor
ligation, PCR amplification and high throughput sequencing, which results in cDNA reads
usually shorter than 200bp (reviewed by Stark [238]). The standard protocol often includes
a selection step for transcripts that contain poly-A tails, thus representing mostly protein-
coding genes and being largely depleted of small non-coding RNAs or enhancer RNAs. If
the poly-A selection step is removed, the library is usually also depleted of rRNA [239].
A number of other modifications can also be applied to the standard protocol, depending
on the aspect of the transcriptome each study focuses on. For example cap analysis of
gene expression (CAGE) can be used to enrich for 5’ cDNA fragments and support iden-
tification of promoters, TSSs and transcribed enhancers [240, 241]. Another innovation
is the addition of unique molecular identifiers (UMIs) [242, 243] to the cDNA fragments
before amplification in order to, subsequently, identify and remove PCR duplicates accurately.
The generated sequencing data can be passed on to downstream analysis to be assigned to
gene transcripts, quantify expression and/or compare between sample cohorts that correspond
to different biological conditions, i.e. differential gene expression analysis. The analysis
starts with quality control and filtering in the same way as for DNA sequencing data. Then
reads are mapped on the reference genome using read alignment algorithms such as TopHat
[244] or STAR [245] that can produce spliced alignments, and subsequently the mapped
reads are assigned to genomic features and quantified with tools such at featureCounts [246]
or Htseq [247]. Alternatively, the read mapping and quantification steps can be performed at
once by more recently developed methods, such as kallisto [248] and Salmon [249], which
do not use a reference genome, but rather a transcriptome assembly. After read counts
are computed, differential expression analysis is performed, including normalisation across
samples and statistical analyses of significant differences between samples. Popular software
packages for that are DESeq2 [250] and edgeR [251].
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1.4 Aims of the thesis
Despite years of research, numerous aspects of gene regulatory mechanisms and their con-
tributions to shaping phenotypic characteristics are not well understood. This thesis aims
to gain insights into mechanisms of transcriptional regulation, focusing particularly on the
binding activity of transcription factors (TFs). The individual projects and analyses make use
of in vivo systems that leverage a pool of regulatory variation to study the activity and roles
of TF binding within a wider functional context. The in vivo systems used include closely
related mouse species where molecular variation is manifested as changes in the sequence
context and/or in the binding activity of the TFs. Also, these changes may be naturally fixed
by evolution in the different species (natural variation), or induced by various factors, for
example mutagenesis as a result of carcinogen exposures. The functional implications of the
underlying molecular variation in TF binding is also evaluated as part of broader functional
contexts, such as higher-order genome organisation, or the neoplastic transformation of a
tumour cell in cancer development.
In the following chapter, I present my study on the functional contribution of CTCF binding
to establishing higher-order genome structures. There, I leverage natural genetic variation
among five mouse species to study the interplay between the CTCF binding evolutionary
dynamics and the demarcation of boundaries of topologically associating domains (TADs).
My main findings reveal the association of TAD boundaries with dynamically evolving
clusters of neighbouring CTCF sites, which contribute to the resilience of TAD structures
and the shaping of regulatory landscapes.
In the third and fourth chapters, I present work carried out as part of a bigger collaborative
project of the Liver Cancer Evolution (LCE) consortium. The project makes use of a model
of chemically induced liver carcinogenesis in different mouse species, to study mutagenesis
mechanisms and the relative contributions of the genome and epigenome to liver cancer
development.
In the third chapter, I present my work on inspecting bulk expression data of monoclonal
liver tumours. There, I characterise the expression profile of the liver tumour cell-of-origin,
the hepatocyte, by leveraging developmental single-cell expression datasets from mouse liver.
I also identify gene dysregulation in the clonal tumour cells that underlies the shift from
their hepatocyte specific to a more dedifferentiated expression phenotype along neoplastic
transformation.
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In the fourth chapter, I further explore associations of gene dysregulation and the hepatocyte
phenotypic shift along liver cancer development with mutagenesis at liver TF binding sites in
the tumour cell-of-origin. My results disentangle different patterns of mutation accumulation
among the distinct categories of TF binding sites based on their functional characteristics,
such as combinatorial binding or association with cis-regulatory elements, and show that TF
binding sites with substantial regulatory roles are generally less mutated. However, I also
reveal subsets of hyper-mutated TF binding sites in liver tumours, which are enriched for
liver-specific biological processes, cellular stress response and abnormal liver phenotypic fea-
tures, and they are associated with dysregulated genes that have hepatocyte-specific functions.
Chapter 2
Evolutionary dynamics of CTCF binding
and higher-order genome structures
This chapter describes my study on evolutionary dynamics of CTCF binding among mouse
species and its role in establishment and maintenance of topologically associating domains
-a layer of the higher order chromatin organisation. The data used in this study have been
mostly generated in the Odom lab, by Sarah Aitken, Christine Feig and Klara Stefflova, while
some of the datasets were retrieved from previously published studies. Except as noted, all
analyses described here were carried out by myself. The manuscript was also written by
myself, edited collectively and agreed upon by all co-authors. The results of this study have
been published in the following paper:
Kentepozidou, E., Aitken, S.J., Feig, C., Stefflova, K., Ibarra-Soria, X., Odom, D.T., Roller, M.,
Flicek, P. Clustered CTCF binding is an evolutionary mechanism to maintain topologically associating
domains. Genome Biol 21, 5 (2020). [252]
Also, part of results from this study, with respect to the effect of Ctcf hemizygosity on CTCF
binding and TAD structures, have complemented analyses in a project led by Sarah J. Aitken
and Ximena Ibarra-Soria. These were included in the following paper:
Aitken, S.J., Ibarra-Soria, X., Kentepozidou, E., Flicek, P., Feig, C., Marioni, J.C., Odom, D.T. CTCF
maintains regulatory homeostasis of cancer pathways. Genome Biol 19, 106 (2018). [253]
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2.1 Introduction
At a sub-megabase scale the genome is organised into topologically associating domains (TADs),
which define regulatory landscapes via their self-interaction patterns [254, 135, 146, 187]. Despite
their conservation and presumed functional importance, the mechanisms underlying their stability
and evolution remain unclear. Accumulating evidence supports a model where the CCCTC-binding
factor (CTCF), colocalised with the cohesin protein complex, plays a causal role in the formation
and maintenance of TADs [210, 255, 256]. CTCF is a ubiquitously expressed protein with a deeply
conserved DNA-binding domain [157, 158]. It is responsible for diverse regulatory functions in-
cluding transcriptional activation and repression as well as promoter and enhancer insulation. Its
diverse functions are based on its role in promoting interactions between distant genomic elements by
mediating chromatin loop formation [162, 159, 170]. A loop extrusion mechanism of TAD formation
has been proposed wherein the cohesin protein complex slides along chromatin forming a growing
loop until it meets two CTCF molecules bound with convergent orientation. This architecture then
prevents cohesin from sliding further, demarcating the TAD boundaries [193, 192]. This model
explains why these boundaries usually harbor CTCF binding sites. Nevertheless, there are ubiquitous
CTCF-bound regions with diverse functions throughout the genome, while only a small fraction of
them occur at TAD boundaries [133]. In addition, a small number of TADs are not flanked by CTCF
binding sites [135, 207, 182, 206]. This has made it challenging to delineate the precise role of CTCF
binding in establishing and stabilizing TAD structures.
Several recent perturbational studies experimentally provide some insights into the role of CTCF
in determining local and genome-wide three-dimensional chromatin organisation. Local disruption
of CTCF binding can lead to abrogation of TAD insulation and formation of ectopic cis-regulatory
interactions between neighbouring TADs [257, 151, 135, 170, 146], although TAD structures have
been reported to remain intact [258, 135, 192]. Local TAD disruptions may also lead to disease
[259, 188–190]. Upon acute, transient genome-wide depletion of CTCF there is marked disruption to
chromatin loop and TAD structures [196, 199, 260], but the degree of TAD destabilisation remains
controversial. The impact of this CTCF-mediated insulation on gene expression remains poorly under-
stood. Indeed, experimental approaches that disrupt CTCF binding remain limited by the fundamental
roles of CTCF in development and cell viability.
The binding profiles of CTCF in present-day mammalian genomes are shaped by repeated waves
of transposable element insertions carrying CTCF binding sequences across mammalian genomes
[176, 164, 261, 262]. Mammalian-conserved sites resulted from ancestral expansions, while recent
expansions have established lineage-specific binding patterns. For example, the B2 family of short
interspersed nuclear elements (SINEs) active in the mouse-rat ancestor shaped the CTCF binding
profile of all Muridae species and specific members of the B2 family remain active in a lineage-
specific manner [176, 164, 261]. The human and macaque genomes also share a large fraction of
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CTCF-associated transposable elements despite the absence of recent large-scale insertional activity
[262]. Moreover, mammals representing distinct vertebrate orders share conserved CTCF binding
sites at their TAD borders [133, 134, 184].
The evolutionary history of CTCF binding facilitates a complementary approach to understanding the
role of CTCF in TAD stability. Specifically, we can leverage the natural genetic variation between
species as opposed to experimental approaches using targeted or systemic CTCF binding disruption.
We can thus investigate the consequences of CTCF binding changes stably fixed by evolution as a
version of an in vivo mutagenesis screen [263]. A unique and important advantage of this approach is
that the physiological cellular system can be assumed to be in stable and homeostatic equilibrium
[264]. CTCF is ideally suited to such an evolutionary approach because in each species the CTCF
binding profile is composed of substantial numbers of both deeply conserved and evolutionarily recent
sites [164, 261].
In this study, I used CTCF ChIP-seq data from five mouse strains and species, which have similar
genomes and transcriptional profiles, to give insight into the establishment and stability of TADs. My
analysis of the genome-wide CTCF binding leverages natural genetic variation between species to
assess the evolutionary dynamics of TAD boundary demarcation. I also investigated the impact of
local losses of CTCF binding on gene expression in adjacent TADs, as well as the effect of CTCF
hemizygosity on TAD structures. The results revealed that TAD borders are characterised by clusters
of both evolutionarily old and young CTCF binding sites. In addition, CTCF bound regions at TAD
borders, regardless of age, exhibit increased levels of sequence constraint compared with CTCF
binding sites not associated with TAD boundaries. Such clusters are consistent with a model of TAD
boundaries in a dynamic equilibrium between selective constraints and active evolutionary processes.
As a result, they apparently retain a redundancy of CTCF binding sites that give resilience to the
three-dimensional genome structure.
2.2 Results
2.2.1 Conservation of CTCF binding sites and association with TAD
borders
To investigate the evolutionary dynamics of CTCF binding, I first determined CTCF binding profiles
in closely related species. In particular, I used ChIP-seq data to identify CTCF enriched regions in the
livers of five mouse species1: Mus musculus domesticus (C57BL/6J, hereafter referred to as BL6), M.
1Although BL6 (Mus musculus domesticus) and CAST (Mus musculus castaneus) are subspecies of the
same species, Mus musculus, hereafter they will be conventionally referred to as species.
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musculus castaneus (CAST), M. spretus (SPRET), M. caroli (CAROLI), and M. pahari (PAHARI)
(Fig. 2.1A, Fig. A.1 - Appendix A). Specifically, for CAST and SPRET I used ChIP-seq data gener-
ated in the Odom lab, while for CAROLI and PAHARI I retrieved previously published ChIP-seq
data [261]. I processed the raw data and determined CTCF peaks in three biological replicates of each
species (see Methods). Peaks present in at least two of the replicates were defined as reproducible and
were used for downstream analyses (Table A.1 - Appendix A, Fig. A.1 - Appendix A).
Fig. 2.1 Mus-conserved CTCF binding sites commonly occur at TAD borders. (A)
CTCF ChIP-seq enrichment tracks around the Chrna1 locus in BL6 and in orthologous
regions of the other Mus species. Raw data from three biological replicates are shown for
each species. (B) Conservation of CTCF binding sites across the five studied Mus species.
Conservation levels at the bottom of the panel indicate the number of species CTCF sites are
shared in (phylogenetic distances are from Thybert et al. [261]). (C) Graphical representation
of using orthologous alignments of the CTCF sites identified in each Mus species to project
them on the genome of BL6 (GRCm38) where TADs are available. (D) Distances of CTCF
sites with different conservation levels to their closest TAD boundary. CTCF sites with a
distance ≤ 50kb are considered TAD-boundary associated, while sites with a distance > 50
kb are referred to as non-TAD-boundary associated.
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Fig. 2.2 Fractions of CTCF binding sites of different conservation levels in each of the
studied Mus species.
Fig. 2.3 Fractions of all Mus CTCF sites of each conservation level that are associated
(d ≤ 50kb) or not associated (d > 50kb) with TAD boundaries.
To characterise the conservation of the identified CTCF binding sites among the mouse species, I
lifted over the binding site regions from one species to another (see Methods). I identified conserved
sites between species as orthologous regions that were ChIP-enriched in each of the compared species.
That way, I determined the conservation level of each CTCF binding site based on whether it is
shared by all species (Mus-conserved or 5-way), fewer than five species (4-way, 3-way, 2-way) or are
species-specific (1-way) (Fig. 2.1B). Mus-conserved and species-specific CTCF binding sites were
the most numerous among the different conservation level groups (Fig. 2.1B, 2.2). A total of ~11,000
CTCF binding sites were found to be Mus-conserved. To put this number in context, it corresponded
to more than a quarter (~27%) of the total number of CTCF sites identified in BL6 (Fig. 2.2). This is
consistent with previous studies that reported high CTCF binding conservation across eutherian mam-
mals, especially compared with other transcription factors such as HNF4A and CEBPA [175, 77, 164].
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To evaluate the CTCF binding evolutionary dynamics with respect to TAD borders, I firstly inter-
sected the CTCF binding profiles with TAD borders identified from published Hi-C in BL6 liver
(Fig. A.2 - Appendix A) [184]. Although I used Hi-C data for only one of the five species, it has
been shown that TADs are largely conserved across species and cell types [133, 184, 209]. For
these closely related mouse species with very similar genomes, transcriptomes and CTCF binding
patterns, I expected that this assumption is valid to a great extent. Therefore, I projected the CTCF
sites identified in each of the five Mus species onto the BL6 genome (GRCm38/mm10) (Fig. 2.1C).
Having grouped all the CTCF sites by conservation level, I measured the distance of each site in
these groups to its closest TAD boundary. Based on this distance and the resolution of the TAD map
used, I further sub-categorised CTCF sites as TAD-boundary-associated (d ≤ 50kb ) and non-TAD-
boundary-associated (d > 50 kb). It is noted that, in this way, ~13% of the genome was classified
as TAD-boundary-associated. Although CTCF sites of all conservation levels were found to occur
at the boundaries of TADs, more highly conserved CTCF sites were, on average, located closer to
TAD boundaries (Fig. 2.1D). Previous studies have highlighted the overlap of TAD boundaries with
sites conserved in more distantly related species, such as human and mouse [134] or mouse and
dog [184]. Yet, an association between CTCF sites of progressively increasing conservation level
and proximity to TAD boundaries is evident even when zooming in in evolutionary time, examining
closely related species. This is exemplified if I consider that 41% of the Mus-conserved CTCF sites, as
compared to 23% of species-specific sites, were found to lie within 50kb of TAD boundaries (Fig. 2.3).
Shifting the perspective from CTCF bound regions to TAD boundaries, the majority of TAD borders
were found to overlap with highly-conserved CTCF binding sites. Nevertheless, a small fraction of
the boundaries did not harbour any Mus-conserved CTCF binding events. In particular, twelve percent
of them contained CTCF sites that were conserved only in one, two or three out of the five studied
Fig. 2.4 Fractions of TAD boundaries with CTCF sites of different conservation levels.
Most TAD boundaries (64%) harbour at least one Mus-conserved (5-way) CTCF site. Lower
percentages of TAD borders do not contain any Mus-conserved CTCF site but overlap with
less conserved sites or do not bind CTCF at all.
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mouse species (Fig. 2.4). Furthermore, nearly 5% of TAD boundaries apparently do not overlap with
any CTCF bound site at all (Fig. 2.4). Other studies have also identified TAD boundaries deprived of
CTCF bound sites and have proposed that even though the connection between CTCF binding and
TAD boundaries was consistently observed, it may not be a strictly necessary feature for demarcation
of TAD boundaries. It has also been suggested that a few TADs, whose borders are not demarcated by
CTCF sites, may be passively shaped between other CTCF-anchored TADs [128, 134].
To summarise, CTCF binding sites were found to be conserved to a large extent across the five studied
Mus species. In addition, 41% of the Mus-conserved CTCF binding sites were associated with a TAD
boundary, while the vast majority (>95%) of all TAD boundaries were shown to harbour at least one
CTCF binding site.
2.2.2 Evolutionary constraints at TAD-boundary-associated CTCF bind-
ing sites
CTCF is known to bind to a 33/34-bp region of the genome consisting of a primary sequence motif
(M1) and a shorter secondary motif (M2). I found that overall binding affinity, as computationally
predicted from the motif sequence, was significantly greater for boundary-associated CTCF sites
compared to non-boundary-associated sites (Mann-Whitney U test, p < 2.2e16) (Fig. 2.5a). I went on
to investigate whether other characteristics of CTCF binding sites -beyond the cross-species conserva-
tion of binding activity- are coupled with TAD boundary association. To this aim, I first assessed the
relationship among CTCF conservation level, TAD boundary association, and CTCF motif strength.
It is noted that CTCF preferentially binds to a 19 base pair-long motif sequence (primary CTCF
binding motif, M1), or to an extended version of it that also includes a secondary, shorter motif
(M2) and spans 33/34 base pairs in total [164]. I scanned our ChIP-seq peak regions, identified
occurrences of the CTCF binding motif, and calculated the binding affinity of each of these motif
sequences (see Methods). Binding affinity was, overall, significantly higher for boundary-associated
CTCF sites compared to non-boundary-associated sites (Mann-Whitney U test, p < 2.2e-16) (Fig.
2.5A). However, according to the previous observation, TAD boundaries are frequently associated
with Mus-conserved sites, while it is also known that species-conserved sites tend to have motifs of
higher sequence constraints and thus higher binding affinity for CTCF than less conserved sites [78].
Based on these, could the observed increase in CTCF binding affinity at TAD-boundary-associated
sites simply reflect a bias of many Mus-conserved CTCF sites occurring at TAD boundaries? To
address this, I grouped the sites based on their conservation level, and repeated the comparison of
TAD-boundary-associated with non-TAD-boundary-associated sites within each conservation level
group. As expected, motif binding affinity increased with the CTCF binding site conservation level.
Yet, TAD-boundary-associated CTCF binding sites of any given conservation level consistently had
greater binding affinity than non-boundary-associated sites (Mann-Whitney U tests between TAD-
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Fig. 2.5 CTCF binding sites at TAD boundaries are subjected to stronger evolutionary
constraints. (A) CTCF-bound sites at TAD boundaries contain motifs with higher binding
affinity for CTCF than non-TAD-boundary-associated sites (Mann-Whitney U test: p-value
< 2.2e-10). (B) Although the binding affinity of CTCF sites is generally proportional
to the conservation level of the site (how many species it is shared by), CTCF sites at
TAD boundaries have stronger binding affinity than non-TAD-boundary-associated sites,
independent of their conservation level (Mann-Whitney U tests between TAD-boundary-
associated and non-TAD-boundary-associated sites: p1-way = 0.001, p2-way = 0.06, p3-way =
6.1e-07, p4-way = 5.2e-13, p5-way = 3.9e-11). (C) TAD-boundary-associated CTCF peaks
display higher ChIP enrichment scores, as calculated by MACS, than non-TAD-boundary-
associated peaks (Mann-Whitney U test: p-value < 2.2e-10). (D) TAD-boundary-associated
CTCF peaks, at every conservation level, display stronger ChIP enrichment than non-TAD-
boundary-associated peaks (Mann-Whitney U tests: p1-way < 2.2e-16, p2-way = 0.002316,
p3-way < 2.2e-16, p4-way < 2.2e-16, p5-way = 2.047e-12). (E) The most information-rich bases
of the primary CTCF M1 motif at TAD boundaries display higher rejected substitution (RS)
scores compared to non-TAD-boundary-associated motifs. The bottom panel shows the
position weight matrix of the CTCF M1 motif from Schmidt et al. [164]. (F) The observation
in (E) is independent of the conservation level of the CTCF sites, as shown for subsets of
sites at each conservation level.
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Fig. 2.6 Higher read coverage at TAD boundary-associated CTCF peaks compared
to non-TAD-boundary-associated peaks. (A) Mapped read counts for TAD boundary-
associated versus non-TAD-boundary-associated peaks in five biological replicates of BL6
liver. The two groups were compared using Mann Whitney U tests. (B) ChIP-seq read
coverage for example loci of 5-way conserved and species-specific peaks at TAD boundaries
(left) compared, respectively, to 5-way and species-specific (1-way) peaks at non boundary
regions (right). The read coverage of TAD boundary-associated peaks is higher than at the
non-TAD-boundary-associated peaks, independently of whether the peaks are conserved or
species-specific. The observations are consistent among the replicates.
boundary-associated and non-TAD-boundary-associated sites: p5-way = 3.9e-11, p4-way = 5.2e-13,
p3-way = 6.1e-07, p2-way = 0.06, p1-way = 0.001) (Fig. 2.5B). In addition to that, CTCF binding sites
at TAD borders were shown to have higher ChIP enrichment than non-TAD-boundary-associated
CTCF sites, independently of conservation level (Fig. 2.5C, 2.5D)2. I further validated this, by using
additional ChIP-seq libraries from BL6 (see Methods) to increase the power. Specifically, I mapped
and quantified ChIP-seq reads at TAD-boundary-associated and at non-TAD-boundary-assocciated
sites of each conservation level group. Sites at TAD boundary regions had higher ChIP-seq read
coverage (Fig. 2.6). These observations were consistent with the stronger predicted affinity of the
corresponding CTCF motif sequences. Overall, these results give new insight into the observation that
2The lower ChIP enrichment of 1-way and 2-way conserved sites compared to more deeply conserved ones,
as shown in Fig. 2.5D, might raise a question about how likely it is that the 1-way and 2-way sites are functional.
It is possible that a (small) fraction of them may represent occasionally and transiently bound sites, or even
correspond to false positive binding sites resulting from ChIP-seq artefacts. However, it is likely that most of
them do have some functionality, as: a) they have been identified against input libraries, and independently in at
least two biological replicates, which is in line with the ENCODE Consortium standards for ChIP-seq based
binding site discovery [265]. Secondly, it has been shown that evolutionarily young CTCF binding sites—even
subspecies-specific ones—generally show functional signatures similar to more deeply conserved binding sites
[266].
48 Chapter 2
mammalian-conserved CTCF sites have higher motif affinity than species-specific sites [164, 184].
Importantly, for all CTCF binding sites, including species-specific ones, proximity to a TAD boundary
was associated with an increase in binding affinity (Fig. 2.5B, 2.5D). This implies that CTCF binding
motifs at TAD boundaries may be under stronger selective constraint than the motif sequences of
non-TAD-boundary-associated CTCF peaks.
To further evaluate this hypothesis, I explored evolutionary sequence constraint of the CTCF binding
motif itself. For this purpose, I measured rejected substitution (RS) scores at each position of every
19 base-long primary CTCF binding motif (M1) and compared the score between (a) TAD-boundary-
associated and (b) non-TAD-boundary-associated regions (Fig. 2.5E, 2.5F). RS score is a measure
of sequence constraint. It reflects the number of base substitutions that were rejected at a specific
genomic position as a result of purifying selection, compared to the number of substitutions that
would have occurred if the sequence was evolving under neutral selection [267]. The M1 motif in
TAD-boundary-associated sites displayed higher RS scores compared to the motifs of non-TAD-
boundary-associated sites (Fig. 2.5E). I further compared the mean RS score per base between the two
categories for CTCF sites at every conservation level and confirmed the generality of this observation
(Fig. 2.5F). In addition, I established that this observation was not caused by an enrichment of specific
motif instances at TAD boundaries (Fig. A.3 - Appendix A).
Taken together, these results showed that CTCF binding sites at TAD boundaries are subject to stronger
evolutionary constraints than the CTCF binding sites located further away, and that this relationship is
independent of evolutionary origin of the sites.
2.2.3 Representation of LINEs and LINE-derived CTCF sites at TAD
boundaries
The above observations reveal that occurrence at TAD boundaries is associated with sequence and
functional conservation of CTCF binding sites. I questioned whether distinct evolutionary mech-
anisms underlie CTCF binding expansion near TAD boundaries as compared to the background
genome. According to previous studies, the genome-wide binding profile of CTCF in mammals is,
to a large extent, driven by expansion of repeat elements [176, 164, 177, 261]. I therefore sought
to characterise the enrichment of transposon classes that drive CTCF binding expansion at TAD
boundaries compared to the whole genome. After distinguishing CTCF sites based on whether
they locate at TAD boundary regions3 or not, and for each group I calculated the number of CTCF
peak centers that were embedded in SINEs, long terminal repeats (LTRs), long interspersed nuclear
elements (LINEs), and DNA transposons. As expected, the largest fraction of CTCF sites in both
3A TAD boundary region, here, is defined between two adjacent TADs as the first nucleotide of the
downstream TAD +/- a 50kb window.
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categories were found to be SINE-derived (Fig. 2.7A) [176]. The fraction of SINE-derived CTCF
sites at TAD borders was slightly, but not significantly, larger than in the rest of the genome (χ2 test
without Yates correction: p = 0.01), implying that SINEs may have uniform potential to establish a
CTCF site at both TAD boundaries and other genomic regions. Similarly, CTCF sites of LTR origin
did not show significant differences between the two categories (χ2: p = 0.015). In contrast, the
relative proportion of DNA transposon-derived CTCF sites was increased at TAD boundaries (χ2: p
= 0.0003) but accounted for less than 3% of the TEs that contribute to CTCF binding (Fig. 2.7A).
The depletion of LINE-derived CTCF binding sites at TAD boundaries compared to the background
genome was the most striking difference (χ2: p = 3.147e-15; Fig. 2.7A) suggesting that CTCF bind-
ing site formation via LINE expansion is significantly less common at TAD borders than genome-wide.
In addition to inspecting CTCF sites derived from transposable elements of different classes, I
evaluated the representation of different transposon classes themselves around TAD boundaries, irre-
spectively of whether they contained CTCF binding sites. In particular, I determined the corresponding
fraction of the 100kb TAD border regions occupied by SINE, LTR, LINE, and DNA transposon
sequences and compared these with random genomic regions of similar size and distribution. I found
that SINE sequences were significantly enriched at TAD boundaries (Mann-Whitney U test: p <
2.2e-16; Fig. 2.7B) [133], which is in line with the observed enrichment of CTCF sites at TAD
borders and the known role of SINEs in CTCF binding expansion. The fraction of LTR-derived
sequences at TAD boundaries was only marginally higher than random genomic regions (p=0.005),
and the fraction of DNA transposon sequences was also slightly higher at TAD borders (p = 9.72e-14;
Fig. 2.7B). In contrast, LINE sequences were significantly under-represented at TAD boundaries,
compared to random genomic regions (Mann-Whitney U test: p < 2.2e-16; Fig. 2.7B), suggesting
that TAD boundaries are depleted of LINEs. That may also explain why LINE-derived CTCF sites
appear under-represented at TAD boundaries (Fig. 2.7A), as shown above. Considering that LINE
elements typically represent longer sequences compared to the other transposons, this observation
potentially indicates that LINE insertion is negatively selected at TAD borders as a consequence
of their characteristic long insertion fragments that might be disruptive for functionally important
regions harboured at TAD boundaries. This result is complementary to recent reports of selection
against long sequence deletions at the functional regions of TAD boundaries, within a wider context of
TAD boundary disruptions being under purifying selection [268]. Moreover, it extends our previous
observations and reinforces the hypothesis that in addition to TAD-boundary-associated CTCF sites
being subjected to stronger sequence and functional constrains, TAD boundary regions as a whole are
under stronger evolutionary pressure [268].
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Fig. 2.7 Differences in representation of TE classes and their association with CTCF
binding sites between TAD boundaries and other genomic regions. (A) Fractions of
TAD-boundary-associated versus non-TAD-boundary-associated CTCF binding sites that
are embedded in different TE classes. LINE-embedded CTCF-sites are under-represented at
TAD boundaries (χ2 test without Yates correction: p = 3.12e-15), while DNA-transposon-
embedded CTCF sites are over-represented (χ2 test: p = 0.0003), although accounting for
just 3% of the TAD-boundary-associated sites. SINE-derived CTCF sites (χ2 test: p =
0.01) and LTR-associated CTCF sites (χ2 test: p = 0.015) show no significant differences
between the two categories. The top bar (Background) shows the percentage of the BL6
genome sequence that corresponds to each TE class, for reference. (B) Fraction of sequence
length of TAD boundary regions (TAD boundary +/- 50kb) occupied by each TE class,
compared to random genomic regions of equal length. SINE sequences are significantly
over-represented (Mann-Whitney U test: p < 2.2e-16), while LINEs are significantly depleted
at TAD boundaries (p < 2.2e-16). DNA transposons are slightly, but significantly, enriched
at TAD borders (p = 9.72e-14), although they account for only 1% of the sequences of the
studied regions on average. Representation of LTR sequences shows no significant difference
between TAD boundaries and random genomic regions (p = 0.005; significance threshold:
0.001).
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2.2.4 Evolutionarily dynamic clusters of CTCF binding sites at TAD
borders
Aiming to gain further insight into the architecture of TAD boundaries, I sought to characterise
the organisation of their contained CTCF binding sites, which had different conservation levels. In
particular, after grouping all CTCF binding sites based on conservation level, I examined their density,
i.e. their proximity to each other, considering also their distance from the TAD boundary. As expected,
TAD borders were shown to be highly enriched for Mus-conserved CTCF binding events (Fig. 2.8A).
However, species-specific CTCF sites were, surprisingly, also enriched at TAD boundaries (Fig. 2.8A).
CTCF sites shared by 2-4 species also seemed to be moderately enriched around TAD boundaries.
Thus, TAD boundaries harbour numerous conserved CTCF binding sites, but also a high concentration
of species-specific CTCF sites in the examined, closely related, rodent species. On a further note,
regardless their conservation level, the average distance of any TAD-boundary-associated site to
its closest neighbouring site was consistently shorter than the corresponding average of non-TAD-
boundary-associated sites, with a median distance equal to ~5.3kb-5.9kb (Fig. 2.8B). In contrast,
CTCF binding sites not associated with a TAD boundary, besides being further apart from each other
(Mann-Whitney U test: p < 2.2e-16), their proximity to their closest neighbouring site was dependent
on conservation level; the less conserved a site was, the further it was located from other sites. The
median distance from the closest neighbouring site was 7kb for 5-way conserved CTCF sites, as
opposed to a median of 10.5kb for species-specific ones (Fig. 2.8B).
Further querying whether CTCF sites organise in specific conformations at TAD borders, I also
investigated potential ancestral clusters from the whole set of Mus CTCF binding sites projected to
the BL6 genome (n = 56,625; Fig. 2.1C). I searched for potential clusters of neighbouring CTCF
binding sites, defining a cluster as a group of at least two CTCF sites being located less than 10kb
apart from each other on the genome. A bit more than half of all CTCF sites (57%) were found to
be part of a cluster; these were 32,393 sites in total ("clustered" sites), making up 11,507 clusters.
The remaining 43% of the sites were "singletons", i.e. not belonging to any cluster. Interestingly,
clustered CTCF sites appeared to be significantly enriched at TAD borders compared to singleton
CTCF sites (Fig. 2.8C). This finding strongly implies that clusters of proximal CTCF binding sites
are a fundamental architectural feature of TAD boundaries.
Then, I further inspected the observed CTCF binding clusters at TAD borders, specifically looking into
potential associations between CTCF binding site clustering, redundancy and presence of conserved
and nonconserved binding events at TAD boundaries. I observed that TAD borders that harboured at
least one 5-way conserved CTCF site also contained a higher number of CTCF sites overall (Fig. 2.8D)
and these sites were mainly clustering with each other (Fig. 2.8E). Generally, a progressive association
between presence of individual conserved CTCF sites with a higher abundance of CTCF sites at a
TAD boundary was outlined. In summary, TAD boundaries seemed to usually contain at least one
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Fig. 2.8 Clusters of both conserved and divergent CTCF binding sites at TAD bound-
aries. (A) Both Mus-conserved and species-specific CTCF binding sites are highly enriched
around TAD boundaries. (B) TAD-boundary-associated sites lie significantly closer to each
other compared to non-TAD-boundary-associated CTCF sites (Mann-Whitney U test: p <
2.2e-16). (C) CTCF binding sites that belong to a cluster (“clustered”) are more enriched
at TAD boundaries than singleton CTCF sites. (D) The violin plots correspond to TAD
boundaries categorised according to the maximum conservation level of CTCF binding they
contain. Each violin plot shows the distribution of the total number of CTCF sites that occur
at the TAD boundaries in the category. TAD boundaries with at least one Mus-conserved site
(right-most violin plot) also have a higher number of CTCF sites overall. In contrast, TAD
boundaries that do not contain any species-conserved CTCF sites (left-most violin plot) have
low numbers of CTCF binding sites.
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(E) The bars correspond to TAD boundaries categorised according to the maximum conser-
vation level of CTCF binding they contain. Dark green demarcates TAD boundaries with
clustered CTCF sites; light green shows TAD boundaries with only singleton sites. TAD
boundaries that harbor species-conserved CTCF sites also contain CTCF site clusters. (F)
Schematic representation of evolutionarily dynamic clusters of CTCF sites that commonly
occur at TAD boundaries. TAD borders usually have at least one 5-way conserved CTCF
site that is clustered with other sites of lower conservation, including species-specific ones.
These CTCF clusters preserve CTCF binding potential at TAD boundaries.
conserved CTCF site surrounded by other sites, frequently species-specific ones, and all the sites were
forming clusters together. Taken together, these findings show that TAD boundaries harbour clusters
of both Mus-conserved CTCF sites and more recently evolved CTCF binding sites (Fig. 2.8F, Fig. 2.9).
I questioned whether this phenomenon is solely a characteristic of TAD boundaries or is it also
found in other part parts of the genome. To address that, I firstly identified 5-way conserved CTCF
sites that were not associated with TAD boundaries and inspected the CTCF binding profile around
them. These were defined as sites with a distance d > 80kb from the closest TAD border, so as to
ensure that, in case of a cluster forming around the given site, the entire cluster would be further than
50kb from the closest TAD border. Additional CTCF sites of various conservation levels, including
several species-specific CTCF sites, were generally found to accumulate around these defined, anchor
Mus-conserved sites (Fig. 2.10). This shows that Mus-conserved CTCF binding events are usually part
of CTCF binding clusters, rather than appearing as singleton sites. Moreover, although the clusters
are apparently stably anchored at 5-way CTCF sites, the cluster as a whole seems to be evolving
dynamically, allowing for integration of many evolutionarily younger lineage-specific binding sites or
loss of binding events in the one or the other mouse species.
The above described CTCF binding features at TAD boundaries were outlined by inspecting the whole
set of Mus CTCF sites projected on the BL6 genome. This allowed for an integrated overview of
CTCF binding in mouse species, focusing on TAD boundaries, and evaluation of its evolutionary
dynamics. I queried whether these evolutionary characteristics of clustered CTCF binding, which
were concluded by assessing the aggregation of CTCF sites in all five species, were also recapitulated
in a single mouse species, specifically in BL6. In that case, I evaluated the aforementioned CTCF
binding features by inspecting only the identified ChIP-seq enriched sites in BL6. In that case, orthol-
ogous aligned regions of putative CTCF binding sites from other species were not considered. This
inspection confirmed that BL6 CTCF sites of any conservation level were enriched at TAD boundaries
(Fig. 2.11A) and that clustered CTCF sites in BL6 were also more frequent at TAD boundaries than
singleton CTCF sites (Fig. 2.11B), as observed in all Mus species (Fig. 2.11A, 2.11C). Moreover, I
found that half of BL6 CTCF binding sites were clustered, similar to the full set of Mus CTCF binding
regions (Fig. 2.11C). It was also shown that the conservation of whole clusters of CTCF sites in BL6
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Fig. 2.9 Examples of TAD boundary regions harboring clusters of both conserved and
divergent CTCF binding sites. (A–C) CTCF ChIP-seq tracks illustrating three examples of
TAD boundary regions harboring clusters of closely located CTCF binding sites. Although
some of the sites are conserved across species, there are also often lineage-specific gains or
losses in the vicinity. Blue shadow boxes highlight the statistically significant peaks identified
by MACS, while pink shadow boxes mark CTCF binding losses (orthologous regions with
no significant peaks). Arrows indicate the orientations of the CTCF binding motif identified
within each peak. In case of more than one motif identified in a peak, the orientation shown
corresponds to the motif with the lowest p value. The contact maps were visualised using
Juicebox [269]
2.2 Results 55
Fig. 2.10 Potential occurrence of CTCF site clusters also away from TAD boundaries.
Enrichment of CTCF sites of different conservation levels around Mus-conserved CTCF sites
that are not associated with TAD boundaries (distance from closest TAD border: d > 80kb).
A high number of species-specific (1-way) CTCF sites are present around these “anchor”
5-way conserved sites, showing that sites of mixed conservation levels can be clustered
together.
Fig. 2.11 Inspection of the CTCF binding profile in BL6 confirms that CTCF sites form
clusters in individual species. (A) Enrichment of BL6 CTCF sites of different conservation
levels at TAD boundaries. (B) Clustered BL6 CTCF sites are more highly enriched than
singleton sites at TAD borders. (C) The fraction of clustered CTCF sites in BL6 is similar
to that of CTCF sites belonging to ancestral Mus clusters. (D) The conservation pattern of
CTCF site clusters, as distinct functional entities, resembles that of individual CTCF binding
sites.
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was similar to that of individual CTCF binding sites (Fig. 2.11D). This implies that clusters of CTCF
sites are evolving under selective pressure similar to that underlying the conservation of individual
CTCF binding sites.
In summary, CTCF binding clusters comprising both species-conserved and species-specific sites are
a common characteristic of TAD boundaries. These clusters are maintained by dynamic evolutionary
processes underlined by deployment of evolutionarily young CTCF sites around older, conserved
ones. In addition, CTCF clusters with similar characteristics can also be found at long distances from
currently identified TAD borders, which suggests a broader role in genome function. That could
be to generally provide a CTCF binding buffer for ensuring CTCF binding at regions where it is of
important functionality.
2.2.5 Localisation of CTCF site clusters with respect to cohesin-occupied
sites and genes
CTCF is known to interact with cohesin to form chromatin loops [170, 202, 203, 270, 201, 271] and
to help establish TAD boundaries [193, 192]. In addition, CTCF is known to frequently bind near
gene promoters [272]. Aiming to gain further insight into possible additional functional roles of
CTCF binding site clusters, I determined the frequency of co-localisation of clustered and singleton
CTCF sites with the RAD21 cohesin subunit, as well as their distance from gene transcription start
sites (TSS) in BL6. To address the first question, I identified cohesin enriched regions on the BL6
genome using ChIP-seq data for the cohesin subunit RAD21 from BL6, which were provided by the
Odom lab. Then I intersected them with the CTCF clusters and singleton sites. CTCF site clusters
were significantly more likely to overlap with RAD21-enriched regions compared with singleton
CTCF sites; the respective fractions of clusters and of singleton sites co-localizing with cohesin were
93% and 69% (χ2 test, p <2.2e-16) (Fig. 2.12A). It is noted that since clusters represent longer
genomic regions than singleton CTCF sites, to control for the length difference of the compared
region sets, I extended the genomic intervals around singleton CTCF sites so that the mean of their
length distribution was equal to that of the CTCF site clusters (Fig. 2.13). This ensured that the higher
overlap frequency of CTCF clusters compared to singletons was not an artefact of their larger length.
Generally, this observation suggests that clusters of closely located CTCF binding sites help stabilise
cohesin at anchors of chromatin loops and/or TAD boundaries. Concerning the characterisation of
CTCF sites with respect to their proximity to genes, I measured the distance of each CTCF site
belonging to a cluster to the nearest gene TSS and compared this distribution to the corresponding
distances for singleton CTCF sites. It was demonstrated that CTCF sites belonging to a cluster are
generally located significantly closer to TSSs (Median distance = 5.3kb) than singleton CTCF sites
(Median distance = 10.9kb) (Mann-Whitney U test, p < 2.2e -16; Fig. 2.12B). This suggests that
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Fig. 2.12 Clustered CTCF sites overlap more frequently with cohesin and locate closer
to genes, compared to singleton CTCF binding sites. (A) 93.7% of the clusters of CTCF
binding sites colocalise with the cohesin subunit RAD21, while the respective fraction of
extended singleton CTCF sites is 69% (χ2 test: p < 2.2e-16). The singleton CTCF binding
regions were extended by a few kilobases prior to intersection with RAD21-enriched regions
to ensure the mean of their length distribution is equal to the mean length distribution of
clusters of CTCF sites. (B) CTCF sites that belong to clusters (clustered) are located closer to
gene TSSs (Median distance = 5.3kb) than singleton CTCF sites (Median distance = 10.9kb)
(Mann-Whitney U test: p < 2.2e-16).
Fig. 2.13 Length distribution of genomic intervals occupied by singleton CTCF sites,
“extended” singleton CTCF sites and clusters of CTCF sites. The extended singleton
CTCF sites represent genomic windows of singleton CTCF sites that were extended so that
the mean of their length distribution becomes equal to that of the length distribution for the
CTCF clusters.
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clusters of CTCF sites may also play an integral role in regulating gene expression.
2.2.6 Impact of species-specific CTCF binding event loss on insulating
function at TAD boundaries
CTCF binding sites lying at TAD boundaries are proposed to buffer contact insulation between
cis-regulatory elements of adjacent TADs [187]. Independent studies have shown that local disruption
of CTCF binding at TAD boundaries can lead to ectopic interactions between promoters and enhancers
[259, 151, 135]. Nevertheless, the impact of such disruptions on local gene expression has not been
systematically investigated. In this study, I leveraged the natural genetic variation in the examined,
closely related mouse species and our own CTCF binding data to study the effect of CTCF binding
site loss in a model fixed by evolution. This approach offers significant advantages over many other
experimental approaches, such as disruption of specific CTCF sites [258, 151, 189, 135], hemizygous
Ctcf deletion [273], or transient acute depletion systems [260, 196, 199] in which there are global
disruptions of cellular equilibrium.
Particularly, I investigated the instances at TAD boundaries where a CTCF binding event was con-
served in all but one of the five study species, i.e. there was a species-specific loss of a TAD-boundary-
associated CTCF binding event. I estimated the impact of these changes on the expression of proximal
genes using RNA sequencing (RNA-seq) in BL6, CAST and CAROLI. In the first place, I identified
either CAST-specific (Fig. 2.14A) or CAROLI-specific losses of individual CTCF binding events at
TAD boundaries (Fig. 2.14D). For each of these lost CTCF sites, I determined the closest upstream
and the closest downstream one-to-one orthologous gene in all three species (Fig. 2.14A, 2.14D) and
calculated the relative gene expression of this gene pair (expressed as log2(fold-change)) in each of
the species (see Methods). I then compared these relative expression patterns among the three species.
There was no detected impact on insulating function due to species-specific losses of individual CTCF
binding events at TAD borders (Fig. 2.14). This suggests that expression patterns of genes at the
borders of TADs are robust to the losses of individual CTCF binding even in cases where the binding
event is preserved in multiple other closely related species. Interpreting that in view of our observed
CTCF binding site clusters, this may underline an interchangeable or additive function of binding
sites contained in a CTCF cluster, which contributes to the maintenance of this functional resilience.
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Fig. 2.14 Gene expression patterns around TAD boundaries are robust to local species-
specific losses of individual CTCF sites. (A) Identified CAST-specific CTCF sites losses at
TAD boundaries and estimated gene expression patterns around them, expressed as log2(fold
change) between the closest downstream to the closest upstream gene. (B, C) Comparisons
of log2(fold change) values of gene pairs flanking the CAST-specific losses of CTCF sites
between BL6 and CAST, with inconsistent CTCF binding, as well as between BL6 and
CAROLI, with consistent CTCF binding. Only genes that have a one-to-one orthologous
relationship and similar gene lengths among BL6, CAST and CAROLI were used. (D)
CAROLI-specific CTCF sites losses at TAD boundaries and estimated gene expression
patterns around them, expressed as log2(fold change) between the closest downstream to the
closest upstream gene. (E, F) Comparisons of log2(fold change) values of gene pairs flanking
the CAROLI-specific losses of CTCF sites between BL6 and CAST, with consistent CTCF
binding, as well as between BL6 and CAROLI, with inconsistent CTCF binding. (G) For
reference, Mus-conserved CTCF sites and gene expression patterns around them (computed
log2(fold change) of the closest downstream to the closest upstream gene) in each of the
species are shown. (H, I) Comparisons of log2(fold-change) values of gene pairs flanking the
examined Mus-conserved CTCF sites between BL6 and CAST, as well as between BL6 and
CAROLI.
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2.2.7 Effect of CTCF hemizygosity on CTCF binding and TAD organ-
isation
I also leveraged the gained insights into Mus CTCF binding evolution to help further inform the
cellular effects of CTCF haploinsufficiency in BL6. It is known that although homozygous deletion
of the Ctcf gene in mouse embryos or in specific cell types causes, respectively, lethality [274] or
dramatic organ dysfunction [275–278], mice with heterozygous Ctcf deletion can develop normally.
However, they are—reportedly—prone to developing cancer [273], while Ctcf has also been identified
as a haploinsufficient tumour suppressor gene in human cancer types [273, 158, 157].
Fig. 2.15 CTCF binding at Mus-conserved sites is robust to hemizygous Ctcf deletion.
We found that the identified differentially bound sites in Ctcf hemizygous cells are depleted
of Mus-conserved CTCF sites. Example genome tracks showing CTCF ChIP-seq enrichment
at a stable CTCF binding site (grey; chr6:120,736,800) and a differentially bound CTCF site
(red; chr2:31,887,060) in BL6 Ctc f+/−. CTCF ChIP-seq enrichment at the corresponding
orthologous regions in the other mouse species is also shown.
Our collaborators, Sarah J. Aitken and Ximena Ibarra-Soria compared genomic features between
cohorts of wild type (WT) and Ctcf hemizygous (Ctc f+/−) mouse embryonic fibroblasts (MEF) from
BL6 mice. Their focus was on investigating differential CTCF binding and its functional implications
in Ctcf hemizygous cells compared to WT. Sarah J Aitken performed experiments and Ximena
Ibarra-Soria processed the generated data. They reported that, despite deletion of one of the Ctcf
gene copies, there is some compensation of the mRNA (63%) and CTCF protein levels (73%) in the
Ctc f+/− MEF hemizygous cells. With respect to the hemizygosity effects on the binding activity of
CTCF, they identified 787 differentially bound CTCF sites motifs of lower binding affinity in MEF
hemizygous cells, as compared to WT. I further found that the Mus-conserved sites, which I identified
and reported above, were depleted among the set of differentially bound sites in Ctc f+/− cells (Fig.
2.15). This shows that CTCF binding at conserved binding sites is robust to low CTCF protein levels
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resulting from hemizygosity.
Motivated by the previously reported evidence that Ctc f+/− mice are prone to cancer development, I
also aimed to address whether the identified differentially bound sites upon Ctcf hemizygosity are
recapitulated by CTCF site mutagenisation in human cancer. Thus, I compared the differentially
bound loci in BL6 Ctc f+/− MEF cells against CTCF binding sites containing mutation hotspots in
human gastrointestinal tumors [279]. Specifically, I projected the identified recurrently mutated CTCF
sites (n=17) from the human genome to mouse (BL6) to find their orthologous regions and examined
whether they coincided with differentially bound sites in Ctcf hemizygosity. However, I did not find
any overlap between the two orthologous sets of sites. Thus, these particular findings of differentially
bound Ctc f+/− sites were not proven to recapitulate the suggested recurrent, driver CTCF mutations
in human gastric cancer.
To investigate the impact of Ctcf hemizygosity on large-scale genome organisation, I called TADs
using normalised Hi-C data that were generated and pre-preprocessed, respectively, by Sarah J. Aitken
and Ximena Ibarra Soria. After calling the TADs, we compared TAD intervals between the two
genotypes and found that the vast majority of self-interacting domains (95%)remained stable in the
Ctcf hemizygous MEFs compared to WT. Ximena Ibarra-Soria further estimated the correlation
coefficient between the interaction profiles of the two genotypes, which was ~0.9.
These results further support the robustness of TAD structures to CTCF binding perturbations, such as
the differential binding caused by Ctcf hemizygosity. Given that TAD boundaries frequently harbour
conserved CTCF sites, their resilience seems to be attributed to the robustness of CTCF binding at
conserved sites, while CTCF site clustering may also enhance this effect.
2.3 Discussion
In this study, I leveraged natural genetic variation in the CTCF binding events of five closely related
species to investigate and characterise features of CTCF binding at TAD boundaries. The findings
highlight that CTCF binding sites at the boundaries of TADs are generally subject to stronger se-
quence constraints compared to CTCF sites in the background genome. Nevertheless, the CTCF
binding profile at TAD borders seems to also be evolving under the effect of dynamic evolutionary
processes. This is indicated by numerous gains of new species-specific CTCF binding sites close to
species-conserved ones, giving rise to mixed clusters with both evolutionarily old and young CTCF
binding sites.
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The described analyses demonstrate that CTCF binding is conserved to a large extent across Mus
species, which is consistent with prior studies showing a high level of CTCF binding conservation
across more distantly related mammalian species [175, 77, 164]. Also in agreement with previous
reports of co-occurring TAD boundaries and CTCF sites that are conserved in mammalian lineages
[134, 184], our data reveal a high occurrence frequency of Mus-conserved CTCF sites at the bound-
aries of TADs. In addition to that, we show that a significant fraction of species-specific CTCF sites
also localise in the vicinity of TAD borders. Moreover, we demonstrate that CTCF binding sites at
TAD boundaries have both stronger sequence constraints and stronger binding affinity, independently
of their conservation across species. Our data also reveal discrepancies in the expansion of TE classes
at TAD boundary regions compared to the background genome. Specifically, TAD boundaries are
relatively depleted of both LINE elements and LINE-derived CTCF binding sites, which may be
evidence of negative selection against insertions of long - potentially disrupting - sequences at TAD
boundaries. This is complementary to observed structural variant depletion at TAD boundaries as
an effect of purifying selection [268]. Overall, these observations suggest that the functional role of
CTCF binding at TAD boundary regions is maintained by multiple evolutionary mechanisms including
local sequence constraint, new site acquisition, and rejection of insertions and deletions.
Our results show that dynamically conserved regions that contain clusters of CTCF sites are another
common characteristic of TAD boundaries. These clusters comprise both conserved CTCF binding
events, which were apparently fixed at TAD boundary regions in the common ancestor, and divergent
sites, which are the result of more recent gains or losses within the distinct mouse lineages. These
clusters create the potential that local turnover events will largely preserve TAD structure and function.
Indeed, a recent study has demonstrated CTCF binding site turnover at loop anchors mediated by TEs
and suggested that this is a common mechanism of contributing to conserved genome folding events
between human and mouse [280]. Based on these observations, we conclude that the formation of
CTCF binding site clusters serves as an additional evolutionary buffering mechanism to preserve the
CTCF binding potential of TAD boundaries and ensure resilience of higher order chromatin structure
by maintaining a dynamic redundancy of CTCF binding sites.
Evolutionarily conserved clusters of CTCF binding site may help explain previous observations of
TAD structures remaining intact upon experimental disruption of individual or multiple CTCF sites,
assuming that such clustered CTCF binding sites can be used interchangeably to provide higher order
resilience against local disruptions. For example, Nora et al. show that the deletion of a TAD boundary
is followed by ectopic cis-interactions locally but adjacent TADs do not merge; they hypothesize
that there must be additional elements within TADs that “act as relays when a main boundary is
removed” [135]. Furthermore, Barutcu et al. demonstrated that TAD structures are preserved upon
deletion of the CTCF-rich Firre locus from a TAD boundary [258]. They hypothesize that additional
CTCF binding sites outside the Firre locus may serve to recruit CTCF and thus help maintain the
TAD boundary. Thus, neighbouring CTCF sites may support CTCF binding activity in a collective
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way. I also found that gene expression around TAD boundaries in cases of species-specific losses of
individual CTCF sites is highly robust. As a whole, these results strongly suggest that the dynamic
conservation of genomic regions harboring clusters of CTCF sites is an important feature of CTCF
binding evolution, which is critical to the functional stability of higher order chromatin structure. Inter-
estingly, such clusters are also found in other genomic regions apart from TAD borders. It is possible
that these regions are related to the establishment of higher order chromatin structure, potentially repre-
senting unidentified TAD boundaries or loop anchors, or other functional and regulatory roles of CTCF.
Further insight into the functional implications of CTCF site clusters come from our results that
CTCF clusters co-localise with the cohesin subunit RAD21 to a greater frequency than singleton
CTCF sites. Moreover, we demonstrate that clustered CTCF sites are located significantly closer to
TSSs than singleton sites. Together, these suggest that clusters play an important role in stabilizing
cohesin at specific genomic regions, as well as in transcriptional regulation. These observations may
provide new mechanistic insight to the previously proposed dynamic loop maintenance complex
(LMC) model, in which cohesin associates with a genomic region for a significantly longer time
than CTCF molecules [173]. Specifically, our observations of clustered CTCF binding sites support
the proposed rapid unloading and rebinding of CTCF molecules in close genomic proximity, which
facilitates rapid cohesin translocation on DNA between CTCF binding sites that act as occasionally
permeable boundary elements [281, 173]. This process apparently facilitates gene transcription by
allowing RNA polymerase II to push cohesin along gene bodies [282, 281, 283].
Finally, it is tempting to speculate a connection between our identified clusters of closely located
CTCF binding sites on the genome and the reportedly observed “clusters” -or “hubs”- of CTCF
protein molecules in 3D [179, 171]. In particular, Hansen et al. have proposed a guided mechanism
where an RNA strand can bind to and gather together multiple CTCF protein molecules near cognate
binding sites. These CTCF molecule “hubs” apparently enhance the search for target binding sites,
increase the binding rate of CTCF to its cognate sites (also as part of the LMC model) and are often
implicated in chromatin loop formation [179, 171]. It is possible that our identified CTCF site clusters
facilitate this mechanism by providing the cognate sites for the concentrated CTCF molecules to bind.
In conclusion, we identified dynamic evolutionary clusters of CTCF binding sites as a feature of
TAD boundary architecture and we propose that these likely contribute to the remarkable resilience
of TAD structures and gene expression to losses and gains of individual CTCF binding sites. Thus,
further studies of seeking a definitive understanding of the functional roles of CTCF might require
consideration of extended regions that harbor clusters of multiple CTCF sites.
This study exemplifies how natural molecular variation in closely related species can be used to gain
mechanistic and functional insights into mechanisms of transcriptional regulation.
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2.4 Methods
2.4.1 ChIP-seq experiments and data analysis
C. Feig performed chromatin immunoprecipitation experiments for CTCF using adult liver tissue
from CAST and SPRETUS. ChIP-seq libraries from three biological replicates of each species were
prepared as described in Schmidt et al. [164]. Subsequently, libraries were sequenced on a HiSeq2000
to produce 100bp paired-end sequence fragments.
In addition, I obtained published CTCF ChIP-seq data from the livers of BL6, CAROLI and PAHARI
[261]. Three biological replicates from each species were used.
I aligned sequenced reads from CAST and SPRET to the reference genome assemblies CAST_EiJ_v1
and SPRET_EiJ_v1, respectively, using BWA 0.7.12 [284]. I also mapped the retrieved raw ChIP-seq
reads from BL6, CAROLI and PAHARI to the genomes GRCm38 (mm10), CAROLI_EIJ_v1.1 and
PAHARI_EIJ_v1.1, using the same method for the sake of performing matched analyses in all species.
CTCF enrichment peaks were called with MACS 1.4.2 [285]. For downstream analyses, I used peaks
identified in at least two replicates of each species.
S. Aitken also performed ChIP-seq in BL6 liver to enable identification genomic regions enriched for
the cohesin subunit RAD21. Sample preparation and chromatin immunoprecipitation was performed
as described in Schmidt et al. [164] using 10 µg RAD21 antibody (Abcam, ab992, lot GR12688-8).
Immunoprecipitated DNA and 50 ng of input DNA was used for library preparation using the Thru-
PLEX DNA-Seq library preparation protocol (Rubicon Genomics, UK). Library fragment size was
determined using a 2100 Bioanalyzer (Agilent). Libraries were quantified by qPCR (Kapa Biosys-
tems). Pooled libraries were deeply sequenced on a HiSeq2500 (Illumina) according to manufacturer’s
instructions to produce single-end 50 bp reads. I obtained 41,260,604 sequenced reads and mapped
them on the mouse genome assembly GRCm38 using BWA 0.6.1 [284]. I then called RAD21 peaks
using MACS2 2.1.2.1 [285].
2.4.2 TADs
I used the boundaries of mouse liver TADs published by Vietri Rudan et al. [184].
2.4.3 Conservation of CTCF binding sites in mice
To investigate the conservation of CTCF binding across the studied Mus species, I first found the
orthologous alignments of the CTCF sites in the genomes of the other species. These orthologous
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CTCF regions across mice were obtained using an extended version of the eutherian mammal Endo-
Pecan-Ortheus (EPO) multiple genome alignment that also included the genomes of CAST, SPRET,
CAROLI and PAHARI [261]. Once the orthologous regions of CTCF sites were identified in all Mus
species, I cross-validated the binding of CTCF in each species using the corresponding ChIP-seq data.
Specifically, I considered that a CTCF site was conserved if a) it had orthologous alignments across
species and b) the orthologous alignments also contained a CTCF peak.
2.4.4 Binding affinity and sequence constraint of CTCF motifs
To identify CTCF binding motifs, I retrieved the FASTA sequences of all CTCF peaks in BL6, using
bedtools getfasta [286] and scanned these sequences for the primary CTCF binding motif (M1) using
FIMO (Find Individual Motif Occurrences) from the MEME suite [287, 288] with default parameters.
I extended the identified 19 base-long M1 motifs to include 20 bases upstream and 20 bases down-
stream in order to ensure I captured the extended version of the motifs (M1 and M2) if present. Finally,
I calculated the binding affinity of these sequences for CTCF using DeepBind [289], and compared
the distributions of the affinity values between motifs found in TAD boundary-associated and in
non-TAD boundary-associated CTCF peaks of each conservation level performing Mann Whitney U
tests.
To retrieve Rejected Substitution (RS) scores for each position of every identified 19 base-long M1
motif in BL6, I fetched pre-calculated conservation scores for each nucleotide of these mouse M1
sequences from Ensembl [290]. These scores have been computed by retrieving genomic alignments
blocks from a multiple genome alignment of eutherian mammals –including mouse- and running the
GERP algorithm [267] on them. The “rejected substitution” (RS) score of a genomic position was
calculated as the difference of observed to expected substitutions. I then averaged the RS score per
position among all motifs and compared these averaged RS scores of TAD boundary-associated M1
motifs with non-TAD boundary-associated motifs (Fig. 2.5E, 2.5F).
2.4.5 ChIP enrichment of identified CTCF peaks
The CTCF sites that I identified in each species were the intersection of the CTCF peaks called in at
least 2 biological replicates. I calculated the ChIP enrichment of each CTCF site by averaging the ChIP
enrichment scores, reported by MACS, over the replicates. The ChIP enrichment scores represent
the pile up of ChIP-seq fragments mapping to each peak region. I then compared the distributions
of average ChIP enrichment between TAD boundary-associated and non-TAD boundary-associated
CTCF sites of each conservation level (Fig. 2.5C, 2.5D).
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2.4.6 Motif-word usage analysis
I scanned all CTCF peaks from each of the five species for the primary CTCF binding motif (M1)
using FIMO from the MEME suite [287, 288]. From the M1 motif instances identified in each
species I retrieved the central, most informative 14mer and estimated its frequency of occurrence
as: the number of occurrences of the 14mer word in CTCF binding regions divided by the number
of occurrences of the word in the whole genome of the species using the procedure of Schmidt et
al., [164]. I filtered out any motif word that occurred fewer than five times in the whole genome. I
illustrated the occurrence frequency of the motif words in each species on a heatmap which is sorted
by distance to the closest TAD border (Fig. A.3).
2.4.7 Association of CTCF sites with classes of Transposable Elements
I used the full set of CTCF sites identified in all species and projected them on to the BL6 genome
(GRCm38), as well as published transposable elements in BL6 [261] (ftp://ftp.ebi.ac.uk/pub/
databases/vertebrategenomics/FOG21/transposableElements/). I intersected the center of each
CTCF binding sites with the transposable elements and reported the number of CTCF site centers that
overlapped with each TE class. The overall representation of each TE class in the whole genome that
is shown as a reference (marked as “background” in Fig. 2.7A) was calculated as: the total length of
all TE class (e.g. SINE, etc) sequences divided by the total genome length.
2.4.8 Representation of TE classes at TAD boundary regions
I defined TAD boundary regions as genomic windows of 50kb upstream and 50kb downstream of
the boundaries of TADs (Fig. 2.7B). To evaluate the representation of each TE class in each of these
regions, I summed the length of sequences that occurred within each TAD boundary region and
corresponded to each TE class, and divided that by the total length of the TAD boundary region, i.e.
100kb. To retrieve random genomic regions of similar length and distribution, I shuffled the TAD
boundary regions using bedtools shuffle, having first excluded chromosome Y, genome scaffolds, and
chromosome ends, where TADs are not called. I repeated the same calculation for these shuffled TAD
boundaries, which correspond to random genomic regions. I then plotted the distribution of these val-
ues for TAD boundary regions and random genomic regions. To determine the representation of each
TE class in the background genome (dotted line in Fig. 2.7B), I divided again -as in Fig. 2.7A- the to-
tal length of all sequences that correspond to each TE class by the total BL6 genome (GRCm38) length.
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2.4.9 Density of CTCF sites at TAD boundaries and clusters of CTCF
binding sites
To determine the enrichment of CTCF binding sites in TAD boundary regions (compared to the
surrounding genome) I measured the distance of each CTCF binding site to its closest TAD boundary
using bedtools closest. I then categorised the CTCF sites based on their conservation level. For each
CTCF site category, I grouped all distance values up to +/- 300kb in bins of 20kb and plotted the
number of CTCF sites in each bin divided by the length of the bin, i.e. 20kb (Fig. 2.8A). To further
characterise the density of CTCF sites at TAD boundaries, I also grouped CTCF sites according to
their conservation level and association with a TAD boundary (vs non association with any TAD
boundary), and for each of these categories I found the distance of each CTCF site from its closest
CTCF site using bedtools closest (Fig. 2.8B).
To identify clusters of CTCF binding sites, I used the full set of CTCF binding sites of all five Mus
species projected onto the BL6 genome (GRCm38), as shown in Fig. 2.1C. I identified instances of
consecutive CTCF sites that were up to 10kb apart from each other, using bedtools cluster. I then
determined and compared the enrichment of clustered and singleton CTCF sites at TAD boundaries
using the same approach as in Fig. 2.8A but having categorised the CTCF sites based on whether they
belong to a cluster ("clustered”) or not (“singletons”) (Fig. 2.8C).
For Figures 2.8D, 2.8E, I again defined TAD boundary regions as TAD boundary +/- 50kb. For
each region I determined the highest conservation level of CTCF sites it contains and based on this I
categorised the TAD boundary region in one of five categories. Subsequently, for each category of
TAD boundary regions I found the total number of CTCF sites it harbored (Fig. 2.8D), as well as the
number of these TAD boundary regions with clustered CTCF sites, as opposed to the ones without
CTCF clusters but only singleton sites (Fig. 2.8E).
For Fig. 2.10, I defined Mus-conserved (5-way) CTCF sites with a distance to the closest TAD border
>80kb as non-TAD boundary-associated. I calculated the enrichment of 1-way (species-specific),
2-way, 3-way and 4-way conserved CTCF sites in their vicinity in the same way as in Fig. 2.8A, but
using as anchor the non-TAD boundary-associated 5-way CTCF sites themselves, instead of the TAD
boundaries.
2.4.10 Clusters in BL6 and cluster conservation analyses
I identified clusters of CTCF binding sites in BL6 (Fig. 2.11) in the same way as for Fig. 2.8C
but using only CTCF peaks called in BL6. I used the same methods as for Fig. 2.8A and 2.8C to
determine the enrichment of CTCF sites of different conservation levels at TAD borders (Fig. 2.11A),
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as well as the enrichment of clustered versus singleton CTCF sites (Fig. 2.11B).
To estimate the conservation of CTCF sites clusters (Fig. 2.11D), I identified all the genomic regions
that correspond to clusters of CTCF sites in each of the five species separately. I then projected
(i.e. found orthologous alignments of) the cluster regions of each species onto the BL6 genome and
determined whether they overlap with the orthologous cluster regions of the other species.
2.4.11 RNA-seq data
I retrieved published liver-derived RNA-seq data from six biological replicates for each of the species
BL6 and CAST [291], as well as from four biological replicates of CAROLI [292]. In addition, K.
Stefflova generated and sequenced two additional RNA-seq libraries for CAROLI in order to have
the same number of replicates in each species, using the methods described in Goncalves et al. [291]
and Wong et al. [292]. Briefly, total RNA was extracted from two independent liver samples using
Qiazol (Qiagen) and DNase treated with DNA-free (Ambion). Polyadenylated mRNA was enriched,
directional double-stranded cDNA was generated and then fragmented by sonication and prepared for
sequencing. Each of the two libraries were sequenced on an Illumina GAIIx to generate 75bp-long
paired-end reads.
2.4.12 RNA-seq data processing and analysis
Adapter sequences were trimmed off with reaper from the Kraken tool suite [293]. The paired-end
RNA-seq reads from each replicate of BL6, CAST and CAROLI were mapped to the corresponding
species genomes (see “ChIP-seq experiments and data analysis” section of Methods) using STAR 1.5.2
[245] with default settings. Raw reads mapping to annotated genes were counted using htseq-count
[247]. I then used the raw read counts to perform differential expression analyses with DESeq2 1.20.0
[250] and default settings.
To determine gene expression patterns around instances of 5-way conserved CTCF sites or species-
specific CTCF site losses at TAD boundaries, I first identified their closest upstream and downstream
genes in each species, as shown in Fig. 2.14A,D,G, using the genesets from Ensembl version 95 [294]
and then calculated the relative gene expression of downstream to upstream gene in each species.
I were not interested in the relative expression of the gene pair flanking a CTCF site per se, but in
whether this ratio for each CTCF site is consistent between species especially when the in-between
CTCF binding changes. For this reason, I only used CTCF sites that were flanked by 1:1 orthologous
genes between the three species. I went on to use DESeq2 [250] in order to compute the log2(fold
change) between the downstream and upstream gene -as a measure of the relative expression of
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genes flanking each CTCF site- in each species, and to subsequently compare this log2(fold change)
between species. Since DESeq2 is not originally designed to normalise for gene lengths, and our aim
was just to get as comparable expression pattern estimations as possible between the species, I also
required all the orthologous genes that I used to have a similar length among the three species (0.7
< len_ratio < 1.3, where len_ratio is: length of gene in species A) length of its orthologous gene in
species B). Finally, I compared the calculated log2(fold-change) values for each gene pair in BL6
with the corresponding value of its orthologous gene pair in CAST (Fig. 2.14B,E,H) and in CAROLI
(Fig. 2.14C, 2.14F, 2.14I).
2.4.13 TAD calling from BL6 MEF Hi-C data
Hi-C experiments were performed by Sarah J. Aitken in three biological replicates from each MEF
cohort, i.e. WT and Ctc f+/−. The corresponding Hi-C libraries were sequenced on a HiSeq4000. The
raw Hi-C data of all three biological replicates from each cohort were merged and Ximena Ibarra-Soria
processed the raw data of each replicate pool, using HiCUP [236] and HOMER [237], to generate
normalised contact matrices between genomic loci at 20kb genomic bin resolution. Subsequently,
I called TADs using the normalised contact matrices and the tadTool software [295] tuning the
parameters as window_size=300kb and cut_off=11.5.

Chapter 3
Cell-of-origin and expression profile of
chemically induced tumours in liver
This chapter outlines my work within a broader collaborative project on liver cancer evolution (LCE).
The LCE project is led by the LCE consortium, which comprises multiple research groups: Flicek
group (EMBL-EBI, Cambridge), Odom group (CRUK, Cambridge and DKFZ, Heidelberg), Taylor
and Semple groups (MRC Human Genetics Unit, Edinburgh) and the Lopez-Bigas group (IRB,
Barcelona). The project makes use of a chemical carcinogenesis model in mouse species to study
mutational processes, as well as the relative contributions of genomic and epigenomic variation in
liver tumorigenesis. To put my own work within the broader context of the project, I firstly provide an
overview of the motivation and the work carried out in the LCE study, as well as the available datasets.
The LCE data presented here have been generated by the LCE consortium at Cancer Research UK
(CRUK) and have also mostly been pre-processed by the LCE consortium. Then I describe my work
on initial exploratory analyses of LCE bulk expression datasets and then combined use of these sets
with external single cell expression data to profile the expression of the cell-of-origin in liver tumours.
The analyses were led by myself, often making use of the LCE consortium pre-processed data. The
distinction between my contributions and the contribution of others is noted in each section. Based on
the analyses presented in this chapter, I drew further research directions to characterise mutagenesis at
transcription factor binding sites in liver tumourigenesis, which will be described in chapter 4.
My work described below was part of the supporting analyses to a particular study of the LCE
consortium that investigated mechanisms of mutagenesis in liver cancer development and tumour
heterogeneity. This first LCE study was published in the following paper: Aitken, S.J., Anderson,
C.J., Connor, F., Pich, O., Sundaram, V., Feig, C., Rayner, T.F., Lukk, M., Aitken, S., Luft, J.,
Kentepozidou, E., Arnedo-Pac, C., Beentjes, S.V., Davies, S.E., Drews, R.M., Ewing, A. Kaiser,
V.B., Khamseh, A. López-Arribillaga, E., Redmond, A.M., Santoyo-Lopez, J., Sentís, I., Talmane, L.,
Yates, A.D., Liver Cancer Evolution Consortium, Semple, C.A., López-Bigas, N., Flicek, P., Odom,
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D.T., Taylor M.S., (2020). Pervasive lesion segregation shapes cancer genome evolution. Nature 583,
265–270. [296]
3.1 Introduction
3.1.1 Liver Cancer and the LCE project
Primary liver cancer is the sixth most common among human malignancies and, by mortality rate,
it ranks fourth. Recent estimates report more than 840,000 cases and 780,000 deaths per year, with
higher incidence rates among men than among women [297, 298]. Hepatocellular carcinoma (HCC)
is the most common histological type of primary liver cancer, accounting for more than 75% of all
liver cancer cases [299], while the second most common type -intrahepatic cholangiocarcinoma-
accounts for 12-15% of the cases [299]. HCC usually occurs in the context of liver diseases, such
as non-alcoholic fatty liver disease (NAFLD), which is frequently associated with diabetes and obe-
sity, chronic viral hepatitis B or C (HBV or HCV), or life style factors, such as increased alcohol
consumption, smoking and dietary aflatoxin exposure [300, 298]. These conditions can lead to
chronic liver disease or cirrhosis, which involve accumulated liver injury, and can eventually cause
HCC development [301]. More than half of the HCC cases are diagnosed at a relatively late stage,
which renders liver tumours resistant to currently available therapies [302]. As in other cancer types,
the potential of cancer cells to evade pharmacological effects is, to a large extent, attributed to the
intrinsic tumour heterogeneity. This heterogeneity is manifested by distinct genetic and phenotypic
characteristics within the same tumour, or between tumours of a single individual or of different
patients [303, 304].
Generally, tumour development in liver, as in other organs, can be viewed as an evolutionary process
that encompasses mutagenesis and selection. This process draws from healthy liver tissue through
the establishment of a clonal cell aggregation -the tumour- that has acquired a selective advantage.
Thanks to this advantage, the clonal tumour can escape the tight regulation programmes that dictate
normal cell behaviour, as well as exogenous constraints on cell proliferation posed by the cellular
environment. It, thus, can display aberrant cell proliferation and outgrow adjacent cell populations.
Further subclones can then be established through subsequent processes of mutagenesis and selection
(reviewed in [305]).
It becomes obvious why, at the molecular level, development of cancer -including HCC- is associated
with the occurrence of somatic mutations. Somatic mutagenesis is caused by exposure to a variety of
endogenous and exogenous DNA damaging factors and can involve faulty DNA replication, enzymatic
modification of DNA, or inefficiency of DNA repair mechanisms [306, 307]. A handful of these
somatic mutations, referred to as driver mutations, have a causal role in driving oncogenesis, as
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they provide the cell with a selective advantage and underline neoplastic transformation [306, 307].
Nevertheless, a cancer genome bears much more than just a small number of driver mutations. The
large amounts of the rest, so-called passenger mutations, although not directly implicated in driving
oncogenesis, reflect the series of mutational processes, which occur throughout tumourigenesis and
tumour progression, and can cause biological perturbations [306, 308, 309]. Hence, they are important
for understanding the historical molecular context of tumour development. In addition, although
driver mutations confer a selective advantage to the tumour cell-of-origin, they do not necessarily
dictate malignant transformation of the cancer cells; in fact this can happen, but it is not always the
case [305]. Therefore, to understand malignancy development, it is useful to study the ensembles
of mutational patterns in the genomes of the cancer cells. Overall, cancer genomes contain several
distinct mutational patterns, or mutational signatures, which are generated as a result of different
mutational processes and are associated with different mutagenic factors.
In HCC genomes, a variety of distinct driver mutations and mutational signatures have been identified.
Most known driver mutations have been identified in coding genes, as it is more straightforward to
infer the functional impact of changes in coding sequences, rather than in non-coding ones. Some
of the most frequent driver mutations are those in: the Tert gene promoter, the tumour suppressor
gene Tp53, the transcriptional regulator Ctnnb1, genes Arid1a and Arid2, which are implicated in
chromatin remodeling, etc [310]. With respect to the different mutational signatures identified in
human HCC, they are associated with various patient factors, such as aging, alcohol abuse, smoking or
aflatoxin exposure [311–313]. These mutational signatures arise as tumour mutations accumulate over
a patient’s entire lifetime and are a consequence of inter-individual differences in genome sequence,
environmental exposures, DNA damage, and repair efficiency [313, 314, 312].
Therefore, the multiplicity of driver genes and mutational patterns identified in HCC genomes demon-
strate the diversity of aetiologies and implicated molecular processes. Moreover, it manifests the
molecular (spatial and temporal) heterogeneity of liver tumours as a response to the various exogenous
and endogenous exposures, germline genetic variation, epigenomic variation and somatic mutational
processes. All this intrinsic tumour heterogeneity and the correlative nature of the mutational sig-
natures poses major challenges in deconvoluting overlapping mutational patterns in cancer, and in
delineating their underlying DNA damage and repair biases, as well as their molecular functional
impact. The challenge further extends to obstructing the interpretation of tumour clonal evolution
dynamics and phenotypic alteration along tumour progression.
This motivated the use of a controlled, physiological cancer model system, by the LCE consortium, to
study liver tumorigenesis while overcoming limitations posed by molecular heterogeneity and diverse
aetiologies in liver cancer development. Within the LCE project, liver cancer evolution was re-run
multiple times via a single chemical carcinogen insult in inbred mice of four different strains and/or
species. These included two strains of the species Mus musculus domesticus, namely C57BL/6J
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(BL6) and C3H, a subspecies of the same species, namely M. m. castaneus (CAST), and another
related mouse species, Mus caroli (CAROLI). Although these include species, sub-species and strains,
hereafter I will conventionally refer to them as species, yet bearing in mind that they are very closely
related. The LCE project generalises an experimental system used for a study of the mutational
patterns in the exomes of C3H mice [315]. In the LCE project, the use of inbred mice from each
species provides a pool of genetically identical individuals, where tumorigenesis was replicated many
times providing high resolution of mutational patterns and increased power for statistical analyses of
the effect of the epigenetic differences between species. The different, yet closely related, genomes
and epigenomes of the mouse species provide a pool of natural genetic and epigenetic variation that
could potentially trigger different responses to carcinogenic factors.
The main aims of the LCE project focus on studying mutagenesis mechanisms in liver cancer initiation
and evolution, as well as on disentangling and evaluating the relative contributions of the genome and
the epigenome to liver cancer development.
3.1.2 Model of chemical carcinogenesis in mouse liver
Fig. 3.1 Model of chemical carcinogenesis in mouse strains that was used in the LCE
project. A single dose of diethylnitrosamine (DEN) was administered to 15 day-old mice
from strains/species: Mus musculus domesticus C57BL/6J (BL6) and C3H/HeOuJ (C3H), M.
m. castaneus CAST/EiJ (CAST), and M. caroli (CAROLI). DEN-treated mice were aged
until they develop liver tumours. A small number of individuals were not treated with DEN
and were aged to develop spontaneous tumours. Samples were collected from DEN-induced
tumours, 15 day-old healthy liver tissue and from a small number of spontaneously induced
tumours, to generate molecular data. Healthy liver tissue from adult mice had also been
collected to be used as a reference.
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Liver tumours were chemically induced using a single dose of diethylnitrosamine (DEN) in 15-day
old, male individuals of four mouse strains and species: Mus musculus domesticus strains C57BL/6J
(BL6) and C3H/HeOuJ (C3H), sub-species M. m. castaneus CAST/EiJ (CAST), and species M.
caroli (CAROLI). DEN is a known carcinogenic compound that gets metabolically activated in liver
by cytochrome P450 enzymes. Upon its bioactivation, it produces metabolites with a prominent
genotoxic effect [316]. The DEN treated mice were aged to develop liver tumours. The time course
from DEN administration to tumour development and collection varied among the different mouse
species; for BL6, C3H, CAST and CAROLI, it corresponded to 35-36 weeks, 23-25 weeks, 39 weeks
and 58-68 weeks, respectively. DEN-induced tumours that were resected from the livers of mice from
each species included mostly dysplastic nodules and a small number of hepatocellular carcinomas
(HCCs). It is noted that dysplastic nodules are lower grade tumours compared to the more developed
HCCs. Moreover, tumours were selected by temporal and morphological criteria (early collection after
onset of tumour development and homogeneity) via histopathological examination, so that they are
monoclonal. Separate untreated mouse cohorts from each species were aged to develop spontaneous
liver tumours. A small number of spontaneously developed tumours was also collected. Based
on subsequent analyses the collected tumours of each species were found to be driven by different
mutations in genes of the EGFR-RAF-RAS signaling pathway. In addition, samples of healthy liver
tissue were collected from adult mice. In detail, samples were collected and data were generated (Fig.
3.1) as following:
• To determine the genomic, epigenomic and expression profile of the liver tissue at the time
point of the carcinogen insult, liver samples were collected from 15 day-old mice of the four
genotypes, prior to DEN treatment. Whole genome sequences and expression data (bulk
RNA-seq) were generated from these samples. Epigenomic marks (CTCF, H3K4me3 and
H3K27ac ChIP-seq) were also mapped using pools of ten liver samples so as to have enough
material.
• A number of samples that had undergone DEN treatments but showed healthy liver phenotype
were collected only from adult normal BL6 mice. Whole genome sequences and RNA-seq data
were derived from these samples.
• DEN-induced tumours, including dysplastic nodules and HCCs, were collected from adult
mice of the four genotypes. Whole genome sequences and RNA-seq data were derived from
these samples.
• Matched normal liver samples were also collected from non-DEN-treated adult mice of the
four strains. Whole genome sequences and RNA-seq data were derived from these samples.
• A small number of spontaneously developed dysplastic nodules and HCCs (no DEN treatment
applied) were collected from aged BL6, C3H and CAST mouse cohorts. Whole genome
sequences and RNA-seq data were derived from these samples.
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Overall, the chemically-induced liver carcinogenesis model used by the LCE project encompasses
the repetition of tumour initiation in individuals of four mouse strains and species upon a single
DEN insult in 15 day-old mice. Observed differences in the latency periods from the carcinogen
insult until tumour development among the strains/species reflect their differential susceptibility to
hepatocarcinogenesis, as has been previously reported [317]. Among the four strains, C3H displays
the highest susceptibility [318] and CAROLI the lowest. In addition, although driver mutations in the
tumours of each strain were identified in the EGFR-RAS-RAF signaling pathway [318, 319, 315, 296],
they were found to occur in different genes of the pathway. The initial phases of the project are focused
on establishing molecular characterisations in each species and examining the reproducibility of the
observed patterns and mechanisms of mutagenesis in the other species, while explicit cross-species
comparisons are to be performed at further stages of the study.
Given this background and data sets and with the aim to understand the molecular characteristics
of the liver tumours, I set out to investigate the expression profile of the cell-of-origin of the col-
lected tumours using the bulk RNA-seq produced by the LCE consortium and externally produced
developmental single cell RNA-seq data from mouse liver (described below). Following that, I also
assessed mutation rates in transcription factor binding sites and their associations with the liver tumour
expression output (Chapter 4).
3.1.3 Liver cancer cell-of-origin
As mentioned above, a main focus of the LCE project is to delineate the roles of genomic and epige-
nomic landscape in the cell’s response to the carcinogen compound. Thus, a fundamental starting
point of the study is the molecular characterisation of the cell that -through mutagenesis and selection-
acquires the growth advantage, and leads to tumour development through neoplastic transformation
and clonal expansion; that is the tumour cell-of-origin. Characterisation of the cell-of-origin would
include determination of its cell type and comprehensive profiling of its expression, genomic, and
epigenomic features.
With regards to the cell-of-origin of HCC, it is typically considered to be the hepatocyte. Yet, this has
generally been a debated subject. A main reason is that the risk of an organ to develop tumours has
been associated with cells that have high generative capacity, such as damage-induced stem cells in
the adult liver [320]. Considering that hepatocytes, the most abundant liver cells, and cholangiocytes,
the second most abundant, are already fully differentiated cells, HCC development has been proposed
to involve activation of hepatic progenitor cells (HPCs, also known as hepatic stem cells) [321].
Generally, HPCs are considered capable of initiating primary liver tumours because they are typically
bipotential cells (hepatoblasts) that, during liver development, differentiate into either hepatocytes or
cholangiocytes. Such progenitor cells, with stemness features, are also present in the adult liver to
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ensure tissue repair upon tissue injury by various damaging factors [322]. Therefore, progenitor cells
can also serve as the cell-of-origin of HCCs that display progenitor-like features. However, recent
studies have provided evidence that the adult hepatocyte is the cell-of-origin of HCC. This can happen
in cases of acute genomic damage that result in direct degeneration of adult hepatocytes into HCC.
Alternatively, adult hepatocytes can dedifferentiate into progenitor-like cells, which will eventually
transform into HCC expressing genes that typically mark progenitor cells. Finally, adult hepatocytes
can also transdifferentiate into biliary-like cells that can give rise to iCCA [323–326]. On another
note, cholangiocytes, which display more limited plasticity, can give rise only to iCCA [327].
Overall, characterising the cell type of the cell-of-origin in our collected liver tumours, as well as its
genomic, epigenomic and transcriptional state at the time point of the carcinogen insult, is important
in order to understand the cell’s response to the mutagenic effect of DEN that leads to neoplastic
transformation and HCC progression. In addition, considering the fact that even among the different
species, but also among inbred mice of the same mouse strain, we had observed some extent of
variation in the selected driver gene, the contribution of the two DEN mutational signatures, as well as
the latency period until the tumours develop, delineating the molecular features of the cell-of-origin
and how they vary among independent tumours, would help understand the factors that contribute to
perturbation of cell homeostasis, selection of driver gene and lead to tumourigenesis.
Therefore, I sought to characterise the cell type and gene expression profile of the cell-of-origin of
the liver tumours by leveraging their derived bulk RNA-seq libraries. A challenge in that case was
that, as the available bulk expression data represent the average expression signal from all cells of a
population, they do not provide high resolution with respect to the profile of the specific cell type.
Nevertheless, given that our collected liver tumours were monoclonal, they were expected to be highly
homogeneous. I reasoned that we can leverage this characteristic of the bulk RNA-seq libraries and
cross-map the expression data of the tumours with expression profiles of single cells from liver, so as
to gain more detailed insights into the transcriptional profile of their cell-of-origin.
3.2 Results
3.2.1 Bulk RNA-seq libraries from LCE tumour samples
To gain insight into the cell-of-origin of our collected liver tumours, I used corresponding bulk
RNA-seq data that were generated by Sarah J. Aitken and pre-processed by the LCE consortium (see
Methods). This expression dataset included a different number of bulk RNA-seq libraries derived
from independent tumours of different individuals from each mouse species (Table 3.1). The available
tumour RNA-seq samples included mostly DEN-induced tumours, as well as a small number of
spontaneously developed tumours (labeled as "None" for Treatment in Table 3.1). In addition, I
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SPECIES BL6 BL6 C3H C3H CAST CAST CAROLI CAROLI
TREATMENT DEN None DEN None DEN None DEN None
liver dysplastic nodule 55 1 175 22 84 6 73 0
HCC 11 2 1 3 0 2 4 0
normal liver 12 0 0 0 0 0 0 0
tail tissue (control) 2 0 0 0 0 0 0 0
Table 3.1 Number of available bulk RNA-seq libraries used by LCE. These include
mostly DEN-induced and to a small extent spontaneously developed (labeled as "None" for
Treatment) tumours, aka dysplastic nodules and HCCs. For BL6, non-tumour liver samples
treated with DEN and two tail samples to be used as controls are also available.
included in the analysis samples of normal liver tissue that was treated with DEN but was not part
of tumours, which were available only for BL6. Finally, I also included two available tail samples
from BL6 to be used as controls (Table 3.1). The expression levels of all expressed genes (sum(TPM)
across all samples > 1) are shown in Fig. B.1, where the tail samples appear as outliers.
3.2.2 Single-cell expression data from hepatobiliary cell differentiation
in mouse liver
To profile the expression of the bulk tumours as close as possible to cell type resolution, I mapped them
onto expression profiles of single cells derived from liver. For this purpose, I used an appropriately in-
formative published single-cell RNA-seq data from fetal mouse liver [328]. The single cells in the set
had been derived from fetal livers of F1 progenies of BL6 and C3H mice, at different developmental
stages (embryonic days: E10.5, E11.5, E12.5, E13.5, E14.5, E15.5, and E17.5). After fluorescent
activated cell sorting (FACS), Yang and colleagues [328] had performed single-cell RNA-seq using
the Smart-Seq2 platform. A total of 447 cells passed quality controls. These included undifferentiated,
proliferating cells at the first embryonic stages of the sampling time course, followed by cells at
intermediate embryonic stages that were either along a hepatoblast-to-hepatocyte differentiation
pathway, or a hepatoblast-to-cholangiocyte differentiation pathway. Finally, cells at the latest sam-
pling time points -the last one being E17.5- corresponded to either fully differentiated hepatocytes or
differentiated cholangiocytes. The hepatoblast-to-hepatocyte transition had been temporally identified
between E13.5 and E15.5, while the hepatoblast-to-cholangiocyte transition had been found to take
place between E11.5 and E14.5. A principal component analysis (PCA) of all single cells by Yang
et al. [328] outlined how cells from the different embryonic stages were distributed across the main
hepatoblast-to-hepatocyte differentiation pathway, and the branching hepatoblast-to-cholangiocyte
differentiation pathway (Fig. 3.2).
I retrieved the RNA-seq data for these 447 single cells from Gene Expression Omnibus (GEO series:
GSE90047), and I quantified their gene expression following the same methods that had been used
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Fig. 3.2 Outline of hepatobiliary cell differentiation based on single-cell RNA-seq data
from fetal mouse liver. Figure adapted from [328]. a,b) PCA of single cells showing
the two branching differentiation pathways from hepatoblasts at earlier embryonic stages
to differentiated cholangiocytes or hepatocytes in the latest embryonic stages. c) Distinct
expression profiles of marker gene clusters, clusters a-d, along the differentiating cells.
Differentiated hepatocytes that are characterised by high expression of cluster c genes are
marked in red frame. cluster a: genes related to cell proliferation and expressed in early
embryonic stages, cluster b: genes expressed in hepatoblasts, cluster c: genes expressed in
hepatocytes, cluster d: genes expressed in cholangiocytes
for the corresponding analysis of bulk RNA-seq samples. Specifically, I used kallisto to calculate
TPM values. Visualisation of the average expression of all genes per single cell was variable (Fig.
B.2a) and lower than that in bulk RNA-seq samples (Fig. B.2a, Fig. B.1). This was expected, as
single-cell RNA-seq measures the distribution of expression levels of each gene across a number of
single cells, while bulk RNA-seq provides an estimate of the average expression level of each gene
across a population of cells.
Yang and colleagues had already identified 1,761 genes that were heterogeneously expressed among
putative cell types along liver development. These genes were grouped in four clusters, with each one
of them marking a distinct cell type. Gene cluster a marked proliferating cells in early embryonic
stages, cluster b included genes that are typically expressed in hepatoblasts, gene cluster c marked
differentiated hepatocytes and genes from cluster d marked differentiated cholangiocytes (Fig. 3.2c
[328]). In further analyses, to deal with the convoluted expression signal of many thousands of genes,
I used only this informative subset of genes that were heterogeneously expressed among cell types
(Fig. B.2b).
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3.2.3 Cross-mapping expression profiles of bulk LCE tumour samples
and single cells from fetal mouse liver
To cross-map the bulk with the single-cell expression profiles, based on the expression of the marker
gene clusters a-d, I performed a principal component analysis (PCA) of both the bulk LCE samples
and the fetal liver single-cells. Overall, the bulk tumours, including both dysplastic nodules and
HCCs, clustered at the end of the hepatoblast-to-hepatocyte differentiation pathway, closest to the
differentiated hepatocytes of the latest sampling embryonic day (E17.5). This indicates that their
expression profile based on cell-type marker genes (gene clusters a-d) resembled that of differentiated
hepatocytes, rather than that of cholangiocytes, hepatoblasts, or undifferentiated proliferating cells
at early developmental stages. As mentioned above, in the BL6 cohort, samples of normal liver
tissue treated with DEN were also included , as well as two tail samples. The normal liver samples
clustered together with the monoclonal liver tumours. Given that 70%-80% of the cells in liver are
hepatocytes [329], this is not surprising, as the expression signal from the bulk normal liver samples
is mostly drawn from the most abundant cell type. The tail samples, which had been kept as controls,
were further from the main cluster of bulk samples (Fig. 3.3). In BL6, two more samples were
slightly off of the main cluster of bulk expression profiles and closer to differentiating hepatoblasts
from earlier embryonic days. These two samples corresponded to HCCs. This might reflect the
onset of a more evident divergence of the cell phenotype from the hepatocyte phenotype as the
tumour is progressing. In fact it seems to reflect dedifferentiation of the hepatocytes as they go
through neoplastic transformation. In CAST, a few tumour samples that were slightly far off of the
clustered bulk tumours corresponded to spontaneously developed tumours ("None" Treatment, Fig.
B.3). This observation seems to reflect differences in the development of tumours under the effect of
a chemical carcinogen insult and the spontaneously developed ones. In the former case, there is a
single carcinogen hit at 15 day-old mice which causes a main mutation burst. In the latter case, the
mutations accumulated in liver probably result from chronic liver damage that accumulates along the
aging of mice. Different aetiologies of liver tumour development are associated with different molec-
ular processes and are reflected in differences among mutational patterns and expression perturbations.
To better characterise the expression profiles of tumours, I inspected the expression levels of genes
included in the marker gene clusters, a-d, in the different liver-derived bulk sample cohorts. On
average, I observed clearly increased expression levels of cluster c genes, genes with hepatocyte
related functions, compared to the genes of clusters a, b and d (Fig. 3.4, 3.5, 3.6, 3.7, Fig. 3.8, Fig.
B.4). I also performed hierarchical clustering of the ensemble of both bulk samples and single cells
using unweighted pair group method with arithmetic mean (UPGMA). All bulk liver-derived samples,
including DEN-treated normal liver, in BL6, and tumours (dysplastic nodules and HCCs) clustered
together and their closest single cells in the hierarchical clustering were the differentiated hepatocytes
of the latest sampling embryonic day (E17.5) (Fig. 3.4, 3.5, 3.6, 3.7). The two tail samples from BL6
had a distinctively different expression profile and appeared as outgroups in the hierarchical clustering
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Fig. 3.3 Principal component analysis of expression profiles of both bulk liver samples
(LCE) and single cell data from mouse liver. Expression profiles are based on expression
of marker gene clusters a-d [328]. The BL6 cohort includes DEN-treated normal liver
samples, liver tumours (dysplastic nodules and HCCs), as well as two samples of tail tissue.
The cohorts of the other species include only liver tumours. The bulk sample expression
profiles mostly map on the latest stage of differentiated hepatocytes. The arrows in the
first panel show the main hepatoblast-to-hepatocyte differentiation pathway (purple) and the
hepatoblast-to-cholangiocyte differentiation pathway (brown). For interpretation also see Fig.
3.2a, 3.2b.
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Fig. 3.4 Expression heatmap of the four marker gene clusters, a-d, for BL6 bulk LCE
samples and single cells from fetal mouse liver. Bulk samples (including mostly mono-
clonal tumours) cluster with differentiated hepatocytes from the latest embryonic stage of the
single cell sampling course.
Fig. 3.5 Expression heatmap of the four marker gene clusters, a-d, for C3H bulk mono-
clonal tumours (LCE) and single cells from fetal mouse liver. Monoclonal bulk tumours
cluster with differentiated hepatocytes.
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Fig. 3.6 Expression heatmap of the four marker gene clusters, a-d, for CAST bulk
monoclonal tumours (LCE) and single cells from fetal mouse liver. Monoclonal bulk
tumours cluster with differentiated hepatocytes.
Fig. 3.7 Expression heatmap of the four marker gene clusters, a-d, for CAROLI bulk
monoclonal tumours (LCE) and single cells from fetal mouse liver. Monoclonal bulk
tumours cluster with differentiated hepatocytes.
84 Chapter 3
(Fig. 3.4). Another general observation within these initial exploratory analyses was that the average
expression levels of cluster c genes (hepatocyte markers), albeit higher than the genes of clusters a, b
and d, showed a decreasing trend along tumour progression, i.e. from dysplastic nodules to HCC in
BL6 and C3H, as well as from DEN-treated normal liver to dysplastic nodules in BL6 (Fig. 3.8). It is
noted that this was a general observation within initial, exploratory analyses, rather than a statistically
tested and substantially confirmed trend. Yet, it triggered questions about expression perturbations of
genes that typically establish and maintain the normal cell phenotype; in this case, specifically, the
hepatocyte.
Fig. 3.8 Distribution of expression levels (measured as log-transformed normalised
counts) of genes contained in the marker gene clusters a-d, in "DEN" and "None treat-
ment" cohort samples per species. Raw read counts were retrieved from the kallisto output
and normalised across samples and species by the LCE consortium. Samples from all cohorts
display distinctly higher expression of cluster c genes, which are hepatocyte markers. In
BL6, a drop of normalised count distribution of cluster c genes is outlined along tumour
progression (from normal liver to dysplastic nodules and subsequently to HCCs). Distribution
shifts are noticed also in the other gene clusters.
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3.2.4 Dysregulation of cell type marker genes in HCC development
Having noticed presumed shifts in the distributions of the expression levels for different marker
gene clusters, I queried whether the genes included in these clusters are significantly dysregulated
in the liver-induced tumours as compared to healthy liver tissue. To address this, I utilised results
of differential expression analyses that had been performed by the LCE consortium for each of the
mouse species. Differential gene expression had been estimated between healthy liver tissue from
adult individuals and DEN-induced tumours that had been grouped according to their identified driver
mutations (Fig. 3.9). Specifically, tumour driver mutations had been found in known driver genes
of the EGFR-RAF-RAS signaling pathway. Yet, a number of different known driver genes were
identified among the tumours of each species, and they were usually mutually exclusive [315, 296].
The few spontaneously developed tumours (labeled as "none" for treatment in Fig. 3.9) had been
excluded from the differential expression estimation, so as to keep the tumour dataset homogeneous
and avoid confounding differential expression results due to potential differences between spontaneous
and chemically-induced tumourigenesis processes.
Fig. 3.9 Number of tumour samples from each cohort with corresponding driver muta-
tions. The identified known driver mutations in the samples were usually mutually exclusive.
"Dysplastic", without indicated driver mutation, labels samples for which no known driver
mutation was identified or had a mix of potential driver mutations.
For each species, I retrieved and visualised the differential expression results for the cell type marker
genes (i.e. genes from clusters a-d) in the distinct tumour cohorts that were driven by different muta-
tions. Indeed in most cohorts over half of the genes from each cluster were significantly dysregulated
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(see barplots in Fig. 3.10, 3.11, 3.12, 3.13). The fractions of dysregulated genes from the marker gene
clusters a, b, c and d, corresponded, respectively, to 51-67%, 33-63%, 36-73% and 29-64% for the
different tumour cohorts (Fig. 3.10, 3.11, 3.12, 3.13) as compared to normal liver. Thus, overall, there
seemed to be consistent dysregulation of genes that typically establish and maintain the phenotype of
the specific cell type, in this case the hepatocyte phenotype, along tumour development. This type
of dysregulation seems to underlie the onset of the cell phenotype shifting from the differentiated
hepatocyte phenotype towards a more dedifferentiated state, a phenomenon that is generally observed
in tumour progression.
Fig. 3.10 Dysregulation of cell type marker genes in BL6 DEN-induced tumours with
different identified driver mutations. Left: Number of significantly dysregulated genes
(up- and down-regulated) from each cell-type marker gene cluster (clusters a-d) for BL6.
Right: Volcano plots of the corresponding, significantly up- and down-regulated genes.
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Fig. 3.11 Dysregulation of cell type marker genes in C3H DEN-induced tumours with
different identified driver mutations. Left: Number of significantly dysregulated genes
(up- and down-regulated) from each cell-type marker gene cluster (clusters a-d) for C3H.
Right: Volcano plots of the corresponding, significantly up- and down-regulated genes.
Fig. 3.12 Dysregulation of cell type marker genes in CAST DEN-induced tumours with
different identified driver mutations. Left: Number of significantly dysregulated genes
(up- and down-regulated) from each cell-type marker gene cluster (clusters a-d) for CAST.
Right: Volcano plots of the corresponding, significantly up- and down-regulated genes.
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Fig. 3.13 Dysregulation of cell type marker genes in CAROLI DEN-induced tumours
with different identified driver mutations. Left: Number of significantly dysregulated
genes (up- and down-regulated) from each cell-type marker gene cluster (clusters a-d) for




As part of first exploratory analyses within the LCE project, I have characterised the expression
profile of cell-type marker genes in the collected monoclonal liver tumours of the different species,
by cross-mapping these profiles with analogous ones of single cells from different hepatobiliary cell
differentiation stages. The expression profiles of the monoclonal tumours of all species match with
those of differentiated hepatocytes, providing further evidence that the HCC cell-of-origin in our
chemical carcinogenesis model is the hepatocyte. Considering that DEN is bioactivated by cytochrome
P450 enzymes (CYP2E1) in centrilobular hepatocytes [330], it is expected that hepatocytes will be
particularly burdened with DEN-caused lesions, many of which will be fixed as somatic mutations. It
is therefore reasonable to establish that, upon a single large mutagenic burst due to DEN exposure, it
is a hepatocyte that acquires a selective advantage, undergoes neoplastic transformation and gives rise
to a DEN-induced clonally expanding tumour in the studied mouse species. A number of studies have
considered the impaired replicative capacity of hepatocytes in chronic liver diseases or massive liver
injury, in human as well as in mouse liver injury models, and have supported a main contribution of
bipotential progenitor cells in initiating liver tumorigenesis [331–336]. Nevertheless, these claims
have been controversial [337, 338]. On the contrary, recent studies indicate the hepatocyte as the
HCC cell-of-origin [339–342, 326]. A number of them have used fate-tracing experiments to show
that HCC originates from hepatocytes in chemically induced carcinogenesis in mice [340, 341],
as well as in cases of models that do not implicate carcinogen treatments [341, 339]. In addition,
the potential of hepatocytes to give rise to tumour development is supported by their remarkable
plasticity. It is known that mature hepatocytes have the capacity to dedifferentiate into a cell state with
progenitor-like features and replenish hepatocytes upon liver injury [325]. It has been shown that their
dedifferentiation can take place upon loss-of-function mutations in the WNT or NOTCH pathways
that might silence the tumour suppressor gene Tp53 [343]. On another note, mature hepatocytes
can also transdifferentiate into biliary-like cells and subsequently give rise to iCCA [324]. Mu et al.
provide evidence that HCC originates from hepatocytes and any observed progenitor-like molecular
features in HCC are attributed to acquired features of transformed hepatocytes, rather than to initiation
of HCC from hepatic progenitor cells [339]. Our collected evidence based on expression profiles of
tumours supports that the DEN-induced liver tumours, including dysplastic nodules and HCCs, in the
mouse strains originate from hepatocytes.
However, despite the clearly prominent expression signal from genes related to hepatocyte functions,
as opposed to the relatively lower expression levels of genes related to cell proliferation in early
embryonic stages, hepatoblast or cholangiocyte functions, a substantial fraction of genes from all
cell-type marker gene clusters show consistent significant dysregulation in tumours with different
driver mutations and in all four species in the LCE study. This may reflect the onset of hepatocyte
transformation, which drives the phenotype of the cell to diverge from the normal hepatocyte pheno-
type to a dysplastic phenotype. It is generally important to understand what aberrations of molecular
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processes can take place throughout the phenotypic shift, destabilise homeostasis and increase the risk
of developing liver cancer and/or the potential of malignant transformation. Such aberrations may be
downstream of the oncogenic driver mutation hit, yet have the capacity to further perturb the cellular
environment and enhance the growth advantage of the cell, eventually making it more resistant to
cancer therapies. Shift of a mature cell phenotype to a less differentiated (or dedifferentiated) cell type
is generally associated with tumour progression, aggressiveness and resistance to medical treatments
[344–346]. In addition, emerging evidence shows that loss of cell differentiation along tumourigenesis
is associated with the capacity of the transforming tumour cells to evade recognition and destruction
by the immune system (reviewed in [347]).
Taken together, this evidence highlights that understanding and dealing with mechanisms of liver
cancinogenesis requires a profound molecular characterisation of the phenotypic shift from a dif-
ferentiated cell type towards a dedifferentiated state. This phenotypic shift is associated with gene
expression alterations in the transforming hepatocyte, which in turn must be underlined by corre-
sponding changes in the regulatory programme of the cell. Therefore, to molecularly characterise
the hepatocyte neoplastic transformation we would need to determine the relevant changes in gene
regulatory mechanisms.
Understanding the molecular changes that take place within the context of a specific cell-type en-
vironment governed by a specific regulatory programme, such as that of the hepatocyte in HCC
development, is also relevant with respect to elucidating the conditions and factors that determine
the choice of the cancer driver gene. It is known that mutations in driver genes exhibit a spectrum of
remarkable specificity in distinct cancer types. Only few driver mutations, such as in TP53 or TERT,
show a broad distribution in a range of cancer types. In contrast, most driver mutations promote
cancer development in specific tissues. For instance, chronic myeloid leukemia is strikingly associated
with the BCR-ABL gene fusion mutation, while retinoblastoma is usually driven by loss-of-function
mutations of particular tumour suppressor genes [348]. Other cancer types appear to be frequently
linked with recurrent mutations in a set of genes involved in particular signalling pathways, such as
the EGFR-RAS-RAF pathway that is also perturbed in cases of HCC or lung adenocarcinoma [349]
(reviewed in [350]). Another example is the case of mutations in BRCA1 and BRCA2 that predispose
specifically for breast and ovarian cancer, even though these genes are ubiquitously expressed in a
range of tissues [351]. In most cases, the underlying molecular mechanisms of tissue-specificity for
distinct sets of driver genes remain elusive. A prevailing hypothesis is that tissue-specificity of driver
mutations is associated with particular aspects of the distinct regulatory programme that is employed
by each tissue in order to establish and maintain the differentiated cell phenotype and suppress the
pluripotent, stem cell gene expression repertoire that can be implicated in tumourigenesis (reviewed
in [352]). This is another aspect that highlights the importance of characterising regulatory state in
the tumour cell-of-origin, monitoring how it might change throughout tumourigenesis and outline
the susceptibilities to cancer initiation this might confer to the cell. However, hereafter I will focus
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particularly on aspects of regulatory changes through the angle of identifying potential implications
in the shift of the cell phenotype along HCC development.
3.4 Methods
3.4.1 Expression quantification in LCE bulk samples and in single cells
Raw RNA-seq data from bulk samples were pre-processed by the LCE consortium. Specifically,
transcriptome indices were generated from cDNA sequences in each species (Ensembl 91) and
transcripts per million (TPM values) were calculated for each transcript isoform using kallisto
(v0.43.1) [248] with the options plaintext, bias, and pseudobam.
To quantify gene expression in the single cell RNA-seq libraries (GEO series: GSE90047) [328], I
followed the same approach used for expression quantification in the bulk RNA-seq libraries by the
LCE. used kallisto v0.43.1 [248]. First, I used kallisto index to generate a transcriptome index of
cDNA sequences in each species (Ensembl 91) also including 92 ERCC spike-in sequences that were
used in the RNA sequncing of the single cells. To calculate TPM values for each transcript isoform, I
used kallisto quant with the options plaintext, bias, single, pseudobam, fragment-length = 350 and
sd = 50. Finally, to calculate TPM values at gene level, I used tximport (v1.10.1) [353]. To enable
comparisons between the single-cells and bulk tumours, I also calculated TPMs at gene levels for the
bulk samples, using tximport (v1.10.1).
3.4.2 Identification of driver mutations in tumours
Driver mutations were identified in each tumour by the LCE consortium using OncodriveFML (v.2.2.0)
[354] and OncodriveCLUSTL (v.1.1.1) [355]).
3.4.3 Differential gene expression analyses
Differential gene expression analyses were performed by the LCE consortium between each cohort
of DEN-induced tumours with a specified driver mutation and normal liver samples. Differential
expression for coding genes was then called using the Wald test from DESeq2 [250] and raw count
values that had been calculated by kallisto and aggregated to the gene level by tximport.

Chapter 4
Mutational landscapes of distinct
transcription factor binding region
categories and functional implications in
chemically induced liver tumours
This chapter describes my work on characterising DEN-caused mutational patterns in distinct groups
of liver TF binding regions, and assessing their functional implications in liver cancer development. It
follows up from the expression profiling of the tumour cell-of-origin discussed in the previous chapter.
To perform the analyses described below, I have used datasets from two different sources: a) mutations
in DEN-induced tumours from three mouse species, which were called by the LCE consortium using
WGS data from the tumours, and b) raw, published ChIP-seq data for three liver TFs in the same mouse
species, which I analysed. Except as noted, all of the analyses described below were carried out by me.
4.1 Introduction
In the previous chapter, I profiled the expression of cell-type marker genes in liver tumours with
different driver mutations, in all four mouse species used in the LCE project. Despite the fact that
monoclonal tumours showed an expression profile that matched that of a hepatocyte, there was
observed consistent dysregulation of hundreds of genes that typically associate with establishment and
maintenance of the hepatocyte-specific phenotype. These differential expression patterns manifest
a dedifferentiation process the hepatocyte undergoes as it transforms to HCC. Understanding and
dealing with liver cancinogenesis requires a profound characterisation of the molecular changes that
are implicated in disruption of the cellular equilibrium and loss of the cell phenotype specificity.
Given that establishment and maintenance of the cell phenotype depends to a great extent on cell-type
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specific regulatory networks, it is possible that gene expression shifts associated with regulatory
changes may contribute to the observed shift of the cellular phenotype. Addressing the cause of
gene dysregulation in HCC development requires to determine how the gene regulatory programme
changes in the transforming hepatocyte.
It is known that important players in establishing gene regulatory networks in distinct cell types are the
transcription factors (TFs) expressed and the genomic sites where they bind and exert their regulatory
function. Therefore, among other factors, it may be useful to identify changes in TF activity with
respect to hepatocyte gene dysregulation along neoplastic transformation. Modifications of TF activity
can encompass changes in at least one of two factors: the expression levels of TF genes themselves,
and the binding of TFs to their corresponding binding sites that, in turn, affects regulation of the TF
target genes. Given that, in general, tumourigenesis is to a great extent a consequence of somatic
mutations, tumour-associated changes in regulatory mechanisms, including TF binding, must be
largely a result of somatic mutations. Mutations that affect TF activity may be in TF-coding genes or
in genes whose products interact with TFs. Alternatively, they can be in binding sites of TFs, having
an effect on the binding affinity.
Although mutational processes in protein-coding genes and their oncogenic effect have been exten-
sively studied, little is known about the implication of non-coding mutations–especially within TF
binding regions–in cancer development. The best known examples are mutations in the promoter
of the TERT oncogene that create novel binding sites for ETS TFs leading to upregulation of TERT
[356, 357]. Similarly, it has been shown that creation of a new TF binding site driven by non-coding
mutations leads to overexpression of the TAL1 oncogene reportedly via regulation by a super-enhancer
[358]. Despite the elucidation of this handful of non-coding driver examples, non-coding mutations
remain largely uncharacterised. Yet, the majority of mutations in cancer occur in non-coding regions
[359]. Most of them are considered passenger mutations, i.e. not directly driving oncogenesis.
However, there is growing evidence that putative passenger mutations have an aggregated contribution
to the whole mutational landscape in a cancer genome, and they can have a collective impact on
molecular functions [360, 361]. It is also suggested that some putative passengers may have a weak
effect on the fitness of cancerous cells, thus contributing to or impeding tumour growth [361, 362].
Recent studies further suggest that putative passengers, even if seemingly not implicated in tumour
initiation, can confer fitness advantages to the tumour cells at subsequent stages of tumour progression
[363, 360]. In addition, it was shown that the collective impact of putative passenger mutations can be
used as a predictor to distinguish between healthy and cancer phenotypes, especially in tumours with
no known driver mutations [360]. Yet, it is acknowledged that small sets of supposedly passenger
mutations may, in fact, represent changes with driver functions [360].
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With respect to mutations in TF binding sites, in a recent study, partitioning the genome into cistromes1,
showed convergence of known risk single nucleotide variants (SNVs) and somatic SNVs in the
cistromes of the TFs AR, FOXA1 and HOXB13 that act as master regulators in prostate tumour
development. In addition, some of these mutations were shown to change the expression output
from the associated regulatory elements [82]. Moreover, in a complementary study by the same
group, inspection of the regulatory plexus of FOXA12 resulted in identification of a set of mutations
in six CREs that regulate FOXA1 expression. These mutations were shown to have an impact on the
transactivation potential of the respective CREs [81].
Motivated by this background and considering that DEN-induced liver tumour development is very
much driven by acute DEN mutagenic effect, we reasoned that HCC-associated expression changes
may be attributed to somatic regulatory mutations, including mutations in TF binding. We therefore
sought to investigate potential associations between TF binding activity alterations and genomic muta-
tions in the DEN-induced liver tumours. As mutations in genic sequences and detailed gene expression
analyses—including TF-coding genes—are being investigated extensively by other consortium mem-
bers, I focused on investigating mutagenesis in TF binding regions in the DEN-induced tumours. To
this end, I utilised the mutations identified in WGS data from the collected LCE tumours, as well
as previously published ChIP-seq data for three TFs expressed in liver, namely CCAAT/enhancer-
binding protein alpha (CEBPA), forkhead box A1 (FOXA1), and hepatocyte nuclear factor 4 alpha
(HNF4A) from three of the mouse species studied in the LCE project, i.e. BL6, CAST and CAROLI
[78]. By combined analyses of the ChIP-seq and the tumour mutation datasets in the three mouse
species, I characterised the mutational profiles of the binding region ensembles, or cistromes, of the
corresponding liver TFs. I further evaluated the relative mutation rates among the three TF cistromes
in each species, as well as among functional sub-categories of cistromes after splitting them based on
a) their potential of combinatorial TF binding and b) their association with cis-regulatory elements.
The results revealed different mutation rates among distinct sets of TF binding regions, potentially
reflecting differential effects of purifying selection according to the functional importance of the
corresponding regions. In addition, the analyses revealed a set of hyper mutated TF binding regions,
largely in cis-regulatory elements, that are associated with dysregulation of genes driving the cell
phenotype. The mutational and gene dysregulation patterns were largely reproducible among the
three mouse species. These results exemplify exploration of non-coding mutation sets with functional
implications in liver tumour development.
1A cistrome is defined as "the set of cis-acting targets of a trans-acting factor on a genome-wide scale, also
known as the in vivo genome-wide location of transcription factor binding sites, or histone modifications" [364]
2The plexus of a gene is defined as its "cell-type-specific three-dimensional gene-regulatory neighborhood,
inferred using Hi-C chromosomal interactions and chromatin state annotations" [365]
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4.2 Results
4.2.1 DEN tumour mutation datasets: abundance of T → N mutations
in all three mouse species
The mutation data I used in this study had been generated, processed and quality filtered by the LCE
consortium. I retrieved the mutation datasets for the BL6, CAST and CAROLI liver tumour cohorts,
and selected only the Single Nucleotide Variants (SNVs)—excluding other types of mutations—that
were identified in DEN-induced tumours. Therefore, hereafter, the use of the term “mutations” refers
to SNVs. Mutation data from C3H were not considered, because there were no available TF ChIP-seq
for this strain. My selected mutation dataset included in total 66, 84 and 79 DEN-induced liver
tumours from BL6, CAST and CAROLI, respectively (Table 4.1 - Appendix C). The total number of
mutations from all the tumour samples of each species were ~5.2 x 106, ~6.4 x 106, ~4.4 x 106, with
a median number of mutations per tumour being approximately 78.8 x 103, 76.6 x 103, 52.8 x 103 for
BL6, CAST and CAROLI respectively (Fig. 4.1a, Fig. 4.1b, Table 4.1). The higher total number of
mutations in CAST than in BL6 (Fig. 4.1a) seemed to reflect the higher number of available CAST tu-
mour samples. However, the median mutation count per tumour (Fig. 4.1b) was very similar between
BL6 and CAST. In contrast, the median number of mutations per tumour was slightly lower in CAR-
OLI, even when accounting also for genome sizes. Whether this is associated with the longer latency
period between the DEN insult and liver tumour development in CAROLI (as mentioned in chap-
ter 3) is not clear based on the current analyses. Yet it provides a future research direction for the study.
BL6 CAST CAROLI
Number of tumour samples 66 84 79
Total mutation counts from all
tumours
5,240,706 6,381,768 4,441,825
Median mutation count per tu-
mour
78,843 76,596 52,819
Median mut. count per tu-
mour divided by genome size
2.99e-05 2.90e-05 2.11e-05
Table 4.1 Counts of DEN-induced tumour samples, aggregated mutations from all tumour
samples, and median mutation count per sample in each species.
To get an overview of the most frequent mutations in the DEN tumours of each species and how
they compare to each other, I calculated and visualised the corresponding mutation spectra. These
showed a similar mutation distribution pattern among the three species, with thymine-to-adenine
(T → A) mutations being the most frequent, followed by thymine-to-cytosine (T → C) mutations,
and subsequently by cytosine-to-thymine (C → T) and cytosine-to-adenine (C → A) mutations (Fig.
4.1c). A high frequency of mutated T’s was generally expected, as it is known that DEN mostly
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Fig. 4.1 Mutational profiles of DEN-induced tumours in each mouse species. a) Total
number of mutations identified in all DEN tumour samples. b) Mutation counts (per kb)
per DEN tumour sample, ranked over x axis. Lines mark median values. Number of
tumour samples (data points) per species shown in Table 4.1. c) Mutational spectra from the
aggregated mutations of all DEN tumour samples in each species.
causes lesions on thymines. Specifically, formation of a O4-ethyl-deoxythymidine adduct on the DNA
thymines is the most common effect of DEN bioactivation [316]. That often leads to fixed thymine
mutations (T → N), or the complement A → N mutations, upon translesion replication or translesion
transcription of the damaged DNA strand segment. This is a result of impaired recognition of the
template nucleotide by the DNA replication machinery when encountering a nucleotide with a lesion,
which can lead to a nucleotide mismatch in the newly synthesized DNA strand. Similarly, the second
most frequent mutations, i.e. C → N, or their complementary guanine mutations (G → N), can also
be explained as a result of the formation of O6 -ethyl-2-deoxyguanosine lesions on guanines upon
DEN bioactivation [316]. The lack of striking differences in the mutation spectra among the mouse
strains is not surprising, as the spectra of nucleotide substitutions basically reveal the DEN mutational
signature. In our previous study of DEN-induced tumours in mouse strains, a detailed inspection of
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mutational signatures was carried out by the LCE consortium, in C3H and in CAST derived liver
tumours. This revealed the presence of a primary DEN mutational signature (DEN1), predominated by
T → N mutations (or the complementary A → N), mostly T → C and T → A, as well as a secondary
mutational signature (DEN2), predominated by C → T mutations (or the complementary G → A).
DEN1 was clearly more prominent in the DEN tumours, while DEN2 had a minor contribution to
the mutational landscape of most tumours (Fig. C.1 - Appendix C) [296]. The overview of mutation
spectra presented here seems to reflect the predominant contribution of the DEN1 signature - as
inferred by the abundance of T → N mutations- and a minor contribution of the DEN2 signature in all
three species (Fig. 4.1c).
4.2.2 Cistromes of liver TFs and categorisation into sub-cistromes based
on combinatorial TF binding and CRE co-occurrence
As mentioned in the introduction, in this study I also used published ChIP-seq datasets for three
liver TFs, namely CEBPA, FOXA1 and HNF4A, in BL6, CAST and CAROLI [78]. I retrieved and
reanalysed the raw ChIP-seq data to determine the genome wide binding profiles of the three TFs
of interest, CEBPA, FOXA1 and HNF4A. Specifically, I mapped the raw ChIP-seq reads on the
updated genome assemblies used by the LCE consortium and identified TF binding regions (TFBRs),
hereby also referred to as TF peaks meaning the peaks of piled mapped reads at the bound sites
showing up in the computational analysis (see details in Methods). Hereafter, the terms TF peaks
and TF binding regions are used interchangeably. In all species, tens of thousands of binding regions
were identified for each TF, exceeding a hundred thousand regions in CAST (Fig. 4.2a, Table C.1
- Appendix C). Small differences in the number of identified peaks among the species are possibly
attributed to experimental or technical differences such as antibody specificity or genome assembly
quality. Overall, there were fewer peaks identified for all TFs in CAROLI, especially for CEBPA,
compared to the other species. The low peak number specifically for CEBPA seems to be partly due
to very poor read quality in one of the CEBPA ChIP-seq libraries that were used. Specifically, the read
mapping rate for this low quality library was < 3%, strikingly lower than the average mapping rate
of ~80% that was observed for all the other ChIP-seq libraries. At the same time, this poor quality
CEBPA library from CAROLI had a much higher sequencing depth (~71 million reads), compared to
the other libraries (~27 million reads on average).
A major focus of my work has been on evaluating the effect of combinatorial binding of distinct TFs
on the mutational patterns of TFBRs. Thus, I also characterised the TFBRs contained in each TF
cistrome based on whether they present binding by only one of the three studied TFs (i.e. CEBPA,
FOXA1 or HNF4A binding alone), a combination of two of the TFs, or a combination of all three TFs.
The corresponding groups were respectively labelled as “1TF”, “2TF”, or “3TF” groups (Fig. 4.2b).
The criterion used to assign a binding region of a given TF (as identified by the ChIP-seq enrichment
signal) to one of the three groups was whether this region overlaps with any binding region of the
4.2 Results 99
Fig. 4.2 Identification and characterisation of genome-wide identified binding regions
for each of the three liver TFs (CEBPA, FOXA1 and HNF4A) in three mouse species
(BL6, CAST and CAROLI). The first column schematically shows the grouping of TFBRs,
the second the number of peaks in each category, and the third the length distribution of the
corresponding TFBRs in each (sub-)cistrome, at different levels of classification: a) TFBRs
per cistrome, b) TFBRs of each cistrome grouped in categories based on the total number of
liver TFs bound to the underlying genomic region. TF_X, TF_Y and TF_Z represent one of
CEBPA, FOXA1 and HNF4A. c) Grouping of the TFBRs of each cistrome based on their
overlap with cis-regulatory elements.
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other TFs (Fig. 4.2b). This type of grouping revealed that the majority of the identified TFBRs have
combinatorial binding of either two or three of the TFs, while the regions that are bound by one TF
alone were relatively fewer, in line with previous studies [366].
TFs are known to often bind within cis-regulatory elements (CREs), such as promoters and enhancers.
To investigate this functional feature of TFs, I also categorised the binding regions of each of the
three TFs based on whether they overlap with any promoter, enhancer, or none of these CREs (Fig.
4.2c). To assign the TFBRs in one of the three groups, I intersected each one of them with promoters
and enhancers identified in livers of healthy BL6, CAST and CAROLI mice by the LCE consortium.
Promoters and enhancers had been determined as genomic regions marked by promoter-associated or
enhancer-associated histone modifications, via analysis of corresponding ChIP-seq data (see Methods).
Promoter-overlapping TFBRs represented the smallest of the three categories, corresponding to
fractions ~14-22% of each cistrome, showing small variety among the cistromes of the different TFs
and species. The following smaller category was the enhancer-overlapping TFBRs, representing
26-40% of the total TF binding regions per cistrome, while the rest of the TF binding regions were not
found to overlap with any of these CREs (Fig. 4.2c). The increased fraction of TFBRs overlapping
with enhancers, as compared to overlap with promoters, seems to reflect the higher total number
of identified enhancers in the mouse genomes, compared to the total count of promoters (Table
C.2 - Appendix C). Other CRE characterisations have similarly reported ratios of 2.5 enhancers per
promoter in mammalian species [367]. Overall, around half of the binding regions in each set were
found to overlap with regulatory elements, either promoters or enhancers.
4.2.3 The majority of TF binding regions contain a combination of TF
binding motifs
To complement the characterisation of the liver TF cistromes, I also identified TF binding motifs
within their contained peaks. Given the extensive combinatorial binding that had been observed, a
particular aspect to be addressed was whether this extent of TF co-binding was also recapitulated
in the motif content of the TF peaks. In the first place, I estimated the relative amount of identified
ChIP-seq TF peaks that contain the binding motif of the corresponding TF. Specifically, I retrieved
the underlying genomic sequences of the CEBPA, FOXA1 and HNF4A peak sets, as identified by
ChIP-seq, and scanned them searching for occurrences of the canonical CEBPA-binding, FOXA1-
binding and HNF4A-binding motif respectively [168] (see Methods) (Fig. 4.3a, b). Most peaks of
each set ( 67-77%) were indeed found to contain at least one occurrence of the binding motif of the
corresponding TF, while a minority of them did not have any motif (Fig. 4.3b). Overall, some tens
to hundreds of thousands of occurrences of each canonical TF binding motif were identified in the
aggregation of peaks of the corresponding TF cistrome (Fig. C.2a - Appendix C). The total number of
identified motifs in each cistrome was generally proportional to the number of TF peaks (Fig. 4.3b),
although there was not a one-to-one relationship, as some peaks might contain more than one motif,
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Fig. 4.3 Motif identification in the ChIP-seq TF peaks. a) Position weight matrices of the
CEBPA, FOXA1 and HNF4A motifs that were searched within the ChIP-enriched regions
for the corresponding TF [168]. b) Number of TF peaks that contain, or not, occurrences of
the searched motif.
while also some others might not contain any. Cross-species differences in the amount of motifs
identified in each TF peak set may be an effect of the different number of peaks included in each
of these sets. For instance, the lower number of CEBPA motifs that were identified in the CAROLI
CEBPA peaks than in the CAST CEBPA peaks is probably attributed to the low number of CEBPA
peaks identified in CAROLI.
Next, I also searched for occurrences of each of the three TF-binding motifs in the cistromes of
the other TFs, for example I searched for CEBPA-binding motif occurrences in the FOXA1 peaks.
Interestingly, numerous occurrences of each motif were also found in the ChIP-seq peaks of the other
TFs, for example thousands of FOXA1-binding motifs were identified not only in FOXA1 peaks but
also in CEBPA peaks (Fig. C.2a - Appendix C). This is indicative of the potential of each TFBR to
bind a combination of TFs, either simultaneously or not. On another note, as a subset of the identified
TFBRs occur within CREs (Fig. 4.2c), also a subset of the identified motifs in the TFBRs occur in
CRE peaks (Fig. C.2b - Appendix C).
To gain further insight into the potential of combinatorial binding at the TFBRs of each cistrome, I
sought to report also the number of peaks from each TF cistrome that contain the binding motif of
other TFs. I observed that, besides the canonical motif of their corresponding TF, the ChIP-seq peaks
of each TF cistrome also contained, to a large extent, the canonical motifs of the other liver TFs (Fig.
4.4a). This further supports that most of the TF peaks have the potential to bind different TFs, very
likely in combinations.
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Fig. 4.4 Content of aggregated TFBRs of each cistrome in canonical CEBPA, FOXA1
and HNF4A binding motifs. CEBPA, FOXA1 and HNF4A motifs were searched in the
underlying sequences of all peaks from each set. a) Total number of TF peaks (y axis)
containing at least one occurrence of each canonical motif indicated on x axis, b) Density
plots showing the number of distinct TF binding motifs (CEBPA, FOXA1 and HNF4A)
contained per TF peak, with the peaks of each cistrome grouped as 1TF-, 2TF- or 3TF-bound
based on ChIP-seq enrichment for the liver TFs.
A particular observation in this analysis was that the amount of CEBPA peaks containing CEBPA-
binding motifs was very similar to the reported number of CEBPA peaks containing FOXA1 and
HNF4A motifs (CEBPA peaks are shown as green bars in Fig. 4.4a). Similarly, the total amount of
occurrences of the canonical FOXA1 and HNF4A motifs in CEBPA peaks was very close to the total
amount of CEBPA-binding motifs in the CEBPA peaks (CEBPA peaks containing occurrences of
different motifs are also shown as green bars in Fig. C.2a - Appendix C). Considering also the relative
fraction of combinatorially bound CEBPA TFBRs (2TF and 3TF groups in Fig. 4.2b), as compared to
the fewer singly bound CEBPA TFBRs (1TF group in Fig. 4.2b) for BL6 and CAROLI, these obser-
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vations may indicate that CEBPA co-binds with the other two TFs at a particularly increased frequency.
Up to this point, I reported total numbers of motif occurrences in the aggregated peaks of each TF
cistrome. In addition to that, I summarised whether the sub-grouping of the peaks of each TF cistrome
into 1TF-, 2TF- and 3TF-bound sub-cistromes (based on ChIP-seq enrichment for the correspond-
ing numbers of TFs) was recapitulated by their content of canonical motifs of one TF, two TFs or
three liver TFs in total. I found that 1TF-bound peaks of the FOXA1 and HNF4A cistromes indeed
contained the canonical motif of only one liver TF (median) (Fig. 4.4b). In contrast, CEBPA peaks
that had been grouped as 1TF contained motifs of a median of 2 TFs, perhaps underlying again a
higher potential of CEBPA to co-bind with the other liver TFs (Fig. 4.4b). Another exception was also
FOXA1 1TF peaks in CAROLI, which also contained motifs of 2 TFs (median). Peaks that had been
grouped as 2TF-bound were found to contain canonical motifs of a median of 2 TFs, consistently
across all TF cistromes and all species. Finally, the 3TF peaks in all cases contained motifs of a
median of 2 TFs, although the corresponding distributions were skewed towards 3 (Fig. 4.4b). This
implies that a TFBR can possibly get bound by three different liver TFs, even if it does not explicitly
contain the binding motifs of all the three corresponding TFs. Overall, the extent of combinatorial
TF binding identified by ChIP-seq enrichment was largely recapitulated by the presence of canonical
motifs for distinct TFs within the combinatorially bound ChIP-seq peak regions.
4.2.4 Fractions of TF binding regions that are mutated in DEN-induced
liver tumours
A major aim of this project was to evaluate the mutation loads of the liver TF binding profiles in
DEN-induced liver tumours. To address this, for each individual species, I performed combined
analyses of both the liver TF cistrome datasets and the corresponding mutation datasets. In the first
place, I intersected each TFBR set with the aggregation of mutations from all DEN tumours in each
species. Overall, less than half of the regions of each set were found to be mutated (Fig. 4.5a, Fig.
4.6). The percentages of mutated TFBRs showed little variation among the peak sets of the different
TFs, corresponding to 27-38%, 41-46% and 27-30% for BL6, CAST and CAROLI respectively (Fig.
4.5a). Differences in the mutated TFBR fractions between corresponding cistromes of distinct species
may reflect differences in the total number of TFBRs identified in the species, the total number of
identified mutations, the available tumour samples, the genome assemblies, or the biology of the
species. However, it is noted that the current phase of the study focuses on characterising the TFBR
mutational patterns in each species separately and check their reproducibility among species, rather
than performing direct detailed cross-species comparisons of measured variables. For the reference,
CAST, which had a higher fraction of mutated TFBRs than BL6 and CAROLI, was also the species
that had the highest total number of identified mutations, the highest number of available tumour
samples from which the mutations were called (N=84, Table 3.1), as well as the highest number of
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Fig. 4.5 Relative fractions of mutated and non-mutated TFBRs in each cistrome and
sub-cistrome. a) all TFBRs per cistrome, b-d) TFBRs grouped in sub-cistromes based on:
the number of (co-)bound TFs in region (b), their overlap with CREs (c), and whether they
contain the corresponding TF motif (d).
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Fig. 4.6 Mutation load per TFBR for each cistrome, in each mouse species. a) Numbers,
and b) Fractions of individual TFBRs in each cistrome that harbour 0, 1, 2, or >2 mutations
(mutation counts per TFBR are based on the aggregated mutation set from all DEN tumours
in each species). The majority of TFBRs do not contain any mutation, while most of the
TFBRs that are mutated harbour only one mutation. TFBRs with >2 mutations are referred to
as outliers. c) Most of the outliers are TFBRs recurrently mutated in >2 independent tumour
samples, while very few of them have >2 mutations in a single tumour sample.
identified TFBRs. In general, the larger size of the CAST data sets were speculated to provide higher
statistical power in relevant analyses.
With respect to the number of mutations occurring in each TFBR, as described above, most TFBRs did
not contain any mutation. Among the mutated TFBRs, the vast majority contained only one mutation,
while there were a number (a few thousands) of outlier TFBRs with higher numbers of mutations (Fig.
4.6). These corresponded mostly to TFBRs that were recurrently mutated in independent tumours of
each species, while only very few of them harboured a relatively high number of mutations in a single
tumour.
As part of exploratory analyses, I furthered investigated whether the relative proportions of mutated
TFBRs differed strikingly between TFBRs sets with distinct functional features. Examining the
mutation loads in TFBRs after splitting each cistrome into sub-cistromes based on the number of
(co-)bound TFs (Fig. 4.5b), their overlap with regulatory elements (Fig. 4.5c), as well as whether
they contain the binding motif of the respective TF or not (Fig. 4.5d), did not show any strikingly
dissimilar distributions of mutated versus non mutated TFBRs among the different subsets. Little
differences in the fractions of mutated TFBRs among sub-cistromes were difficult to evaluate at
this stage, as the different TFBR sets were not corrected for potential biases in their total number
of mutations (given that they were called based on different numbers of tumour samples), the total
number of their contained TFBRs, the length distribution of the TFBRs, as well as their sequence
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context. Therefore, this overview of mutated TFBR fractions is rather part of the comprehensive
description of the dataset, while comparison of mutation loads between (sub-)cistromes would require
normalisation for potential inherent differences in their included regions.
4.2.5 Weighted mutation rate in TF cistromes and sub-cistromes
As explained in the previous section, to evaluate the relative mutation rates of the liver TF cistromes
and sub-cistromes, it was necessary to first correct for potential inherent biases of these different TFBR
sets. Thus, to enable comparison of mutation loads between distinct (sub-)cistromes, I developed an
approach to calculate mutation rates that included correction for potential batch effects.
The first issue I accounted for was that the vast majority of TFBRs contain no or only one mutation. A
simplistic approach to estimate and compare mutation rates between cistromes would be to calculate
the mutation density of each TFBR in a cistrome, i.e. divide the number of mutations in a TFBR by
the length of the TFBR, and average across all TFBRs of the cistrome. However, the fact that—as
shown above—the vast majority of TFBRs contains only one mutation would be problematic in the
calculation of mutation density per TFBRs. The reason would be that since most TFBR mutation
density fractions would have a numerator (number of mutations) equal to one, the denominator (TFBR
length) would be the defining factor of the mutation density value, thus making TFBRs with larger
length (aka large denominator) appearing as more lowly mutated. This means that different mutation
rates between distinct TFBR sets could reflect differences in their contained TFBR length distributions
rather than differences in their mutation burdens. Therefore, to deal with this issue, rather than
calculating mutation rate per individual TFBR in a (sub-)cistrome, I calculated the mutation rate in
the aggregation of all TFBRs in a (sub-)cistrome (Fig. 4.7).
An additional parameter I took into account to calculate mutation rates across different sets of TFBRs
was the sequence context. The sequence context can affect the observed mutation rate, because not
all nucleotides have the same probability of being mutated. For example, as explained above, the
mutagenic effect of DEN is more prominent on thymines. This means that mutation rates between
distinct (sub-)cistromes might appear different as a result of their different nucleotide composition. In
that case, it would be difficult to distinguish when a mutation rate difference between two TF peak
sets represents a nucleotide composition bias, or it is attributed to differences in biological processes,
such as repair efficiency in the underlying regions or negative selection effects. Therefore, in my
calculation of mutation rates, I also corrected for the sequence context biases of the regions included
in the aggregated (sub-)cistromes.
Taken together, I calculated the mutation rate in each aggregated (sub-)cistrome, weighting it by
trinucleotide context frequency (weighted mutation rate, wmr). Specifically, I first retrieved from the
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reference genome all TFBR sequences of a specified (sub-)cistrome and aggregated them. Within
the sequence aggregation, I counted the occurrences of each possible trinucleotide, creating a vec-
tor of 64 trinucleotide counts for the aggregated (sub-)cistrome. Then, I determined the number
of mutations per trinucleotide that occurred within the specified (sub-)cistrome, in each individ-
ual tumour sample. This means that, in each sample, I counted the occurrences of each mutated
nucleotide, conditioned on its 5’ and 3’ nucleotides, i.e. accounting for its trinucleotide context.
That resulted in a vector of size 192, containing the occurrence count of each of the 192 possi-
ble trinucleotide changes, in the aggregated (sub-)cistrome in each individual sample (Fig. 4.7).
I then calculated the mutation rate for each of the 192 trinucleotide changes as the number of
occurrences of the specific trinucleotide mutation in the aggregated cistrome in a given sample
(N(trinucl.changes)in_aggr.cistrome,in_sample), divided by the total count of the corresponding trinu-
cleotide in the aggregated cistrome (N(trinucl.occurrences)in_aggr.cistrome), and then weighted that
fraction by multiplying by the frequency of occurrence of this trinucleotide in the genome of the





The sum of the mutation rates for all possible trinucleotide changes in a given tumour sample was the




× f(trinucleotide)in_genome (Fig. 4.7).
Using the above described method, I calculated the weighted mutation rate for each defined TF
cistrome (CEBPA, FOXA1 and HNF4A) and sub-cistrome (1TF, 2TF, 3TF and promoter-overlapping,
enhancer-overlapping, no-CRE-overlapping) in every tumour sample of each species (Fig. 4.8a).
Fig. 4.7 Overview of approach developed to calculate weighted mutation rate (wmr) for
a given cistrome or sub-cistrome, per tumour sample. The reference sequences of all TF
binding regions contained in the (sub-)cistrome were aggregated. First the wmr of each of
the 192 possible trinucleotide changes was calculated in the specified cistrome, in a given
sample. The final wmr for the aggregated cistrome in the given sample was total sum of all
192 trinucleotide context wmrs.
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Within each species, pairwise comparisons were performed between each pair of cistromes and pairs
of sub-cistromes, using Mann-Whitney U tests.
Consistently in all the three species, no significant difference was observed between the cistromes of
the liver TFs (Fig. 4.8a). This suggests that none of the three TF cistromes shows particularly higher
or lower tolerance to accumulating mutations in the DEN-induced liver tumours.
Then, I performed pairwise comparisons among the wmrs of the 1TF, 2TF and 3TF sub-cistromes
of each cistrome. The 1TF-bound TFBR groups of the CEBPA and FOXA1 cistromes, showed
significantly higher mutation rates than the corresponding 3TF-bound groups. This pattern was repro-
ducible in all three species, although in CAROLI the p-values were slightly higher (p-values < 0.01,
as opposed to the other significant p-values < 0.001) (Fig. 4.8b). Moreover, only in BL6, 1TF-bound
regions of the HNF4A cistrome also showed significantly increased wmr compared to the 3TF-bound
HNF4A regions (Fig. 4.8b), while the corresponding comparison in the other species did not show
significant differences. Interestingly, in all species, the CEBPA binding regions that were co-bound
by a total of 2TFs (as inferred by the ChIP enrichment analysis) also showed significantly higher
mutation rates than the 3TF-co-bound CEBPA regions (Fig. 4.8b). Finally, pairwise comparisons
between 1TF- and 2TF-bound regions of the different cistromes did not show significant differences.
The only exception was the 1TF-bound FOXA1 regions specifically in BL6 that exhibited higher
mutation rates than the corresponding 2TF-bound regions of the FOXA1 cistrome (Fig. 4.8b). Overall,
mutation rate profiling revealed a progressive reduction of mutation loads from regions bound by one
TF alone to regions that are co-bound by different TFs.
In addition, for each species, I compared the weighted mutation rates of the promoter-overlapping,
enhancer-overlapping and no-CRE-overlapping sub-cistromes of each TF cistrome (Fig. 4.8c). All
possible pairwise comparisons between promoter-overlapping, enhancer-overlapping and no-CRE-
overlapping sub-cistromes revealed statistically significant differences. Specifically, in all species and
for all three liver TFs, binding regions in promoters showed the lowest mutation rates, followed by
enhancer-overlapping binding regions, and lastly by TFBRs that do not overlap with CREs, which
had the highest mutation rates (Fig. 4.8c). This suggests a strong effect of overlap with promoters or
enhancers on the mutation burden of TF binding regions.
Finally, I revisited the issue of low and relatively invariable mutation counts per TFBR that I described
at the beginning of this section (i.e. the fact that the vast majority of TFBRs contained no or only
one mutation). I, specifically, sought to determine whether this issue had been effectively corrected
for by aggregating the TFBRs of each cistrome. The motivation for this arose from the fact that the
3TF sub-cistromes, which were shown to have the lowest mutation rates compared to the 1TF and
2TF groups, were also observed to generally contain longer TFBRs than the 2TF and 1TF-bound
TF peak regions (Fig. 4.2b). In addition to that, the 3TF groups in most cases were shown to
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Fig. 4.8 Distribution of weighted mutation rates per sample in each cistrome and sub-
cistrome of the studied mouse species. Distribution of wmr per sample for a) the CEBPA,
FOXA1 and HNF4A cistrome in each species, b) the 1TF, 2TF and 3TF sub-cistrome of each
cistrome shown in (a), and c) the promoter-overlapping, enhancer-overlapping and no-CRE-
ovelrapping sub-cistromes of each cistrome shown in (a). Each data point represents the wmr
in a single DEN tumour sample. Pairwise comparisons between cistromes or sub-cistromes
were performed using Mann Whitney U tests. ** indicates p-values < 0.001, * indicates
p-values < 0.01. Non-significant comparison results are not labelled. Number of tumour
samples (data points) for each species are shown in Table 3.1
110 Chapter 4
Fig. 4.9 Correlation between counts of mutated trinucleotides (y axis) in each aggre-
gated sub-cistrome of every tumour and total counts of trinucleotides (x axis) in each
aggregated sub-cistrome (in reference genome). a) Each possible sub-cistrome in a sam-
ple is shown as a data point, b) same data points as in (a) but split in sub-cistromes by overlap
with regulatory elements (upper panel) and sub-cistromes by number of (co-)bound TFs
(lower panel). A linear model is fitted in each case and Pearson’s correlation of mutated
trinucleotide counts with total trinucleotide counts is shown.
include a higher number of TFBRs than the 1TF or 2TF groups (Fig. 4.2a), which would result in
the corresponding sequence aggregation of sub-cistromes of the 3TF groups having a larger total
length than the aggregated 2TF and 1TF aggregations. If the “invariable mutation counts” problem
was persistent even after the aggregation of TFBRs within (sub-)cistromes, i.e. the total mutation
count was consistently low among all aggregated cistromes and the total length was presenting large
differences, that would be reflected in a relatively invariable numerator (mutated trinucleotides) across
the different cistromes, as opposed to a highly variable denominator (total trinucleotide counts in
the aggregated cistrome) in the wmr fractions (equation in Fig. 4.7). That would cause inflation of
mutation rates in (sub-)cistromes with smaller total length of the aggregated sequences, thus smaller
total trinucleotide counts. To gain further evidence that the wmr differences between aggregated sub-
cistromes are not determined only by the length differences of their contained (aggregated) regions, I
went on to examine the relationship of mutated trinucleotides with the total number of trinucleotides
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Fig. 4.10 Representation of promoter-overlapping, enhancer-overlapping and no-CRE-
overlapping TFBRs in the 1TF, 2TF and 3TF sub-cistromes (a), and vice versa (b).
(which is proportional to aggregated cistrome length) in each aggregated sub-cistrome per sample. In
case of persisting "invariable mutation counts" problems, i.e. relatively stable mutation counts across
the (sub-)cistromes, yet different lengths of the aggregated sub-cistromes, the two variables would not
be changing linearly and plotting them would reveal a plateau trend. I confirmed that this was not the
case. Instead, mutated trinucleotide counts were shown to increase linearly with total trinucleotide
counts in aggregated sub-cistromes, having also a high correlation (Pearson’s r = 0.85 - 0.9) (Fig.
4.9). This increased the confidence that wmr differences do not reflect region length biases.
Overall, among the TF peak groups with different number of (co-)bound TFs, the 3TF-bound regions
had the lowest mutation rates (Fig. 4.8b), while among the TF peak groups with different CRE
associations, the promoter-overlapping regions also exhibited the lowest mutation rates (Fig. 4.8c).
This observation raised the following question: could the 3TF binding region groups coincide with the
promoter-overlapping region groups of each cistrome? In other words, could the reduced mutation rate
of regions that display combinatorial binding of liver TFs be explained by the fact that these regions
coincide with promoter regions and/or vice versa? To address this question, I further investigated the
association of the 1TF, 2TF and 3TF groups with the promoter-overlapping, enhancer-overlapping
and none-overlapping groups. Specifically, I computed and reported the representation of each of the
latter groups in each of the former ones (Fig. 4.10). I observed that indeed promoter-overlapping
binding regions were very often more highly represented in 3TF groups, and this over-representation
was often in cases where the 3TF group had been shown to have significantly lower mutation rate
than the 1TF group. However, that was not always the case; for example, in CAROLI CEBPA and
FOXA1 cistromes, the 3TF groups were not more enriched for promoter-overlapping regions, but
they were significantly less mutated than the 1TF groups. Nevertheless, the 3TF groups were more
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enriched for enhancer-overlapping regions. Overall, there seemed to be a progressively increasing
representation of binding regions associated to enhancer and to promoters with increasing number of
(co-)bound TFs (Fig. 4.10).
4.2.6 Pairwise comparisons of mutation spectra per position of TF bind-
ing motifs between sub-cistromes
As already mentioned, an important feature of TFs is their ability to recognise and bind specific
motifs. To gain further insight in the mutational patterns of the TF binding regions in different groups,
I characterised the mutational profile of their binding motifs. In case the binding motif in the more
highly mutated TF peak sets was accumulating mutations at a specific position, this could have an
impact on the TF binding and, therefore, potential functional implications.
Therefore, I profiled the mutational spectra of the motif sequences, which were identified in the
ChIP-seq peaks of each group, and their direct flanking sequences. For each ChIP-seq peak set, I
collected the identified motif occurrences for the corresponding TF, e.g. for the identified CEBPA
ChIP-seq peaks, I considered their contained CEBPA motif occurrences (motifs identified as explained
in 4.2.3, Fig. 4.3, also see Methods for motif identification details), independently of whether the
underlying region was also bound by other TFs. Moreover, for peaks containing more than one motif
occurrence, I considered only the one with the lowest p-value in the FIMO output (see Methods for
motif identification). That was done to avoid including overlapping motif sequences, which would
result in counting their contained mutations multiple times. A motif occurrence was assigned to one
of the 1TF, 2TF or 3TF groups, based on the corresponding grouping of the TF peak it was identified
in. Similarly, a motif was assigned to one of the promoter-overlapping, enhancer-overlapping, or
no-CRE-overlapping groups based on the corresponding categorisation of the TF peak it was identified
in.
I retrieved the FASTA sequences of the identified motifs, centred them at their middle nucleotide and
extended by N=50bp both upstream and downstream. Having all the extended motif sequences of
equal length, I stacked them together accounting for their orientation, so that their corresponding
positions are aligned. For each relative position around the motif centre I calculated the raw mutation
counts for each possible nucleotide change and, putting all calculations together, I visualised the
mutation spectra per position (Fig. 4.11, 4.12, 4.13). Then I performed pairwise comparisons of
the mutation spectra (i.e. the different nucleotide change contexts) of corresponding motif positions
between the different groups of TF binding motifs, by applying Fisher’s exact tests. Specifically,
for every pairwise comparison between two motif groups (e.g. 1TF vs 3TF group), I ran a Fisher’s
exact test for each nucleotide change context at every relative motif position between the two groups
that were compared. The contingency tables I used included the nucleotide change counts at a given
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Fig. 4.11 Mutation spectra per relative position around the CEBPA motif centre for mo-
tif occurrences identified in each TF sub-cistrome, in all studied mouse species. CEBPA
motif occurrences were identified in each cistrome, extended +/- 50bp and stacked together,
centred at the motif centre and in the same orientation. Pairwise comparisons were performed
for mutation spectra at each corresponding position between groups, by running Fisher’s
exact tests and Bonferroni multiple testing corrections. In red are marked positions with
significantly different enrichment of mutation spectra between two groups.
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Fig. 4.12 Mutation spectra per relative position around the FOXA1 motif centre for mo-
tif occurrences identified in each TF sub-cistrome, in all studied mouse species. FOXA1
motif occurrences were identified in each cistrome, extended +/- 50bp and stacked together,
centred at the motif centre and in the same orientation. Pairwise comparisons were performed
for mutation spectra at each corresponding position between groups, by running Fisher’s
exact tests and Bonferroni multiple testing corrections.
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Fig. 4.13 Mutation spectra per relative position around the HNF4A motif centre for mo-
tif occurrences identified in each TF sub-cistrome, in all studied mouse species. HNF4A
motif occurrences were identified in each cistrome, extended +/- 50bp and stacked together,
centred at the motif centre and in the same orientation. Pairwise comparisons were performed
for mutation spectra at each corresponding position between groups, by running Fisher’s
exact tests and Bonferroni multiple testing corrections. In red are marked positions with
significantly different enrichment of mutation spectra between two groups.
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position and the reference nucleotide counts at the same position in the two compared groups. For
example, the contingency table for the comparison of T → A mutations at position 2 of a given
extended motif between 1TF with the 3TF groups would be:
1TF 3TF
Pos 2: T > A (nucleotide change context) Raw counts Raw counts
Pos 2: T (reference nucleotide) Raw counts Raw counts
Given that there are twelve possible nucleotide change contexts (A→C, A→G, A→T, C→A, C→G,
C→T, G→A, G→C, G→T, T→A, T→C, and T→G), for every pairwise comparison between motif
groups, twelve independent Fisher’s exact tests were performed for each position of the stacked
extended motif sequences. This way I performed all possible pairwise comparisons between the
motif groups 1TF, 2TF and 3TF, as well as the promoter-overlapping, enhancer overlapping and
no-CRE-overlapping groups. To correct the p-values of the multiple performed tests, I applied a
Bonferroni multiple testing correction including all pairwise Fisher’s exact tests. None of the pairwise
comparisons of nucleotide change context enrichment per position passed the Bonferroni multiple
testing correction.
However, this method of comparing mutation spectra per position of the extended motif had an
important caveat: it did not take into account the probability of each individual position to be mutated
based on its sequence context. Even if there were identified certain motif positions with significantly
different mutation loads between two TFBR groups, it would be hard to conclude whether this could
reflect potential sequence context biases between the groups, especially considering that DEN causes
numerous lesions mostly on T’s. Therefore, I sought to apply another method that would take into
account the sequence context.
4.2.7 Pairwise comparisons of sequence context-conditional mutation
counts per position of TF binding motifs between sub-cistromes
Following from the approach described above, I compared sub-cistrome groups with respect to their
mutation load per motif position, normalised by sequence context. I stacked, as described above, the
extended motif sequences, but besides the observed mutation counts per position, I also calculated the
expected mutation load (i.e. mutation counts) of each position conditioned on its probability to be
mutated (see Methods). The expected mutation load could then be used as a reference to evaluate
the observed mutation load. To compute the observed mutation load per position, I counted all
mutations occurring at a position, without splitting the mutation counts by nucleotide change context
as was done in the mutation spectra analysis above. The total mutation count at a given position
of the stacked motifs would give an estimation of this motif position being susceptible to mutation
accumulation in general, independently of the nucleotide change context of the occurring mutations
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(i.e. independently of whether the occurring mutations would, for example, be mostly A → T, or G →
A, etc). In addition, it would increase the statistical power, as the number of mutations would not have
to be split in smaller sets by nucleotide change context. To compute the expected mutation counts
of a position, I did take into consideration the probability of every position to be mutated based on
its trinucleotide composition. For this, I precalculated mutation probabilities of each trinucleotide
context (see Methods). This approach was an adaptation of a computational method from Frigola et al.
(2017) [368] that calculates observed and expected mutation loads in aggregations of stacked genomic
sequences. By adapting and implementing this method, I generated and overlaid the observed and
expected mutation counts per position in the stacked extended motif sequences (Fig. 4.14, 4.15,
4.16). Then, I performed pairwise comparisons of mutation loads between corresponding positions of
motif sets from the different sub-cistromes. For the pairwise comparisons, I applied Fisher’s exact
tests, but this time in the contingency tables I included the observed and expected mutation counts
at a given position. For example, to compare the mutation burden at position 2 of stacked extended
motif sequences between the 1TF and 3TF groups, I used the following contingency table in the
corresponding Fisher’s exact test:
1TF 3TF
Observed mutation counts at pos. 2 Raw counts Raw counts
Expected mutation counts at pos. 2 Raw counts Raw counts
Although visualisation of observed and expected mutations showed some positions where the devia-
tion of the observed mutation from the expected mutation load seemed to differ between different
sub-cistromes, the Fisher’s exact tests did not show any statistically significant results. This means
that, based on this analysis, there was not identified any specific position of the extended TF binding
motifs (CEBPA, FOXA1 and HNF4A motifs) that is more susceptible to accumulating mutations.
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Fig. 4.14 Observed versus Expected mutation loads per position of the extended
CEBPA motif in the sub-cistromes of each species. The sequences of identified CEBPA
motif occurrences within each sub-cistrome were stacked, centred on the motif middle nu-
cleotide. Observed mutation loads represent raw mutation counts at each relative position
around the motif centre. Calculation of expected mutation loads accounts for the mutational
probability of each position, based on its trinucleotide context.
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Fig. 4.15 Observed versus Expected mutation loads per position of the extended
FOXA1 motif in the sub-cistromes of each species. The sequences of identified FOXA1
motif occurrences within each sub-cistrome were stacked, centred on the motif middle nu-
cleotide. Observed mutation loads represent raw mutation counts at each relative position
around the motif centre. Calculation of expected mutation loads accounts for the mutational
probability of each position, based on its trinucleotide context.
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Fig. 4.16 Observed versus Expected mutation loads per position of the extended
HNF4A motif in the sub-cistromes of each species. The sequences of identified HNF4A
motif occurrences within each sub-cistrome were stacked, centred on the motif middle nu-
cleotide. Observed mutation loads represent raw mutation counts at each relative position
around the motif centre. Calculation of expected mutation loads accounts for the mutational
probability of each position, based on its trinucleotide context.
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4.2.8 Functional analysis of hyper-mutated TFBRs
As mentioned in section 4.2.4, although the vast majority of mutated TFBRs were hit by only one
mutation from the whole mutation aggregation of all tumour samples in a species, there were some
thousands of TFBRs with more than two mutations (appearing as outliers in Fig. 4.6a). Most of these
TFBRs were recurrently mutated in different tumour samples, while very few of them had more than
two mutations in a single sample (Fig. 4.6c). I questioned whether these hyper-mutated TFBRs can be
associated with expression changes in HCC or with any dysregulated pathway. I first sought to profile
how these TFBRs distribute across the defined sub-cistromes of each TF. Interestingly, the majority of
the hyper-mutated TFBRs were found to fall in the category of 3TF bound regions, and more than half
of them also occurred in CREs, primarily enhancers (Fig. 4.17). This was not expected as TFBRs in
the 3TF category had lower mutation rates than the 1TF and 2TF groups of TFBRs (Fig. 4.8b), while
CRE overlapping TFBRs also had relatively low mutation rates (Fig. 4.8c) overall. However, it should
be noted that, although the wmr calculation accounts for the total number of sliding trinucleotides in
the aggregated cistromes (denominator in formula in Fig. 4.7), which in fact represents the length
of the corresponding TFBRs, it is possible that large length differences among TFBRs may still be
a confounding factor. For example, 3TF-bound TFBRs with exceedingly high length may be more
likely to accumulate a high number of mutations, thus showing up as hyper-mutated TFBRs.
Fig. 4.17 Distribution of hyper-mutated TFBRs (TFBRs with more than 2 mutations)
across the sub-cistromes.
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I further sought to gain insights into the functional roles of these hyper-mutated TFBRs. For this
purpose, I used GREAT (Genomic Regions Enrichment of Annotations Tool) [369] to perform
Gene Ontology (GO) enrichment analyses and support biological interpretation of the observations.
In brief, GREAT is suitable for associating non-coding regions that have potential cis-regulatory
functions—such as ChIP enriched regions—with genes. Specifically, for each gene in the whole
genome annotation, GREAT determines by default a "gene regulatory domain" as a genomic window
of 5kb upstream and 1kb downstream of the gene TSS. It then extends this basal regulatory domain
to both directions until it meets the nearest gene, or until it reaches a maximum extension of length
1,000kb. It also performs further refinement by using global control regions with experimentally
validated regulatory domains. Finally, it performs GO enrichment analyses using binomial tests
[369], accounting for the variability of regulatory domain sizes and considering the genome frac-
tion that is associated with a given ontology term, as well as the number of input regions that are
associated with it. Statistical enrichments calculated by GREAT are therefore relative to a back-
ground set, which can be either the whole genome or a control set of certain regions. I performed
a GREAT analysis for the hyper-mutated TFBRs in each species, using as a background set the
corresponding non-mutated TFBRs. Finally, GREAT supports analyses on the BL6 genome assembly
(mm10), but not on the CAST and CAROLI genomes. Thus, to enable analyses also in these two
mouse species, I lifted over their hyper-mutated TFBRs onto the BL6 genome assembly (see Methods).
GREAT analysis of the hyper-mutated TFBRs in BL6 showed enrichment of terms related to catalytic
activity (protein-glycine ligase activity, protein-glycine ligase activity, initiating) and transmem-
brane transport (pyrimidine- and adenine-specific:sodium symporter activity). In addition, the results
included phenotype terms related to abnormal B-cell differentiation and abnormal morphology of
peripheral lymph nodes (increased early pro-B cell number, enlarged cervical lymph nodes), which
generally indicate abnormal morphology of the immune system (Fig. 4.18).
The hyper-mutated TFBRs in CAST showed association with catalytic activity (chitinase activity),
transmembrane transport and signalling (negative regulation of iron ion transmembrane transport,
glucagon-like peptide 1 receptor activity, trace-amine receptor activity, lysophospholipid transporter
activity, JUN kinase kinase kinase activity, transmembrane transporter activity), metabolic processes
(peptide cross-linking), response to stress (negative regulation of transcription from RNAP II promoter
in response to stress), as well as abnormal organ development and morphology, including abnormal
cardiovascular development (absent cardiac neural crest cells, absent coronary sinus, abnormal
Meissner’s corpuscle morphology), abnormal kidney morphology (tubular nephritis) nervous system
morphology (abnormal pacinian corpuscle morphology, abnormal Meissner’s corpuscle morphology),
as well as abnormal immune system morphology (lymphatic vessel hyperplasia) (Fig. 4.19). Finally,
the hyper-mutated TFBRs also showed association with specific genes involved in metabolic processes
(Plcxd3) and signalling receptor activity and response to stimulus (e.g. Ly6c2, Ly6c1, Ly6g, Vmn2r20,
Glp1r) (Fig. 4.19). Interesting is also the gene Cited2 (Cbp/p300-interacting transactivator 2), which
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encodes a transcriptional co-activator involved in cellular processes that are known to be perturbed in
carcinogenesis , such as transforming growth factor beta (TGFB) signalling and stimulation of the
tumour suppressor WT1-mediated transcription activation. A more detailed investigation of these
results would be of great interest.
Finally, CAROLI hyper-mutated TFBRs were associated with terms related to catalytic activity
(cholesterol 24-hydroxylase activity, genes Gal3st2b, Cyp46a1), regulation of transcription (chromatin
silencing at rDNA), nucleosome assembly (DNA replication-dependent nucleosome assembly), and
response to external stimuli and stress (defense response to bacterium, defense response to protozoan,
gene Gm4951) (Fig. 4.20). The Cholesterol 24-hydroxylase gene (Cyp46a1) that encodes a member of
the Cytochrome P450 (CYP450) enzyme superfamily would also be of particular interest, as CYP450
is known to metabolise DEN in the hepatocytes.
Overall, the hyper-mutated TFBRs in all three species showed association with transmembrane
transport and signalling, as well as catalytic activity. The results in BL6 and CAST also included
immune system aberrations. Additional terms that were enriched in one or two of the species were
related to metabolic processes, abnormal organ morphology, nucleosome assembly and transcriptional
regulation.
Fig. 4.18 Enriched GO terms associated with the hyper-mutated TFBRs in BL6 DEN
tumours, as computed by GREAT.
To further investigate the functional impact of the mutation load in the hyper-mutated TFBRs, I aimed
to explore associations of these TFBRs with dysregulated genes in liver cancer. To address this, I
utilised the differential gene expression (DGE) analyses results between tumours with different drivers
and normal adult liver in each mouse species. The DGE analyses had been previously performed by
the LCE consortium using DESeq2 [250]. To infer whether the hyper-mutated TFBRs are associated
with dysregulated genes, I first identified the closest gene of each of the hyper-mutated TFBRs. Then,
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Fig. 4.19 Enriched GO terms associated with the hyper-mutated TFBRs in CAST DEN
tumours, as computed by GREAT.
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Fig. 4.20 Enriched GO terms associated with the hyper-mutated TFBRs in CAROLI
DEN tumours, as computed by GREAT.
I retrieved the differential expression analysis results for the identified closest genes and visualised
them (Fig. 4.21a).
Indeed, a few hundreds to thousands of genes that were associated with hyper-mutated TFBRs were
significantly dysregulated in the liver tumours of each species (Fig. 4.21a). This is indicative of the
functional impact of high mutation loads in this specific set of TFBRs. In addition, small subsets of
these dysregulated genes were included in the cell-type marker gene clusters, clusters a-d, that had
been described in Chapter 3 (Fig. 4.21b). This observation suggests that the mutational patterns of the
specific TFBR set may be associated with gene dysregulation that is relevant to the shift of the cell
phenotype.
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Fig. 4.21 Significantly dysregulated genes in DEN-induced tumours that are associated
with hyper-mutated TF binding regions. a) For each species, volcano plots of genes that
are associated with hyper-mutated TFBRs and are also significantly upregulated (red) or
downregulated (blue) in tumours with different driver mutations. b) Number of corresponding
dysregulated genes. A small subset of all dysregualted genes that associated with hyper-
mutated TFBRs are included in the cell-type marker gene clusters that were described in
Chapter 3: clusters a, b, c and d correspond respectively to genes involved in cell proliferation




In this chapter, following up the identified dysregulation of cell-type marker genes in the transform-
ing/dedifferentiating hepatocyte throughout HCC development in three mouse species (BL6, CAST,
CAROLI), I set out to explore the mutational landscapes of transactivated regulatory regions and
their potential association with expression perturbations and the cell phenotype shift along neoplastic
transformation. To this end, I determined the cistrome of each of three liver TFs, CEBPA, FOXA1
and HNF4A, and characterised their respective mutation rates in the DEN-induced liver tumours of
each mouse species. A focus has been on distinguishing sets of TF binding regions (TFBRs) within
each cistrome based on their functionally relevant features that may be associated with shaping the
corresponding mutational landscapes; these were their combinatorial TF binding potential and their
co-occurrence with CREs (promoters and enhancers). Evaluation of the relative mutation rates of
sub-cistromes showed that combinatorially bound, as well as CRE-overlapping TFBRs display signifi-
cantly lower mutation rates than other TFBR sets. Nevertheless, a set of hyper-mutated TFBRs was
also identified, which was unexpectedly enriched for combinatorially bound and CRE-overlapping re-
gions. Interestingly, functional analyses of these hyper-mutated regions demonstrated their association
with transmembrane transport and signalling, response to stress, catalytic activity, as well as immune
system aberrations. In addition, many of their associated genes—as inferred by linear genomic
distance—were significantly dysregulated in the liver tumours. Running the analyses independently
on the three different mouse species confirmed the reproducibility of the observed mutational patterns
in the TFBR ensembles and revealed commonalities among the functional analyses. A potential bias
source that should be taken into account before drawing final conclusions are the length differences
among TFBRs and TFBR sets. Even though the TFBR lengths are accounted for (as total trinucleotide
counts) in mutation rates calculation, particularly large length differences could possibly still act as a
source of bias, especially when identifying TFBRs with particularly higher mutation load than other
(hyper-mutated TFBRs). A better establishment of the importance of length differences with respect
to the observed results would further improve the present study.
4.3.1 Characterisation of TF sub-cistromes based on functionally rele-
vant features
To separate out distinct mutational patterns within identified TF cistromes, I sub-categorised each
cistrome according to functionally relevant features of its contained TFBRs. In particular, based on
the number of different TFs they (co-)bind, the binding regions of each TF were distinguished into
1TF-, 2TF-, or 3TF- bound. In a parallel categorisation based on whether they co-occur with cis-
regulatory elements, they were also distinguished into promoter-overlapping, enhancer-overlapping or
non-CRE-overlapping. The majority of the regions were found to present combinatorial binding of
either three (to a larger extent) or two of the studied liver TFs: CEBPA, FOXA1 and HNF4A. That was
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confirmed both by ChIP-seq enrichment signal for the different TFs and by the content of the TFBRs
in binding motifs for each TF. In addition, about half of the binding regions of each cistrome were
found to bind to CREs. Overall, liver TFs were shown to largely bind in concert to genomic regions.
Evidence from previous studies using knock out experiments of one of the TFs CEBPA, FOXA1 and
HNF4A in the liver of mice has shown that stabilisation of one factor at typically combinatorially
bound regions depends on the binding of the other TFs [78]. In addition, compared to singly TF
bound regions, combinatorially bound ones tend to be more evolutionarily conserved, as shown by the
cross-species conservation of their binding activity [78, 370], as well as by lower rates of nucleotide
substitutions in their motifs compared to other regions [78]. On top of that, it has been shown that
species-conserved TFBRs, including many combinatorially bound TFBRs, tend to display stronger TF
binding [78]. Taken together, these findings suggest that combinatorial TF binding is associated with
more stable binding of the individual TFs. Also, the underlying combinatorially bound sequences are
less tolerant to nucleotide substitutions, which probably reflects their functional importance. Another
indication of their functional importance is the large extent of overlap ( 75%) between the set of
3TF co-bound regions with the TFBRs coinciding with promoters (Fig. 4.17). Therefore, liver TFs
appear to mainly bind and act at regulatory elements in concert. The importance of combinatorial
binding of TFs in governing spatial and temporal gene expression patterns has been highlighted in a
number of previous studies [371, 372, 370, 373, 374, 78, 375, 376]. Especially, tissue-specific gene
regulation is, to a great extent, a function of tissue-specific combinations of distinct TFs that act in con-
cert via binding to specific TFBR sets, and thus forming tissue-specific regulatory networks [372, 376].
4.3.2 Mutation rates in TF (sub-)cistromes, their underlying molecular
and evolutionary processes, and hyper-mutated TFBR
Profiling the mutation rates of the whole binding region sets of the three TFs in all mouse species
showed that none of the three cistromes seems to accumulate mutations at a particularly higher or
lower rate in HCC development, compared to the other TFs. Although each of the three TF cistromes
includes a number of singly bound TFBRs (classified in the 1TF group), the three liver TFs were
shown to largely co-bind, which indicates the extent of their synergistic activities and involvement in
similar regulatory functions. Therefore, the fact that they are affected in similar ways by DEN-caused
mutagenesis is not surprising. Interestingly, a recent study on the binding profiles of 13 distinct TFs
showed convergence of somatic mutations with germline variants at cistromes of a particular subset
of these TFs that act as master transcriptional regulations in prostate cancer. This TF set also included
FOXA1 [82]. It would be interesting to implement a similar approach of combining somatic with
germline SNVs for the three studied liver TFs, as well as to examine and compare a larger number
of TF cistromes with respect to their mutational patterns in HCC development, in order to see if any
more specific patterns would be observed as in the case of prostate cancer.
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With respect to comparisons among the sub-cistromes of each TF, the 3TF combinatorially bound
regions displayed significantly lower mutation rates compared to regions bound by one TF alone
(1TF category), in all cases except for HNF4A in CAST and CAROLI (Fig 4.2b). Similarly to
the lowly mutated 3TF bound regions, significantly lower mutation rates were observed in TFBRs
occurring in promoters compared to TFBRs within enhancers, which in turn were significantly less
mutated than no-CRE-overlapping TFBRs. It is generally expected that the mutational landscapes of
TFBRs in HCC development are forged by a number of distinct molecular processes, which may have
opposing effects. These include DNA damage upon bioactivation of DEN, inefficiency of DNA repair
mechanisms, as well as purifying selection/evolutionary constraints.
With respect to the DEN-caused damage, it is not considered to differentially affect distinct sets of
genomic regions based on their characteristics. The load of DEN-caused lesions must be relatively
homogeneous across the genome, with the only established bias being in the sequence context (e.g.
more lesions on T’s). It is noted, though, that mutation rates calculated in this study were normalised
for sequence context biases.
Regarding the potential reduced repair activity at TFBRs, it would be expected to inflate local mutation
rates. A number of studies have shown that TF binding regions exhibit high mutation rates in various
cancer types [88, 84, 83]. These high TFBR mutation rates are attributed to impaired access of DNA
repair enzymes to the TF-occupied genomic regions and, thus, incapacity to repair DNA lesions
caused by mutagenic factors, such as DEN [88, 84, 83]. Unrepaired lesions can then be fixed to
somatic mutations via faulty DNA replication during cell division.
On the other hand, assuming that many TFBRs—especially the combinatorially bound and CRE-
overlapping ones— have essential regulatory roles, their observed low mutation rates may reflect the
effect of purifying selection against potentially deleterious mutations in these functionally important
regions. Nevertheless, this assumption would require further investigation before conclusions are
drawn.
The differences in mutation rates of distinct TFBRs may reflect differences in the relative contributions
of the molecular and evolutionary processes, such as lesion repair efficiency and selective pressures,
that are in effect in each TFBR set with distinct functional characteristics. For example, the negative
selection against mutations may be weaker in TFBRs with lower implication in gene regulatory
networks, such as the 1TF-bound regions, or the ones that do not overlap with CREs. Many of these
regions may even represent occasionally and transiently bound regions, without fundamental regula-
tory roles. A number of them could also correspond to false positive TFBRs resulting from ChIP-seq
artefacts. On the contrary, functionally important TFBRs with essential regulatory roles may be under
stronger evolutionary constraints, thus less tolerant to accumulating mutations. Deleterious mutations
in these regions may be lethal and, thus, do not make it through tumour evolution. That is also a
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reason why it would be difficult to measure the effect of purifying selection. In the case of coding
regions, that could be done by comparing the rates of non-synonymous with synonymous mutations
[368]. However, this approach is not as easily applicable in the case of non-coding regions that are
not translated. Overall, determining the extent to which the mutation landscapes in these regions are
attributed to reduced repair efficiency or to neutral selection would require further investigation.
Considering the observed low mutation rates in presumably functionally important regions, such
as 3TF bound regions and CREs, the enrichment of the hyper-mutated TFBR set for such regions
appears as a paradox. There are thousands of regions recurrently mutated across independent tumours
in each species, and though very few are mutated in a single tumour, they harbour a remarkably high
load of mutations given their short length. These hyper-mutated regions are associated with functions
related to transmembrane transport and signalling, response to stress, catalytic activity, abnormalities
of the immune system and metabolic processes. Perturbation of such cellular processes, e.g. immune
response, metabolic processes, signalling pathways and response to stress, are generally known to
characterise the development of various cancer types. In addition, the observed association with
catalytic activities could be an interesting point to further examine with respect to potential enzyme
activity perturbations in chemically induced HCC development. Especially the implication of the
Cyp46a1 gene, in CAROLI, that encodes for a member of the DEN-metabolising CYP450 would be
of particularinterest. Furthermore, most genes associated with these hyper-mutated TFBRs are found
to be dysregulated in DEN tumours. Given these insights into potential functional associations of the
hyper-mutated TFBRs, it is possible that these regions are associated with some functional impact
along the neoplastic cell transformation. As long as mutations in these TFBRs are not lethal for the
cell, relatively higher mutation loads could be tolerated. An emerging question is whether mutations
in these regions could even confer fitness to the tumour cell. This could potentially be addressed via
investigating whether there is a signal of positive selection in the mutations of the hyper-mutated
TFBRs. Although it may be challenging to study the effects of selective pressure in non-coding
regions, it is possible that machine learning could be used in order to distinguish sequence patterns
that are associated to function. Such an approach has been recently implemented to detect positive
selection signals in enhancers and in TF binding regions [377] [378]. This could also be adapted to
investigate potential positive selection effects in the hyper-mutated TFBRs that are associated with
dysregulated genes in HCC development. However, it should be highlighted again that more detailed
analyses to rule out the effect of potential length and sequence biases would be encouraged in order to
provide more rigorous identification and functional characterisation of hyper-mutated TFBRs and
infer robust conclusions.
Other future directions of the study could focus on a more comprehensive characterisation of the set
of hyper-mutated TFBRs. Within this frame, a first point to be further addressed would be to establish
in more detail the association of each hyper-mutated TFBR with regulatory elements. In the case of
promoter-overlapping hyper-mutated TFBRs, it would be interesting to examine whether the gene
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associated to the corresponding promoter is highly or lowly expressed at the time of carcinogenic
insult. This direction is motivated by the fact that the local effects of transcription coupled repair
(TCR) on lesions are related to the expression levels in the region; TCR activity is known to be high
at actively transcribed genomic regions. Therefore, regions with genes that are actively transcribed at
the time of the carcinogen insult in the tumour cell-of-origin will exhibit a lower mutation rate in their
vicinity, because lesions will be more efficiently repaired by TCR, compared to other regions with
silenced genes where TCR will not be recruited. This could provide a link between the expression
state of the cell-of-origin at the time of the carcinogen insult with the finally observed mutational
landscape in the tumours.
Another possible direction to be pursued is a better establishment of associations between the individ-
ual hyper-mutated TFBRs and their target genes, on which they exert some regulatory effect. The
approach that has been followed here was based on the linear genomic distance of each TFBR from
its closest gene. However, this could be further improved by setting biologically relevant threshold
on the allowed distances, or by identifying plexuses of the TFBRs of interest with their target genes.
Such plexuses can be inferred from Hi-C data analysis and identification of looping interactions,
particularly relevant for TFBRs within putative enhancers. In addition, comprehensive pathway
enrichment analyses of the identified target genes should be performed.
One limitation of the study is the lack of TF binding profiles in tumours. Although we were able to
identify genome-wide profiles of liver TF binding in normal liver and can investigate mutagenisation
of these regions, we are not able to directly conclude whether there is differential TF binding at the
mutated regions. In addition, we may miss newly created TF binding events at other genomic regions
or losses of TF binding at others as a result of mutations, which may be implicated in the neoplastic
transformation of the hepatocytes. Still, although not directly, conclusions can be drawn via inferring
associations between TFBRs and dysregulated genes, as I have described in this chapter.
4.3.3 Mutational load of TF binding motifs and their flanking sequences
Analyses of the TF binding motifs identified in distinct sub-cistromes with different functional char-
acteristics (1TF, 2TF, 3TF, and promoter-overlapping, enhancer-overlapping, no-CRE-overlapping)
have not shown enrichment of recurrent occurrence of mutations at particular motif positions. The
approach of comparing mutation spectra in corresponding positions of motifs assigned to different
functional TFBR categories was limited by the fact that it did not account for the sequence context. A
possible correction would be to also calculate the expected mutation count for each nucleotide change
context (based on its mutation probability) and use it as a reference to evaluate the corresponding
observed mutation counts per nucleotide change context per position. However, such analysis would
have reduced power, as splitting the motifs into functional categories according to the TFBRs they are
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found in, combined with splitting the mutations at each motif position by nucleotide change context,
results in many subsets with few data points. Therefore, an approach for calculating observed versus
expected mutation counts per motif position was implemented without splitting the mutations by
their nucleotide change context, yet accounting for the conditional probability of each position to
be mutated based on its trinucleotide context. However, this analysis did not show any significant
differences between functional categories of TFBRs with respect to mutation enrichment at any of
their individual extended motif positions.
Nevertheless, even if no particular motif position of the studied TFs is susceptible to accumulating
mutations in one functional TFBR category compared to another, it is possible that the whole motif
sequence of a particular TFBR category is more tolerant to mutations than the motifs of another
TFBR category. An approach to test this hypothesis would be to calculate weighted mutation rates
(wmr) only for motif sequences identified in the different sub-cistromes, besides calculating the wmrs
over aggregation of the whole TF bound regions (defined by ChIP-seq peaks) as was described in
this chapter. An alternative method to evaluate mutation load in motifs and compare among distinct
TFBR categories, would be to look at the relative comparison of the observed versus expected overall
mutation load of the whole motif sequence, rather than looking at each individual position of a motif.
In any case, it is important to conclude whether the short motif sequences that bind TFs are disrupted
by mutagenesis in cancer or, in our case, in chemically induced liver cancer. Given that the TF binding
motifs are the actual sequences that are explicitly recognised and bound by the TFs, dysregulation of
gene epxression as a result of mutagenesis in TFBRs should, in principle, be mediated by differential
binding affinity of the TFs to their target motifs because of changes in their nucleotide sequence.
However, another aspect to consider is that the observed phenotypic changes (cell phenotype shift in
neoplastic transformation) mediated by gene dysregulation do not necessarily have to narrow down to
mutation enrichment in a very particular motif sequences set of a particular functional category of
TFBRs. As shown here, the identified hyper-mutated TFBR set is enriched for functional categories of
TFBRs that overall have low mutation rates (3TF, CRE-overlapping). This exemplifies how individual
regions with different functional characteristics can be mutated and may have a collective impact on
the expression output, and in turn on the phenotype. If these regions are studied only within their
predefined functional categories (i.e. within the whole set of 3TF or promoter-overlapping TFBRs),
the signal of their particular mutation patterns—deviating from the "rule"—is not possible to be
detected.
Overall, there might be mutations in TF binding motif sequences that mediate dysregulation of genes
via differential TF binding although identifying them is challenging. Approaches such as the use of
machine learning to detect sequence patterns associated with function, and thus potential signals of
positive selection (as described above), may be relevant here.
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4.3.4 Importance of studying mutagenesis of TF binding regions and
general future perspectives
Overall, the results of this study disentangle different patterns of mutation accumulation among diverse
categories of TF binding regions. In addition, they provide insights into how gene dysregulation
via mutagenesis of TF binding regions can lead to distortion of the hepatocyte phenotype in HCC
development. Importantly, they also highlight the necessity of studying the activity of TFs bound both
in a singleton manner and in concert, and within their broader functional context. Partitioning the
binding regions of TFs into functionally relevant categories is also very useful for identifying inherent
variation in the binding activity and the underlying sequence contexts of each TF. Yet examination and
comparison of TF binding regions in ensembles (such as functionally relevant categories of TFBRs)
can be complemented by investigation of individual regions or region sets that seemingly deviate
from the typical molecular patterns observed in the distinct TFBR catagories. Finally, combined
studies of somatic mutagenesis in the cistromes of higher numbers of distinct TFs, as well as in
combination with germline variants are expected to provide more comprehensive insights into the role
of non-coding, regulatory mutations, such as in TFBRs during cancer development.
Besides elucidating aspects of cell-type specific gene dysregulation and distortion of the cell pheno-
type (cell dedifferentiation) along the tumour progression, this system also provides an appropriate
frame for better understanding the effect of cistrome SNVs on gene expression regulation and for
gaining insights into complex tissue-specific gene regulatory networks. Though not a specific cell type
such as those of a cell line, the liver is quite a homogeneous tissue ( 75% composition of hepatocytes)
which makes it a suitable system for studying cell type specific regulatory networks in vivo and, in a
wider context, regulatory mechanisms in vertebrates.
4.4 Methods
4.4.1 Mutation calls in the DEN induced tumour samples
The SNVs had been previously identified in the mouse tumours, within the frame of the LCE
consortium work, as described in Aitken et al. 2020 [296]. In brief, whole genome sequenc-
ing had been performed for the different tumour samples derived from BL6, CAST and CAR-
OLI livers, and sequencing reads had been mapped to the reference genome assemblies GRCm38,
C3H_HeJ_v1, CAST_EiJ_v1, CAROLI_EiJ_v1.1 (Ensembl release version 90) [379, 261] with
bwa-meme (v0.7.12) [226]. Identification of single nucleotide variants (SNVs) was performed using
Strelka (v2.8.4) [380] with default settings. SNVs were subjected to multiple filtering steps. Firstly,
low-confidence SNV calls were identified and removed by using the gatk-tools package (version 0.2.2,
https://github.com/crukcibioinformatics/gatk-tools). Filtering was based on low mapping and
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base quality scores, proximity to alignment ends, and low absolute read counts. Germline variants
(defined as those shared exclusively by tumours originating from a single mouse, or within a single
litter of mice) were were also removed. Also, SNVs with an allele frequency smaller than 2.5% were
removed.
In addition, a number of genomic regions had been found to display low read coverage during the
process of SNV calling, resulting on disability to call mutations in these regions. I considered the
so-identified low coverage regions and also excluded them from all my downstream analyses, where I
identified TF peaks etc.
4.4.2 TF peak calling
Transcription factor binding regions were identified in the mouse genomes by analysing raw ChIP-seq
data from Stefflova et al. 2013 [78]. These included two biological replicates from each mouse
species. The ChIP-seq data were downloaded from ArrayExpress (E-MTAB-1414). I called TFBRs
on the updated reference genome assemblies (Ensembl 90) using the raw reads from each of the two
ChIP-seq libraries. Following the Stefflova et al. approach for TF peak calling, I also generated a third,
technical, replicate by pooling together the reads from the two biological replicates. I performed read
quality controls using FastQC (v0.11.5) (https://www.bioinformatics.babraham.ac.uk/projects/fastqc/),
which overall showed a high read quality in all libraries. The only exception was one of the two
CEBPA ChIP-seq libraries from the biological replicates in CAROLI. This was probably reflected
in the lower number of CEBPA peaks identified in CAROLI, compared to the other species (Fig.
4.2), in the downstream analysis. I then mapped the reads of the two biological and the one technical
replicate on the corresponding genome of each species (Ensembl 90) using bwa (v0.7.17) [226]. I
also discarded multiply mapped reads setting the MAPQ threshold in samtools (v1.9) equal to 1. I
then called ChIP-seq peaks for each replicate using MACS2 (v2.1.2) [285]. To distinguish the real
ChIP-seq signal of TF binding from the artefact signal due to genome repeats and open chromatin
I used, as controls, input ChIP-seq libraries from each species, which were also retrieved from
Stefflova et al. (2013) [78], and processed the same way as the ChIP-seq libraries for the different
TFs. To further eliminate the ChIP-seq signal noise, Vasavi Sundaram performed an additional
filtering on the identified peaks using ChIP-seq greylists that she had generated while identifying
epigenomic/regulatory regions from ChIP-seq data within the LCE project. The grey lists had been
generated with GreyListChIP package from R Bioconductor [381]. Finally, I identified reproducible
peaks among the three replicates. In particular, I determined as reproducible the peaks that were
shared by at least two of the three replicates.
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4.4.3 Identification of promoters and enhancers by the LCE consor-
tium
Promoters and enhancers had been determined, within the LCE consortium, by performing ChIP-seq
experiments for histone modifications in pooled livers of healthy, 15day-old mice from each of the
studied mouse species. The generated ChIP-seq data were analysed and genomic regions marked
by H3K4me3 and H3K27ac, as well as regions with only H3K4me3 were identified as promoters.
Regions with only H3K27ac were identified as enhancers.
4.4.4 Splitting the TF cistromes in sub-cistromes
I assigned every TFBRs in one of the 1TF, 2TF or 3TF groups as following: I used bedtools intersect
(v2.29.2) [286] to identify if the called ChIP-seq peak of a given TF overlaps with at least one
ChIP-seq peak of another TF (2TF category) or at least one ChIP-seq peak from each of the other two
TFs (3TF category). It is noted that each TFBR is assigned uniquely to one of the groups. Similarly, to
conclude whether each TF binding region coincides with promoters or enhancers, I checked whether
there is any overlap of each ChIP-seq TF peak with any promoter or any enhancer using bedtools
intersect (v2.29.2) [286].
4.4.5 Identification of TF-binding motifs
TF-bound motifs were identified within the ChIP-seq peak regions of each TF, using FIMO from
the MEME suite (v 5.0.5) [287], with p-value threshold = 0.001, providing the genome of the
corresponding species in markov background model format (option -bgfile), and setting the param-
eter -max_stored_maches = 1,000,000. In particular, the ChIP-seq peaks of CEBPA, FOXA1 and
HNF4A were scanned for the position weight matrices MA0102.2 (CEBPA-binding motif), MA0148.1
(FOXA1-binding motif), MA0114.3 (HNF4A-binding motif), which I retrieved from the JASPAR
database [168].
4.4.6 Computing and visualizing observed and expected mutations in
extended motif regions
To evaluate the mutational load in the motif sequences and their flanking regions, I worked as in the
mutation spectra analysis. I collected the FIMO identified motifs from the ChIP-seq peak regions,
determined their middle nucleotide and extended them by N = 50bp on each side, upstream and
downstream. I then intersected these extended motif regions of equal length with the mutations from
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DEN-induced tumours. I retrieved the extended motif sequences with their contained mutations, and
stacked them together also taking into account their orientation. That means that motifs with a reverse
orientation were flipped to be added onto the stack of motif sequences with forward orientation, so
that they all have the same directionality.
Having the motif sequences stacked so that the individual motif positions are aligned, I calculated
the observed mutation load by summing up the number of mutations occurring at each position
of the aligned aggregated sequences. As in the mutation spectra analysis, potentially overlapping
motifs—especially after their up- and down-stream extension—could share a number of mutations
and thus cause inflation of the mutation count estimates if their contained mutations were counted
multiple times. Therefore, I aimed to make sure that each mutation was accounted for only once.
To achieve this, I only considered one motif per ChIP-seq peak, that was the motif with the lowest
p-value in the FIMO output.
4.4.7 Calculating the expected mutation load of extended motif sequences
To calculate the expected mutation load of each position, considering also the sequence context, I first
calculated the occurrence probability of each trinucleotide change in the genome. By trinucleotide
change, here, I refer to the mutation -i.e. single nucleotide substitution- but considering it as a triplet
with its 5’ and 3’ nucleotide, AiX jCk → AiXlCk.
The calculation of the mutation probability per trinucleotide was performed as following:
• First, I calculated the trinucleotide counts in the genome, that means the number of occurrences
of each of the 64 possible trinucleotides in the whole genome sequence, N(AiX jCk).
• Second, I computed the counts of each trinucleotide alteration in the whole genome, that is
the count of a trinucleotide AiX jCk (reference trinucleotide) changing into AiXlCk (altered
trinucleotide), N(AiX jCk → AiXlCk) That resulted in a vector of 192 count values, one for every
possible trinucleotide alteration.
• Then I calculated the relative frequency of each trinucleotide alteration, f (AiX jCk), by dividing
the trinucleotide alteration count by the count of the reference trinucleotide in the genome
N(AiX jCk) : f (AiX jCk → AiXlCk) =
N(AiX jCk→AiXlCk)
N(AiX jCk)
• Finally, I normalised the frequency of each trinucleotide alteration by dividing by the sum of the
relative frequencies of all 192 trinucleotide alterations: f (AiX jCk → AiXlCk)=
f (AiX jCk→AiXlCk)
∑
192 f (AiX jCk→AiXlCk)
• Given that a trinucleotide can have three possible alterations (with its middle nucleotide
changing), I determined the mutation probability of each trinucleotide as the sum of its three
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normalised trinucleotide alteration frequencies. These are the mutation probaiblities of the 64
trinucleotides that I used in the downstream calculations to estimate the expected mutation load




f (AiX jCk → AiXlCk)
To calculate the expected mutation load at each position of a stacked set of extended motif sequences,
first I counted the total number of observed mutations in the stacked motif region. Then I retrieved
the reference fasta sequence of the region and identified all its sliding trinucleotides. To each of the
determined trinucleotides, I assigned its corresponding mutation probability from the calculations
described above Pmut(AiX jCk). Then I summed up the assigned mutation probabilities of all trinu-




Pmut(AiX jCk) Then I divided the mutation probability





In that way, I converted the mutation probabilities into a system where they add up to 1. Finally,
I multiplied the mutation probability of each position in the motif sequence by the total number




∗N(mutations in sequence). That is the
expected mutation load of the given position in the extended motif region.
To visualise the observed together with the expected mutation counts across the extended motif
regions, I made use of a python script available by Frigola et al. (2017) [368] that, besides the raw
mutation counts, also plots smoothed observed and expected mutation counts using a polynomial fit.
4.4.8 Functional analyses of hyper-mutated TFBRs
As GREAT (Genomic Regions Enrichment of Annotations Tool) does not support analyses on CAST
and CAROLI, to enable GREAT analyses of the hyper-mutated TFBRs in these species, I lifted
over the corresponding TFBR intervals from each species onto the BL6 genome assembly (mm10).
For the liftovers I used the halLiftover tool [382] and a multiple whole genome alignment (HAL
alignment) for the mouse species, which is available within the LCE consortium. The orthologous
alignments of a number of the genomic intervals from each species onto the BL6 genome contained
short gaps. To avoid accounting the projection of any given TFBR interval as multiple intervals, I





Unraveling the big picture of phenotypic diversity among lineages, individuals, as well as within
organisms requires a profound understanding of the underlying gene regulatory mechanisms and their
variation. Transcriptional regulation is the most frequently employed level of gene regulation, which
further encompasses a variety of mechanisms and components. Important players among them are the
transcription factor (TF) proteins that bind to regulatory sequences of the genome and contribute to
gene expression control.
In my thesis, I gained insights into the binding activities of particular TFs, their evolutionary dynamics
and their contribution to broader functional contexts and phenotypic outputs, by investigating natural
and induced variation in their binding profiles. Although I studied TF binding in different contexts,
the approaches I used were based on a number of similar principles. The first was the use of in
vivo systems, specifically mouse models, that allow studying molecular components within their
complex cellular environments, and evaluation of their functional roles within a system that includes
synergies and interactions with other components. Besides that, the vast majority of the data analysed
here were derived from mouse liver, which makes a good model organ for studies of regulatory
networks, as it is highly homogenous consisting from hepatocytes to its largest volume [375, 329].
The second important underlying principle of the approaches used was the leverage of molecular
variation, manifested as variation in the sequence context and/or in the binding activity of the TFs,
either among closely related species of mice (natural variation) or among different conditions under
the effect of exogenous factors, such as tumour development upon exposure to a carcinogen with
mutageneic effects (induced variation). The last core principle has been that TF binding was studied
with respect to its role within a broader functional context or phenotypic output.
Following these principles, in the first part of my thesis, I leveraged natural variation among five
mouse species to examine the evolutionary dynamics of CTCF binding, within the functional context
of establishing and maintaining higher order chromatin structures and regulatory landscapes. In
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the second part of my thesis, I investigated a specific phenotypic output, the hepatocyte neoplastic
transformation along chemically induced HCC development, in four mouse species. I characterised
the expression profile of the hepatocyte, the tumour cell-of-origin, and identified dysregulated genes
along neoplastic transformation. Following this characterisation, I investigated mutational patterns
in the sequence context of liver TF binding profiles, upon a carcinogen insult, and their functional
implications. Below, for each of these projects, I summarise the main findings, the limitations, the
future perspectives and general conclusions.
5.1 Evolutionary dynamics of CTCF binding at TAD bound-
aries
The first study in this thesis, on evolutionary dynamics of CTCF binding within the context of three di-
mensional genome organisation, was motivated by limitations in the current understanding of CTCF’s
role in demarcating TAD boundaries. Although it is known that CTCF, together with cohesin, plays
an important role in TAD establishment, evidence of TAD boundaries being robust to CTCF depletion
has confounded the understanding of its exact role. To gain insights into the role of CTCF binding in
TAD establishment, I assessed how CTCF binding patterns stably fixed by evolution in five mouse
species contribute to the establishment and evolutionary dynamics of TAD boundaries. This study
revealed that CTCF binding is maintained at TAD boundaries under a balance of selective constraints
and dynamic evolutionary processes. Particularly, regardless of how conserved they are across species,
CTCF binding sites at TAD boundaries were found to be subject to stronger sequence and functional
constraints compared to other CTCF binding sites in the genome. The study also provided a character-
isation of transposable elements enrichment at TAD boundaries compared to the background genome.
Indicated depletion of LINEs and LINE-derived CTCF sites at TAD boundaries likely also reflected
purifying selection against insertions of long sequences at TAD boundaries, further supporting the
evolutionary constrains at these regions. Nevertheless, TAD boundaries were also shown to frequently
harbour dynamic clusters of both evolutionarily old and young CTCF sites, which contribute to the
resilience and flexibility of the TAD structures. Specifically, clusters of CTCF sites are often found at
orthologous regions of the studied mouse species, in the vicinity of TAD boundaries. These clusters
can contain both a number of species-conserved CTCF sites and divergent CTCF sites that result
from repeated acquisition of new species-specific sites close to conserved ones, or species-specific
losses of individual binding events. Finally, identification of pronounced co-localisation of CTCF site
clusters with cohesin and their frequent proximity to gene TSSs, compared to non-clustered CTCF
sites, suggests that CTCF clusters particularly contribute to cohesin stabilisation and transcriptional
regulation. Overall, the study showed that dynamic conservation of CTCF site clusters is an important
feature of CTCF binding evolution and apparently critical to the functional stability of higher order
chromatin structure. It also highlights the necessity of examining the binding of CTCF not only as
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individual binding sites, but also as an ensemble of potentially functional sites that can exert their
actions synergistically, additively or interchangeably, and contribute to fostering regulatory landscapes
and in turn phenotypic features.
Although the study provides novel insights into how the architecture and evolutionary dynamics
of CTCF binding sites at TAD boundaries contributes to the establishment and resilience of the
three-dimensional genome organisation, the extent and the depth of the study has been restricted by
the lack of Hi-C in all the mouse species. In addition, the available Hi-C data in one of the species
(BL6) is of relatively limited resolution. With the improvement and upscaling of the underlying
technologies and experimental methods, a larger number of high resolution datasets are becoming
available. More extensive comparisons of both CTCF and cohesin binding profiles combined with
the use of distinct, high resolution Hi-C maps for different species could provide an ever clearer
outline of the interplay of these architectural proteins with all levels of three dimensional genome
structures and their functional features. This work also motivates a more detailed characterisation of
the composition of distinct families and sub-families of transposable elements at TAD boundaries.
This profiling would complement the understanding of evolutionary forces that drive CTCF binding
and cohesin in these regions and help clarify their importance. Finally, besides the role of CTCF and
cohesin in defining TAD boundaries, a general topic that requires further clarification is the extent of
conservation of TADs across more evolutionarily distant lineages [383] and across tissues. Further
cross-species and cross-tissue comparisons of genome-wide contact maps would further elucidate the
evolutionary dynamics and functional importance of TADs.
5.2 Mutational landscape of TF binding profiles in hepato-
cellular carcinoma
The second study included in this thesis is part of a collaborative project within the Liver Cancer
Evolution (LCE) consortium. The LCE project makes use of a model of chemically induced liver
carcinogenesis in different mouse species, which offers a controlled biological system with natu-
ral genomic and epigenomic variation. One of the project’s main goals is to evaluate the relative
contributions of the genome and the epigenome of the tumour cell-of-origin to determining the
mutational landscape induced upon carcinogen exposure and how this landscape gives rise to the
liver cancer phenotype. Here, I first presented my work on characterising the expression profile of
the hepatocyte, as the cell-of-origin of chemically-induced liver tumours in mice. There I outlined
dysregulation of genes in HCC that is associated with changes in the cell phenotype along neoplastic
transformation. Following that, I explored the mutational landscapes of liver TF binding regions that
underlie dysregulation of genes with hepatocyte related functions, reflected in shift of the hepatocyte
phenotype along HCC development. Specifically, I characterised the mutation rates in binding region
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ensembles of three liver TFs (CEBPA, FOXA1 and HNF4A) in chemically induced mouse liver
tumours, considering their potential of combinatorial TF binding and their overlap with cis-regulatory
elements (CREs; specifically promoters and enhancers). I reported that binding regions that present
combinatorial TF binding and/or occur in CREs are significantly less mutated than others, possibly
as a result of negative selection against mutations in these functionally important regions. However,
I identified a few thousand hyper-mutated binding regions that are enriched in the combinatorially
bound and CRE-overlapping binding region sets, and are associated with gene expression perturba-
tions. These findings disentangle different mutation rates among distinct functional categories of TF
binding regions in liver cancer development, and provide insights into potential associations of liver
TF binding region mutagenesis with neoplastic transformation of hepatocytes. Finally, they highlight
once more the necessity of studying the activity of TFs bound both in a singleton manner and in
concert and within their broader functional context.
More accurate evaluation of the contribution of hyper-mutated TFBS to tumour evolution requires
further evidence on their functional implications and their potential to enhance the fitness of tumour
cells throughout the tumour evolution. Further functional TFBS characterisations can be performed via
more precisely establishing associations of these TFBS with their target genes and with cis-regulatory
elements, for example through additional assays of epigenomic state and/or chromatin conformation.
Further evidence on whether these hyper-mutated TFBS enhance tumour fitness can be obtained by
searching for signals of positive selection in the underlying mutated sequences of these TFBS. Finally,
combined analyses of somatic with germline variants would be useful in addressing the interplay
of somatic mutagenisation due to environmental exposures with genetic predisposition for specific
cancer types.
A limitation of the study has been the lack of TF binding profiles in the liver tumours. Performing dif-
ferential TF binding analyses between healthy and tumour liver would help establish the direct impact
of DEN caused mutations (or other somatic mutations in tumours) on TF binding and gene expression
disruption. However, TF binding profiles corresponding to healthy tissues at the carcinogenic insult
can be used to infer functional implications of mutations, as shown in this study. Yet, addressing how
the TF binding at mutagenised genomic regions changes in tumour would provide further proof of
their functional impact.
Finally, the results presented in this study could be further expanded by including additional binding
profiles of more TFs. Here, I have defined combinatorial binding based on the ChIP enrichment
of three specific TFs, which does not exclude co-binding of one of these TFs with another TF not
included in the study. It would also be particularly interesting to characterise binding regions of liver
TFs according to co-binding with architectural TFs, such as CTCF, and in combination with chromatin
looping data. That would help gain further insights in the regulatory networks in healthy tissues and
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their potential disruption and implications in cancer development.
5.3 Final remarks
The findings reported in this thesis provide insights into a) the role of CTCF binding and its evolution-
ary dynamics in establishing and maintaining topologically associating domains, and b) the mutational
landscape of the binding profiles of liver TFs and their implications in neoplastic transformation and
tumour evolution. Taken together, these insights highlight how the regulatory functions of a given
TF binding site are exerted via a great extent of synergistic activity with other sites, co-binding of
others TFs, chromatin modifications indicative of promoters and enhancers, and three dimensional
chromatin conformation. Furthermore, the binding sites of TFs are evolving units that—to a large
extent—contribute to the gene regulatory programme of a cell collectively. Therefore, the presented
studies emphasise the necessity of examining TFs and their binding sites, both as singletons and in
concert.
These general concepts can also be applied to the wider context of studying gene regulation. Overall,
elucidation of regulatory mechanisms requires, on the one hand, disentanglement of their individual
components and interrogation of their characteristics and functions. On the other hand, it is equally
important to examine these components and their activities as an ensemble. These approaches com-
bined can account for the context of each component’s activity and for potential synergistic forces
that underline relevant molecular functions that, in turn, affect the phenotype. Implementation of such
approaches can enhance our understanding of the mechanisms and functions of gene regulation at a
fundamental level, their evolution, as well as their roles in genetic diseases and cancer, and open new
perspectives for medical applications.
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Table A.1 Mapping and peak calling statistics for CTCF ChIP-seq data in the five Mus species
















CTCF 685304.0 do3065 37,067,110 32,106,748 87 27,927 40,289
Mus musculus
domesticus
CTCF 685305.0 do3066 63,240,749 53,082,610 84 45,718
Mus musculus
domesticus
CTCF 85922.0 do3073 49,861,065 45,543,182 91 44,202
Mus musculus
domesticus
input 85304.0 do3071 46,823,684 44,348,418 95 NA NA
Mus musculus
castaneus
CTCF 74636.0 do3075 68,333,659 65,956,183 97 38,833 38,373
Mus musculus
castaneus
CTCF 74874.0 do3076 37,740,031 36,120,900 96 39,542
Mus musculus
castaneus
CTCF 76993.0 do3069 69,732,659 60,847,415 87 40,009
Mus musculus
castaneus
input 74636.0 do3079 66,991,879 54,675,669 82 NA NA
Mus spretus CTCF 1a do3180 80,500,930 76,032,454 94 37,042 24,183
Mus spretus CTCF 2c do3181 72,366,179 67,433,478 93 17,974
Mus spretus CTCF 3e do3182 48,076,327 44,763,098 93 24,185
Mus spretus input 3e do3185 30,940,333 29,778,137 96 NA NA
Mus caroli CTCF 76791.0 do3177 84,228,625 78,277,357 93 41,519 37,027
Mus caroli CTCF 76792.0 do3178 75,520,746 71,218,023 94 38,604
Mus caroli CTCF 78713.0 do3179 118,560,403 113,114,517 95 38,467
Mus caroli input 76791.0 do3184 43,083,604 41,392,442 96 NA NA
Mus pahari CTCF 66009.0 do3174 75,214,636 66,852,515 89 33,462 29,924
Mus pahari CTCF 82898.0 do3176 70,433,073 64,809,159 92 28,353
Mus pahari CTCF 82903.0 do3175 70,754,788 64,160,019 91 32,802
Mus pahari input 66009.0 do3183 50,780,061 47,658,093 94 NA NA
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Fig. A.1 CTCF peak reproducibility among replicates of each Mus species. Venn diagrams
(A) and binding heatmaps (B) showing reproducibility of peak calling among the three
biological replicates from each species. We used peaks that were identified in at least two of
the three replicates.
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Fig. A.2 Hi-C contact maps from published C57BL/6J liver data. The contact maps generated
from the published C57BL/6J Hi-C data [184] were visualized using Juicebox [269]. They
show example regions from chromosomes 1 and 4, zoomed at different scales.
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Fig. A.3 There is no evidence of any enrichment of specific motif words at TAD boundary
regions among the species. Heatmap of the ~1,500 motif words found in CTCF peaks in the
five Mus species. Each row corresponds to a motif word, while the color density represents
its frequency of occurrence. The occurrence frequency of each motif word in the CTCF
peaks is normalized by the number of its occurrences in the whole genome for the respective
species. Motif words in the heatmap are sorted based on their distance to the closest TAD
boundary. There is no evidence of any selected set of motif words being used with significant
frequency at TAD boundaries among the species. The lower density of motif words is M.
spretus reflects the smaller number of CTCF binding sites identified in that species.
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Fig. B.1 Distribution of transformed TPMs (log2(TPM+1)) of expressed genes per bulk
RNA-seq sample in each species. The tail samples of BL6 are marked red.
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Fig. B.2 Distribution of transformed TPMs (log2(TPM+1)) of expressed genes in single cells
from fetal mouse liver (Yang et al. 2017). a) All expressed genes per single cell, b) Only
genes from gene clusters a-d, which mark distinct putative cell types in liver.
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Fig. B.3 Principal component analysis of expression profiles of both bulk liver samples (LCE)
and single cell data from mouse liver [328]. Expression profiles are based on expression of
marker gene clusters a-d. The bl6 cohort includes DEN-treated normal liver samples, liver
tumours (dysplastic nodules and HCCs), as well as two samples of tail tissue. The cohorts
of the other species include only liver tumours. The bulk sample expression profiles mostly
map on the latest stage of differentiated hepatocytes. Same data as in Fig. 3.3, albeit labeled
by Treatment.
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Fig. B.4 Distribution of expression levels (measured as transformed normalised counts across
samples and species) of genes contained in the marker gene clusters a-d, in "DEN" and "None
treatment" cohort samples per species. Samples from all cohorts display distincly higher
expression of cluster c genes, which are hepatocyte markers. In bl6, a drop of normalized
count distribution of cluster c genes is outlined along tumour progression (from normal liver
to dysplastic nodules and subsequently to HCCs). Distribution shifts are noticed also in the
other gene clusters.
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Supplementary figures and tables for
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Fig. C.1 DEN1 and DEN2 mutational signatures, as identified from DEN-induced tumours of
C3H mice and reproduced in CAST [296]. Underlying analyses of this figure were run in the
LCE consortium in parallel with mine and figure is adapted from Aitken et al. (2020) [296]
bl6 cast caroli
CEBPA 67,237 117,069 33,865
FOXA1 94,408 106,850 67,455
HNF4A 90,940 102,133 62,432
Table C.1 Number of genome-wide identified TF peaks in each mouse species.
bl6 cast caroli
promoters 16,005 17,032 14,434
enhancers 45,165 41,660 34,808
Table C.2 Number of genome-wide identified promoters and enhancers in each mouse species,
within the LCE consortium.
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Fig. C.2 Numbers of identified canonical TF binding motifs in the peaks of each TF
cistrome and in CREs. Canonical CEBPA, FOXA1 and HNF4A motifs were searched in
the underlying sequences of all peaks from each set. a) Number of identified motifs in the
ChIP-seq peaks of each cistrome (CEBPA, FOXA1, HNF4A peaks), b) Number of identified
motifs in the intersection of the TF peak sets with cis-regulatory elements (CREs)
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